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Abstract 
Fibroblast growth factors (FGFs) regulate a broad spectrum of biological 
processes and aberrant FGF signalling has been linked to many disorders and 
diseases. Heparan sulphate (HS) is a highly sulphated glycosaminoglycan, which 
regulates the activity of its protein ligands, mainly through anionic interactions. The 
interactions between HS, FGF and FGF receptors (FGFRs) depend on the size and 
the spatial distribution of the anionic moieties of the saccharides. To test the effects 
of these on FGF signalling, the activities of well-defined HS oligosaccharides were 
screened in bioassays. The aim of this thesis was to study the structural determinants 
which underpin the specificity/selectivity in HS-FGF-FGFR interactions. 
 
Two approaches were initially explored to generate suitable saccharides for 
screening. Firstly, the preparation of libraries of HS oligosaccharides was attempted 
by enzymatic digestion of porcine mucosal HS using heparinase III. This was 
followed by the sequential fractionation using size exclusion chromatography, strong 
anion-exchange and cetyltrimethylammonium strong anion-exchange 
chromatography. However, with regards to preparing saccharides of sufficient purity 
and amounts, this was found to be a limiting factor for bioassay screening. Secondly, 
the dimeric modular synthesis of HS octasaccharides was attempted by means of in-
solution multi-step synthesis. The synthesis of a small oligosaccharide library was 
partially successful and resulted in novel synthetic routes for generation of 
pentasaccharide precursors, but not sulphated saccharides for screening. An 
alternative strategy was taken to exploit nineteen existing fully defined chemically 
and chemoenzymatically prepared oligosaccharides. Screening in bioassays of 
specific FGF ligands, using BaF3 cells expressing single receptors, showed that both 
general and specific structural changes, as subtle as a single additional sulphate 
moiety, significantly impact the ability of saccharides to support FGF signalling in a 
ligand-receptor complex-dependent manner. The size of the saccharides, the 
presence/absence of 2-O-, 6-O- and N-sulphate groups were shown to be crucial 
factors for functional activity. Most notably, the presence of a single 3-O-sulphate 
group towards the non-reducing end of the saccharides was related to high levels of 
activation for FGF1-FGFR1c, FGF1-FGFR2b and FGF7-FGFR2b and was 
demonstrated for the first time.  
 
Overall, this thesis provides new evidence concerning structural determinants 
in HS that modulate FGF signalling, using fully defined saccharides for the first time. 
The results support the view that significant selectivity is involved, and contribute to 
a better fundamental understanding of how HS modulates FGF-FGFR-HS complex 
formation. Ultimately, this information could be relevant for the development of 
better targeted HS saccharide-based therapeutics. 
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1.1. Glycans and glycobiology 
Biomolecular interactions underlie all biological processes in living organisms, from 
physiological processes to responses to stimuli, including growth and development, 
adaptation, homeostasis, survival and reproduction. The nature and mechanisms of 
these interactions are diverse and driven by specific molecular recognition. 
Understanding these interactions is essential to comprehend the different functions of 
the biomolecules involved in such processes. Interacting molecules include DNA, 
RNA, proteins, polypeptides, polyphenols, lipids or carbohydrates. It is now 
understood that biomolecules are interconnected (Varki 2009) and that a given 
biomolecule may be involved in hundreds of interactions, concurrently with several 
types of other components, which makes their study a challenging task. 
The science of the biosynthesis, structure and biology of glycans, also called 
glycobiology, is a reasonably new section of biological sciences (Rademacher et al. 
1988). Even though glycans represent the major part of the biomolecules in cells, 
their biological roles have been fairly underappreciated in comparison to nucleic 
acids and proteins, which have monopolised attention. This is mainly explained by 
the complexity and heterogeneity of their chemical structures and biosynthetic 
origins. Although being a significant obstacle to deciphering their functions, this 
structural heterogeneity is also an essential factor that explains the broad range of 
roles played by glycans at the cellular level. In recent decades, they have been shown 
to play critical roles in storage and transport of energy, but also as structural 
molecules, signalling co-effectors, or even recognition markers. Therefore, glycans 
are essential actors in the transmission of important biological signals at the cellular 
level.  
1.2. Proteoglycans 
Proteoglycans are found in all mutlticellular organisms and are major constituents of 
the extracellular matrix (ECM), the cell surface and also in secretory granules 
(Kjellen and Lindahl 1991). These macromolecules are involved in a multitude of 
processes, ranging from the basic structural organisation and mechanical support of 
tissues to highly specialised biological processes such as cellular growth, 
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specialisation and maturation through their interactions with a broad variety of 
proteins, including cytokines and growth factors (Lennarz 2012). Proteoglycans are 
comprised of a core protein to which polyanionic glycosaminoglycan (GAG) chains 
are covalently attached (Figure 1). 
1.3. Glycosaminoglycans 
GAGs are linear heteropolysaccharides whose repeating disaccharide units are made 
of hexosamine (either N-acetyl-D-galactosamine/D-galactosamine or N-acetyl-D-
glucosamine/D-glucosamine-N-sulphated) and hexuronic acid (either D-glucuronic 
acid or L-iduronic acid) residues, except for keratan sulphate, whose repeating 
disaccharide unit is made of a D-galactosamine and a N-acetyl-D-glucosamine 
residues (Hook et al. 1984). These polyanionic structures have been classified into 
different species mainly based on their disaccharide repeating unit structure: 
hyaluronic acid (HA), chondroitin sulphate (CS), dermatan sulphate (DS), keratan 
sulphate (KS), heparan sulphate (HS) and heparin (Hp) (Figure 1). These 
polysaccharides are sulphated at different positions of the chains, except for the non-
sulphated HA. The diversity of roles played by the proteoglycans, to which they are 
associated (except for HA, which is the only GAG that is not attached to a core 
protein), is mainly explained by the heterogeneity of their structures and their ability 
to bind many types of ligands (mainly proteins and protein conjugates) (Lindahl and 
Hook 1978).  
1.4. Heparan sulphate proteoglycans 
Heparan sulphate proteoglycans (HSPGs), which consist - as suggested by their 
name - of HS polysaccharide chains attached to a core protein, are an important class 
of proteoglycans (Varki 2009). Their classification is based on the type of core 
protein and their number of HS chains (Table 1). As for the other proteoglycans, 
HSPGs are implicated in a broad variety of biological phenomena, ranging from 
angiogenesis and  organogenesis to cell adhesion and migration, wound healing, 
blood coagulation regulation and lipid metabolism (Bishop et al. 2007, Sarrazin et al. 
2011). They are also involved extensively in signalling pathway mechanisms, for 
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example for fibroblast growth factors (FGFs), vascular endothelial growth factors 
(VEGFs), Wnt and Hedgehog (Hh) (Forsberg and Kjellén 2001). 
 
 
 
Figure 1: Schematic representation of a proteoglycan basic structure and of 
the disaccharide repeating units of the common GAGs. 2S: 2-O-sulphate; 3S: 
3-O-sulphate; 4S: 4-O-sulphate; 6S: 6-O-sulphate; Gal: D-galactosamine; 
GalNAc: N-acetyl-D-galactosamine; GlcA: D-glucuronic acid; GlcNAc: N-
acetyl-D-glucosamine; IdoA:  L-iduronic acid. R = N-acetyl or N-sulphate; R
1
 = 
H or SO3
-
; R
2
 = Ac or SO3
-
. 
*
HA is the only GAG which is not bound to a core 
protein. 
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Class Proteoglycan 
Core protein 
(kDa) 
Number of GAG chains 
Extracellular 
matrix 
Agrin  ~200 HS (2-3) 
Collagen XVIII ~180 HS (1-3) 
Perlecan ~400 HS (1-4) 
Membrane-
bound 
Glypicans 1-6 ~60 HS (1-3) 
Syndecans 1-4 ~35 
HS (1-2) 
CS (1-3) 
Table 1: Major HSPG families and their tissue distribution (Iozzo 1998, 
2001, Bandtlow and Zimmermann 2000) .  
 
1.5. Heparin and heparan sulphate 
1.5.1. Biosynthesis 
Unlike HS, which is synthesised by almost all types of cells, Hp is made exclusively 
in mast cells (Rabenstein 2002). Amongst GAGs, Hp and HS display the highest 
variability in sequence. The latter can be regrouped into a vast repertoire called the 
“heparanome” (Turnbull et al. 2001). This observed heterogeneity results from the 
complex biosynthetic processes involved in their generation. Currently, the exact 
biosynthesis mechanism still remains unknown. The sequential pathway described by 
Lindahl et al. (1989) is commonly agreed, even though it does not explain some 
structures such as GlcNAc6S (Rudd and Yates 2012). Both Hp/HS biosynthetic 
pathways are similar, template-free driven, mainly take place in the Golgi apparatus 
and are regulated by more than 20 enzymes and their isoforms (Liu and Pedersen 
2007). The enzymes operate in a stepwise manner in four main stages (Figure 2), 
which are described in more detail in the following sections: the initiation, the chain 
elongation, the enzymatic structural modifications and finally the post-synthetic 
modifications.  
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1.5.1.1. Initiation 
Prior to the synthesis of the Hp/HS polysaccharide backbone, the tetrasaccharide 
linkage D-GlcA β(1→3) D-Gal β(1→3) D-Gal β(1→4) D-Xyl β(1→O) [Serine] is 
produced (Sugahara and Kitagawa 2000). The first step of the synthesis of the 
linkage region consists of the attachment of a xylose (Xyl) residue to a serine residue 
of the core protein, performed by the enzyme xylosyltransferase (XylT), which exists 
as two isomers XylT-1 and XylT-2 in mammals (Gӧtting et al. 2000). The next step 
is the successive transfer of two galactose (Gal) residues by the enzymes 
galactosyltransferases 1 and 2 (GalT-1 and GalT-2) respectively at the non-reducing 
end of the nascent polysaccharide chain. The final addition of a glucuronic acid 
(GlcA) residue by glucuronyltransferase 1 (GlcAT-1) completes the synthesis of the 
linkage region, which has been found to be common to Hp, HS, CS and DS. Several 
structural modifications may occur, such as the 2-O-phosphorylation of the xylose 
residue (Fransson et al. 1985) or the 2-O-sulphation/6-O-sulphation of the Gal 
residues in the case of CS/DS (Sugahara and Kitagawa 2000). The nature of the fifth 
residue attached to the non-reducing end of the linkage domain GlcA residue then 
determines the type of polysaccharide chain: the addition of N-acetyl-D-glucosamine 
(α(1→4) D-GlcNAc) will lead to Hp/HS chains whereas the introduction of N-acetyl-
D-galactosamine (β(1→4) D-GalNAc) will lead to the formation of CS/DS chains 
(Sugahara and Kitagawa 2000). 
1.5.1.2. Elongation 
The addition of the fifth sugar motif α(1→4) D-GlcNAc by the enzyme N-
acetylglucosaminyltransferase 1 (α-GlcNAcT-1) triggers the elongation process 
(Fritz et al. 1994). The stepwise and alternating addition of β(1→4) D-GlcA and 
α(1→4) D-GlcNAc residues is achieved by the action of two glycosyltransferase 
enzymes encoded by the genes EXT-1 and EXT-2 and which work as a complex 
(McCormick et al. 1998, 2000, Stickens et al. 2005). As the Hp/HS chain is extended 
(the chains are generally 50-200 disaccharides long, 25-100 kDa), it undergoes 
several enzymatic modifications, in a sequential manner. In this way, the product of 
an enzymatic reaction serves as the substrate for the next reaction. 
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Figure 2: Schematic representation of the Hp/HS biosynthesis , as proposed 
by Lindahl et al. (1989). The synthesis starts with the tetrasaccharide linkage 
preparation (Xyl-Gal-Gal-GlcA), attached to a serine residue of the core 
protein. The sequential addition of the GlcA and GlcNAc residues is followed 
by several steps of chain modifications, including: N-deacetylation, N-
sulphation, GlcA C5 epimerisation and 2-O-, 6-O- and 3-O-sulphations. PAPS 
is used as a sulphate donor. D-Gal: D-galactosamine; D-GlcA: D-glucuronic 
acid; D-GlcNAc: N-acetyl-D-glucosamine; D-GlcNH: D-glucosamine, L-IdoA:  L-
iduronic acid; D-Xyl: D-xylose. 
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1.5.1.3. Chain modifications 
Unlike the polymerisation process, enzymatic modifications of the HS backbone may 
occur in a concomitant manner, even though a relatively well-established order can 
be drawn from researchers’ observations. The GlcNAc residues of the unmodified 
polysaccharide HS chain first undergo N-deacetylation followed by N-sulphation, 
both catalysed by Hp/HS GlcNAc N-deacetylase/N-sulphotransferases (NDSTs). 
Four different isomers are found in vertebrates and display sequential different 
catalytic activities (Orellana et al. 1994, Aikawa et al. 2001). The N-deacetylation 
step is generally immediately followed by the transfer of a sulphate group (provided 
by the sulphate donor 3'-phosphoadenosine 5'-phosphosulphate (PAPS) (Liu and 
Pedersen 2007)). However, this reaction is not always completed and so can lead to 
the formation of rare unsubstituted D-glucosamine residues. This first step is of 
utmost importance as N-sulphated glucosamine (GlcNS) is needed for some of the 
subsequent modifications. More specifically, the presence of GlcNS at the non-
reducing end of D-GlcA is required for the epimerisation of this latter into L-IdoA 
(Jacobsson et al. 1984). Studies have shown that HS C5-epimerase is selective 
towards non-sulphated uronic acids or the ones that are not adjacent to O-sulphated 
glucosamine units (Bäckstrӧm et al. 1979, Jacobsson et al. 1984, Hagner-McWhirter 
et al. 2000, Qin et al. 2015). In another study, the epimerisation step has been shown 
to be crucial for the sulphation of the Hp/HS chain (Feyerabend et al. 2006). These 
findings strongly suggest that the epimerisation of the uronic acids most likely occurs 
before the sulphation of both uronic and glucosamine residues.  
Besides the epimerisation reaction, uronic acid units may also undergo 2-O-
sulphation by the action of the enzyme uronosyl-2-O-sulphotransferase (2-OST) 
(Habuchi et al. 1998). Despite its ability to catalyse the sulphation of both types of 
uronic acids, 2-OST shows a net preference towards IdoA over GlcA, resulting in the 
rarity of GlcA2S (Rong et al. 2001). Remarkably, other studies have shown that 2-O-
sulphation of uronic acids may have an impact on N-deacetylation/N-sulphation of 
glucosamine units as a lack of 2-O-sulphated iduronic acids resulted in the increase 
of N-sulphated-glucosamines (Bai and Esko 1996, Merry et al. 2001). These findings 
suggest that these steps may concomitantly occur, that the order may be more 
flexible than expected or that the process can go backwards and be repeated. The 
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next enzymes to go into action are the three isoforms of 6-O-sulphotransferase (6-
OST-1, 6-OST-2 and 6-OST-3) which transfer a sulphate group to the C6 position of 
the D-glucosamine units. The majority of the 6-O-sulphation reactions in most of 
tissues is through the action of 6-OST-1 (Habuchi et al. 2007). As for the other 
enzymes, 6-OST-1-3 display different substrate preferences, even though, ultimately, 
GlcNS are generally sulphated more than GlcNAc (Habuchi et al. 2000, Smeds et al. 
2003). 
The final but rarest step of Hp/HS chain modification consists of 3-O-sulphation of 
the D-glucosamine residues, performed by 3-O-sulphotransferases (3-OSTs), 
remarkably found as seven different isomers in vertebrates (Liu et al. 1999, Shworak 
et al. 1999). Each isoenzyme displays different substrate preferences, which impacts 
the synthesis of specific sequences necessary for some vital interactions of Hp/HS 
with proteins (Xia et al. 2002, Ding et al. 2005). The abundance of isoforms, their 
substrate specificities and the importance of such a transformation (e.g., for the 
interactions between Hp/HS with anti-thrombin III and herpes simplex virus) clearly 
indicate the importance of 3-O-sulphation pattern in the regulation of biological 
functions. 
1.5.1.4. Post-synthetic modifications 
Until recently, the enzymatic modifications described above were believed to be the 
only ones to occur and to shape Hp and HS polysaccharide chains. However, a study 
led by Dhoot et al. (2001) highlighted the role of a class of cell-surface enzymes in 
the biosynthetic pathway of Hp/HS. Two endosulphatases (Sulf-1 and Sulf-2) 
(Morimoto-Tomita et al. 2002) selectively remove 6-O-sulphate groups from N-
sulphated glucosamine residues (Ai et al. 2006, Lamanna et al. 2006). The 
importance of these enzymes has been re-evaluated, as new studies showed both the 
impact they have on the structure of the polysaccharides and their interactions with 
proteins (Lamanna et al. 2007). They have also been directly linked to cancers 
(Solari et al. 2014, Vicente et al. 2015). The enzymatic activity of Sulf-1 has been 
shown to decrease FGF binding (Wang et al. 2004), but to promote Wnt1 signalling 
(Dhoot et al. 2001). 
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1.5.2. Structural properties 
1.5.2.1. Structures 
Despite sharing the same biosynthetic pathway, Hp and HS are relatively distinct 
products (Table 2). Unlike the fairly homogeneous Hp chains (high level of 
sulphation: 2.0-3.0 sulphate groups/disaccharide unit) which mainly consists of 
repeats of the trisulphated disaccharide IdoA2S-GlcNS6S (Gallagher and Walker 
1985), HS chains display a higher degree of structural diversity (with a relatively low 
level of sulphation: 0.5-2.0 sulphate groups/disaccharide unit). These diverse 
structural compositions are explained by the incomplete synthetic activities of the 
enzymes, which are template-free driven. However, fairly recent studies have helped 
understand the underlying mechanisms regulating the whole process. 
Characteristics Heparan Sulphate (HS) Heparin (Hp) 
Site of synthesis Virtually all cells Mast cells 
Core protein Many Serglycin 
Cell membrane attached? Yes No 
Size 20-100 kDa 7-20 kDa 
Alternate NS/NA domains Yes Minimal 
Average 
sulphate/disaccharide 
0.5-2.0 2.0-3.0 
IdoA 20-50% ≥80% 
N-sulphate 30-60% ≥80% 
2-O-sulphate 10-40% ≥80% 
6-O-sulphate 10-40% ≥80% 
Binding to antithrombin 0-0.3% ~30% 
 
Table 2: Major differences between Hp and HS. Adapted from Xu and Esko 
(2014).  
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Theoretically, no less than 48 different disaccharides can be found in native Hp/HS. 
However, only 23 different disaccharides have yet been found to occur in nature 
(Esko and Selleck 2002). In vivo and in vitro studies have also shown that important 
structural changes can be observed depending on the nature, the maturity and the 
health state (healthy/disease) of the tissues (Maccarana et al. 1996, Cheng et al. 
2001, Netelenbos et al. 2001, Allen and Rapraeger 2003, Ledin et al. 2004). 
However, the structures of the HS extracted from the same tissues are consistent 
amongst individuals (Ledin et al. 2004). This suggests that the physical and chemical 
state of the Golgi and cellular environments have a direct impact on the biosynthetic 
outcome. Therefore, some kind of regulation must be ordering the whole process. 
Substrate specificities and incomplete activities of the enzymes are directly 
responsible for the formation of heterogeneous structures and the creation of domain 
structure. The selective and incomplete action of NDST in particular, which has been 
shown to act on the chain in both random and ordered fashions (Sheng et al. 2011), is 
mainly responsible for the presence of three types of domains found along the sugar 
chains (Figure 3).  
 
Figure 3: Schematic representation of the domain structures of Hp/HS 
polysaccharides.  The three types of domains that are found all along the 
polysaccharide chains are represented: the highly sulphated NS domains, the 
unmodified NA domains and the mixed NA/NS domains. D-GlcA: D-glucuronic 
acid; D-GlcNAc: N-acetyl-D-glucosamine; D-GlcNH: D-glucosamine; L-IdoA:  L-
iduronic acid. 
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The NS domains consist of repeating disaccharide units displaying N-sulphated units, 
whereas NA domains essentially contain unmodified N-acetylated disaccharide units, 
both delimited by transition structures containing alternating N-acetylated/N-
sulphated units (NA/NS domains) (Turnbull and Gallagher 1990, Maccarana et al. 
1996, Murphy et al. 2004). The layout and formation of those domains are still under 
investigation, even though noticeable advances have been made in this area (Murphy 
et al. 2004, Rudd and Yates 2012). The structure of the repeating disaccharide unit 
differs, depending on the domain type. NA domains are constituted of unsulphated 
disaccharide units and of GlcA residues only. On the contrary, NS domains are 
constituted of heavily sulphated disaccharide units. Therefore, the disaccharide unit 
IdoA2S-GlcNS represents the major repeating unit throughout the NS region (Merry 
et al. 1999). 2-O-sulphation is generally restricted to the IdoA units of the NS 
domains (Merry et al. 1999). 6-O-sulphation does not display such restrictions and 
may occur on both NS and NA/NS domains, even though it may not be automatically 
found in those regions. Finally, NS and NA/NS regions also contain the rare 3-O-
sulphated residues as well as the unsubstituted glucosamine residues at a very low 
rate (Van Den Born et al. 1995, Liu et al. 1999). These different domains, which are 
specific to HS, confer on these polysaccharides several structural (chemical and 
physical) properties, such as specific conformations or the presence of unusual 
sequences, and to a much higher extent than for Hp polysaccharides.  
1.5.2.2. Conformations 
Owing to their compositional differences, each domain found along the HS chains 
possesses its own structural characteristics. The three-dimensional properties of these 
GAGs are dictated by several parameters such as the nature of the saccharides, the 
presence and nature of functional groups as well as the glycosidic bonds. Based on 
the results obtained from solid experimental data (Nieduszynski et al. 1977, Gatti et 
al. 1979, Mulloy et al. 1993), the proposed helix conformation adopted by both Hp 
and HS polysaccharide chains, similar to the one adopted by nucleic acids, was 
initially thought to be rather rigid. However, Hp and HS are soluble polysaccharides, 
which indicates some flexibility. This flexibility can be explained by the interactions 
between the polysaccharides and molecular water (Almond and Sheehan 2003). 
Work published later showed that modified Hp polysaccharides actually display 
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some flexibility (Hricovini et al. 1995). Additional work identified that this 
flexibility is actually due to the highly sulphated NS regions, as the NA domains 
(which are mainly composed of GlcA-GlcNAc disaccharide units) have been shown 
to be relatively rigid (Hricovíni et al. 1997). D-glucosamine residues and D-
glucuronic acid units indeed adopt a rather rigid 
4
C1 ring conformation for steric 
hindrance reasons (Figure 4). Nuclear magnetic resonance (NMR) studies 
demonstrated that the flexibility of the NS domains is mainly caused by the IdoA2S 
units which display quite a high level of conformational plasticity as they oscillate 
between 
4
C1, 
1
C4 and 
2
SO forms - the two latter forms being generally preferred in 
polysaccharides (Sanderson et al. 1987, Ferro et al. 1990). The sulphation state of 
both IdoA units and the one of their adjacent monosaccharides has a direct impact on 
their conformational equilibrium (Ferro et al. 1990, Mulloy and Forster 2000). More 
specifically, all 2-O-, 3-O- and 6-O-sulphate groups have been shown to have an 
influence, up to a certain extent, on the ring conformation of the L-iduronic acid 
residues (Muñoz-García et al. 2012, 2013, Hsieh et al. 2016). These conclusions 
have yet been drawn from the study of isolated structures and more systematic 
studies are required. The sulphation of the D-glucosamine (GlcNS) and L-iduronic 
acid (IdoA2S) residues have been shown to be linked to the observed variations of 
the glycosidic linkages, unlike the 6-O-sulphate groups, which seemed to have much 
less impact (Rudd and Yates 2010). Moreover, it has been shown that the glycosidic 
bonds of the NS domains are less flexible than the ones of the NA domains. This 
relative rigidity is explained by the presence of the N-sulphate groups which tend to 
lock the GlcNS-IdoA(±2S) disaccharide units by forming a hydrogen bond with the 
hydroxyl group of the uronic acid moiety (Yates et al. 1996). Finally, the nature of 
the counter/coordinate ions can also alter the conformations of the polysaccharide 
chains and therefore their activity (Ayotte and Perlin 1986, Rabenstein et al. 1995, 
Rudd et al. 2007). 
1.6. HS structures in biology: HS-protein interactions 
Owing to their intrinsic properties (wealth of structures, polyionic properties, chain 
flexibility, structural conformations, etc.), HS possesses the ability to interact with a 
vast interactome, comprising hundreds of protein ligands. These interactions are of 
upmost importance and regulate a broad variety of biological functions (Ori et al. 
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2008). Many of these interactions remain a mystery regarding their biological 
importance. This is mainly due to the difficulties encountered by researchers aiming 
to decipher the interactions of such complex polysaccharides with their ligands, even 
though many advances have been made (Xu and Esko 2014).  
 
Figure 4: Conformational structures of the monosaccharide units found in 
Hp/HS.  Unlike both D-glucuronic acid and D-glucosamine residues, which are 
locked in 
4
C1 conformation, L-iduronic acid residues oscillate between 
4
C1, 
1
C4  
and 
2
SO forms. D-GlcNS6S: N-,6-O-disulphated-D-glucosamine; D-GlcA: D-
glucuronic acid; L-IdoA2S: 2-O-sulphated-L-iduronic acid. 
 
1.6.1. HS-protein binding: basic principles and structural 
requirements for the HS chains and the ligands 
Prior to triggering any biological activity, the HS chain must be put in contact with 
its ligands. This first binding step is thought to be mainly driven by electrostatic 
forces between the anionic groups at the surface of the carbohydrate chains (sulphate 
and carboxylate groups) and the amino acids of the proteins bearing cationic charges 
(arginine and lysine) (Rabenstein 2002). Proteins interacting with HS often bear a 
charged sequence called HS-binding domains (HSBD), which has been the subject of 
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many studies. Cardin and Weintraub (1989) were first to investigate the structural 
features required for GAG-protein interactions. The comparison of a set of heparin-
binding sequences from several proteins led to the first identification of two 
consensus sequences XBBXBX and XBBBXXBX where B represents a basic amino 
acid and X represents a hydropathic residue (neutral or hydrophobic). Further 
studies, conducted by Sobel et al. (1992) and Hileman et al. (1998), led to the 
identification of two other consensus sequences: XBBBXXBBBXXBBX and 
TXXBXXTBXXXTBB, for the von Willebrand factor and for growth factors 
respectively (T represents a turn). However, these rigid linear models do not 
universally fit all HS-protein interactions, suggesting that other HSBD architectures 
are possible, such as the spatial distribution of basic amino acids along longer linear 
sequences that, when the protein is folded, provide residues close in the tertiary 
protein structure, as suggested by Spillmann and Lindahl (1994). The proposed 
helical nature of HS chains leads to the projection of its negatively charged moieties 
out of the backbone towards the protein residues (Casu 1979). These anionic 
moieties could hence interact with amino acids from juxtapositioned loops.  
At the saccharide level, the protein-binding domain sizes often vary from a few 
disaccharides (such as the prototypic antithrombin-binding pentasaccharide) up to 
dodecasaccharides. Sometimes, even longer domains are needed (Spillmann et al. 
1998, Gallagher 2001), as first indicated for binding of HS to interferon-γ (Lortat-
Jacob et al. 1995).  
Importantly, once the HS chain and the protein interact, conformational changes may 
be observed on both polysaccharide and protein levels (Faller et al. 1992, Skinner et 
al. 1997, Guimond et al. 2009, Li, Sun, et al. 2016). Earlier work claimed that the 
changes induced were actually negligible on the protein scale, but these results were 
based on X-ray experiments (Faham et al. 1996). The free energy released by these 
conformational changes is part of the total energy involved in the binding 
mechanism. Along with the electrostatic forces, other forces are believed to modulate 
the interactions. Thompson et al. (1994) showed that solely 30% of the binding free 
energy derives from electrostatic forces in the case of Hp polysaccharides interacting 
with FGF2. Other factors such as van der Waals’ forces and hydrogen bonding 
(Hileman, Jennings, et al. 1998) or even the interactions with the hydrophobic amino 
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acids adjacent to the HSBD (Jairajpuri et al. 2003) are believed to take part in the 
binding process. 
1.6.2. On the specificity/selectivity in HS-protein interactions 
Owing to the apparently controlled biosynthesis of HS polysaccharides and its 
resulting consequences (presence of structural domains, tissue specificity of the 
polysaccharide chain compositions - see Section 1.5.2.1), a high degree of 
specificity/selectivity could, on the face of it, be expected for the interactions of these 
polysaccharides with proteins. The partial and specificity-based activities of the 
enzymes suggest that some sequences could be preferentially synthesised, implying 
that HS-protein interactions could be sequence-specificity driven. HS-anti-thrombin 
III (AT-III) interaction is often referred as the example which endorses this 
hypothesis as it has been shown, originally in the 1900’s, to require the well-defined 
DEFGH pentasaccharide sequence to take place (reviewed in Petitou et al. (2003)). 
Any alteration to this pentasaccharide sequence results in significant binding and 
functional defects (Desai et al. 1998, McKeehan et al. 1999, Petitou et al. 2003). By 
way of example, Petitou et al. (1988) claimed that the rare 3-O-sulphate group borne 
by the F residue is of critical importance. However, these types of studies, meant for 
finding binding sequences, are often restricted in terms of sequences that are actually 
screened in the salt-based screens generally used. They also tend to find the most 
avid binders, which are usually the most highly charged saccharides. However, low 
sulphated structures have also been shown to fairly strongly interact with proteins 
(Yates et al. 2004, Duckworth et al. 2015). Other AT-binding sequences have also 
since been identified (Guerrini, Guglieri, et al. 2008, Guerrini et al. 2013). Another 
interesting example is the case of HS interacting with herpes simplex virus 1 (HSV 
1). Studies conducted to determine the minimal HS-binding sequence provided 
evidences suggesting that an octasaccharide sequence is needed to induce the 
infection of the target cell (Copeland et al. 2008). A high-specificity interaction has 
not yet been fully established for HSV 1 (Liu et al. 2002, Copeland et al. 2008). 
At the very opposite of its high-specificity interaction with AT-III, HS interacts with 
the counterpart thrombin in a more non-specific manner, requiring simply a highly 
sulphated saccharide sequence (Olson et al. 1991).  Other studies showed that 
Chapter 1 – Background 
17 
 
distinct HS sequences may interact with a protein with comparable affinities, 
showing that unique sequences are not always needed for protein-binding and 
biological activity (Ashikari-Hada et al. 2004, Zhang, Zhang, et al. 2009, Rudd et al. 
2010). These findings indicate a broad range of relative selectivities. Salmivirta et al. 
(1996) however proposed that a few common residues arranged in a specific order 
may provide specificity/selectivity to HS-protein interactions as well. These epitopes 
would however be masked in the whole HS or Hp chain, thus explaining why some 
proteins might appear to interact with HS in a “non-specific” manner. Thus, Hp may 
bind to many ligands, yet the minimum binding sites are cryptic within its highly 
sulphated sequences. This could at least apply in cases where excess sulphation does 
not inhibit binding. 
Owing to the lack of template-regulated biosynthesis, the synthesis of long very 
specific sequences appears unlikely. Instead, more discrete sequences and specific 
structural features could be more easily produced compared to whole sequences. The 
presence of such unusual residues may be the key aspect of specificity/selectivity in 
HS-protein interactions. This view is supported by the presence of very specific and 
rare structural modifications, such as 3-O-sulphations or unsubstituted glucosamines. 
As mentioned above, the 3-O-sulphate group is a vital feature for interaction with 
both AT-III and HSV 1. In the case of HSV 1, evidence suggest that an 
octasaccharide sequence bearing a 3-O-sulphate (Shukla et al. 1999, Tiwari et al. 
2005, O’Donnell et al. 2006) as well as an N-unsubstituted  D-glucosamine residue 
(Liu et al. 2002), is required to induce the infection of the target cell. The 
interactions of HS with L-selectin and Cyclophilin B, as other examples, have also 
been linked to the presence of these unusual residues (Norgard-Sumnicht and Varki 
1995, Vanpouille et al. 2007).  
According to the accumulation of data obtained in recent decades (as illustrated by 
the examples given above), there is little evidence that HS recognise their targets 
with high specificity through entire long sequences. The view that HS-protein 
interactions are regulated by the specific spatial distribution of the sulphate groups 
only, as assumed by some groups (Kreuger et al. (2001), Nakato and Kimata (2002), 
Gama et al. (2006) and Lamanna et al. (2007) to name a few), is also compromised. 
An appreciation of the HS polysaccharide structures should not be confined to their 
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primary and linear structural layout and substitution patterns only. Instead, the three-
dimensional aspect should be appraised, as well as the impact of the saccharides’ 
direct environment on their architecture and behaviours. The role of many factors 
such as the chain flexibility and plasticity (Casu et al. 1988, Mulloy and Forster 
2000, Solari et al. 2015), the domain organisation of the HS chains (Kreuger et al. 
2002), the counter/coordinated ions (Hileman, Fromm, et al. 1998, Guimond et al. 
2009), the solvent (Hricovíni 2011, Li et al. 2014) or even the specificities of the 
HSBDs of the ligands (Mosier et al. 2012) should hence be taken into account. As an 
example, the different conformations adopted by the L-iduronic acid residues, which 
are found in all characterised HS binding sites, allow the sulphate and carboxylate 
groups as well as the hydroxyl hydrogens to be presented to the amino acids in 
different ways in order to favour stronger electrostatic interactions (Das et al. 2001, 
Raman et al. 2003). However, these factors should not be considered separately, as 
they may depend on factors such as the L-iduronic acids’ plasticity and the sulphation 
pattern (Hsieh et al. 2016). The investigation of the physico-chemical attributes of 
these GAGs may also offer a subtler view. Seyrek and Dubin (2010) recently 
suggested that glycosaminoglycans should be considered as polyelectrolytes, owing 
to their polyanionic nature. By doing so, many aspects, such as the role of non-
specific electrostatic forces (Raman et al. 2003, Seyrek et al. 2007), the charge 
density of the GAGs (Meneghetti et al. 2015) and the nature and concentration of the 
ionic environment (Seyrek et al. 2003) for example, should be considered in the 
recognition process. All the factors cited above are believed to have an impact on 
both binding and biological activation pathways, as they also do for the coordinated 
ions which have been shown to alter both the structural properties of the ligands and 
the biological function (Rudd et al. 2007, Guimond et al. 2009). However, it should 
be noted that high affinity binding does not always imply high functional activity 
even though both phenomena appear to be regulated by similar rules (some binding 
sequences may be inhibitory, for example, as shown by Ashikari-Hada et al. (2009)). 
In light of what is discussed above, it clearly appears that the notion of 
specificity/selectivity is still being debated and finding a definitive answer to this 
question necessitates further investigation. As an example, understanding the exact 
biosynthesis pathway of Hp/HS could be a first step to decipher the nature of natural 
variation in HS that underpins its interactions with ligands. Alternatively, the study 
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of HS Structure Activity Relationship (SAR), with well-defined HS saccharides, 
would clearly be expected to lead to new insights. 
1.7. HS-FGF-FGFR interactions 
1.7.1. Fibroblast Growth Factors 
The fibroblast growth factor (FGF) family is a family of small extracellular 
signalling peptides (~150-300 amino acids in total, between 17 and 34 kDa) which 
all share a core domain of ~120-130 amino acids, with 28 and 6 highly conserved 
ones and invariant amino acids respectively (Ornitz 2000, Itoh and Ornitz 2004). 
FGFs are found in both vertebrates and invertebrates and a total of twenty-two 
members (FGF1-FGF23) have been identified in humans and mice - considering that 
FGF19 is the human homolog to the rodent FGF15 (Ornitz and Itoh 2001). The 
human proteins are classified into seven subfamilies according to their structural 
homologies, as well as their biochemical and developmental properties (Figure 5) 
(Oulion et al. 2012). In addition, they can also be divided into two major groups, 
according to their mode of action/secretion: the secreted signalling group and the 
intracellular non-signalling group (Ornitz and Itoh 2015). The secreted signalling 
group comprises both paracrine (FGF1-FGF10, FGF16-18, FGF20 and FGF22) and 
endocrine factors (FGF19, FGF21 and FGF23). The intracellular non-signalling 
group comprises of the rest of the factors (FGF11-14, also called fibroblast growth 
factor homologous factors (FHFs)). FHFs’ members do not signal through a tyrosine 
kinase receptor unlike the secreted FGFs (Olsen et al. 2003). Instead, they target and 
regulate the intracellular voltage-gated channels (Goetz et al. 2009).  
 
Chapter 1 – Background 
20 
 
 
Figure 5: Phylogenetic tree of human FGF family . FGFs are divided into 
three main groups: the paracrine, endocrine and intracrine FGFs which interact 
with Hp/HS with high, moderate or no affinity, respectively. Adapted from Itoh 
and Ornitz (2011) with permission of Oxford University Press.  
 
FGFs have been shown to be involved in and to regulate a broad spectrum of 
biological processes, including developmental and physiological processes, such as 
cellular proliferation and migration (Wesley et al. 2005), survival (Bouleau et al. 
2005), differentiation (Spivak-Kroizman, Mohammadi, et al. 1994), morphogenesis 
(Qiao et al. 1999) as well as tissue homeostatis (Yamashita et al. 2002), wound 
healing (Mellin et al. 1995), and angiogenesis (Ornitz and Itoh 2001). The 
development of many organs also strongly relies on the signalling of FGFs (Park et 
al. 1998, Robinson 2006, Bates 2007). The importance of FGFs for the integrity of 
the organisms has been shown by many genetic studies (Itoh and Ornitz 2011). The 
phenotypes displayed by the knockout mice range from lethality to changes of the 
physiology of the adult individuals for the majority of the factors (Table 3) (Powers 
et al. 2000). Under normal laboratory conditions, FGF1 knockout mice do not 
display any significant phenotype as they are viable and look normal (Miller et al. 
2000). Jonker et al. (2012) recently showed that FGF1 is intimately induced in 
adipose tissues. Moreover, diverse studies have shown that an aberrant signalling of 
FGFs also leads to diverse human pathologies (Beenken and Mohammadi 2009) such 
as cancer (Jorgen et al. 2011), but also Michel aplasia hereditary disease (Tekin et al. 
2007) or even phosphate wasting disorders (White et al. 2000), to name a few. 
Chapter 1 – Background 
21 
 
FGF Phenotype of knockout mouse Physiological role 
FGF1
*
 
Diabetes; aberrant adipose 
expansion (high-fat diet conditions) 
Adipose remodelling; metabolic 
homeostasis 
FGF2 
Loss of vascular tone; slight loss of 
cortex neurons 
Not established 
FGF3 Inner ear agenesis in humans Inner ear development 
FGF4 Embryonic lethal 
Cardiac valve leaflet formation; 
limb development 
FGF5 Abnormally long hair Hair growth cycle regulation 
FGF6 Defective muscle regenration Myogenesis 
FGF7 
Matted hair; reduced nephron 
branching in kidney 
Branching morphogenesis 
FGF8 Embryonic lethal 
Brain, eye, ear and limb 
development 
FGF9 
Postnatal death; gender reversal; 
lung hypoplasia 
Gonadal development; 
organogenesis 
FGF10 Failed limb and lung development Branching morphogenesis 
FGF16 Embryonic lethal Heart development 
FGF17 Abnormal brain development 
Cerebral and cerebellar 
development 
FGF18 Delayed long-bone ossification Bone development 
FGF19 Increased bile acid pool 
Bile acid homeostasis; lipolysis; 
gallbladder filling 
FGF20 No knockout model Neurotrophic factor 
FGF21 No knockout model 
Fasting response; glucose 
homeostasis; lipolysis and 
lipogenesis 
FGF22 No knockout model Presynaptic neural organiser 
FGF23 
Hyperphosphataemia; 
Hypoglycaemia; immature sexual 
organs 
Phosphate homeostasis; vitamin D 
homeostasis 
 
Table 3: Physiology of FGFs. Adapted from Beenken and Mohammadi (2009) , 
with permission of Oxford University Press. 
*
:  see (Jonker et al. 2012) 
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1.7.2. Fibroblast Growth Factor Receptors 
The FGF receptors (FGFRs) are essential for the secreted FGFs to signal (Coughlin 
et al. 1988, Lee et al. 1989). A total of five genes encoding for the FGFRs have been 
identified in mammals (Ornitz and Itoh 2015): four which encode for the tyrosine 
kinase receptors (FGFR1-4, ~800 amino acids) and one which encodes for the non-
tyrosine kinase receptor (FGFR5, ~500 amino acids) (Wiedemann and Trueb 2000). 
The tyrosine kinase receptors consist of two distinct parts, separated by a 
transmembrane domain (TM). The extracellular part is composed of a cleavable 
signal peptide (S), followed by three immunoglobulin (Ig)-like domains (IgI-III) with 
an acid box situated between Ig-I and Ig-II, a Hp-binding site and a cell adhesion 
molecule (CAM) homology domain (CHD). The intracellular part comprises of a 
juxtamembrane region (JM), a split tyrosine kinase (TK) domain separated by a 
kinase insert domain (KI) and a C-terminal tail (CT) (Figure 6) (Mohammadi et al. 
2005).  
 
 
 
Figure 6: Schematic representation of the FGFR structure. 
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Several splice variants naturally occur for each variant, except for FGFR4 (Ornitz 
and Itoh 2015), and  their tissue-specific expression has been demonstrated (Fernig 
and Gallagher 1994). The splicing isoforms differ in their extracellular part, and thus 
display relatively specific ligand interaction properties (Table 4) (Ornitz et al. 1996, 
Eswarakumar et al. 2005, Zhang et al. 2006).  One main splicing event leads to 
receptors lacking the Ig-I domain (Johnson et al. 1991). However, the major splicing 
event occurs at the Ig-III domain level and leads to the formation of three types of 
isoforms. The first of those variants, called Ig-IIIa, codes for a secreted FGF-binding 
protein which terminates in the Ig-III domain (Duan et al. 1992). The two other 
splice variants, namely Ig-IIIb and Ig-IIIc, are of upmost importance as they 
determine the ligand-binding properties of the receptors (Ornitz and Itoh 2015). 
FGF-FGFR specificity has been investigated, mainly with the help of BaF3- and L6 
myoblast-based bioassays. FGF1 was found to signal through all receptors whereas 
some FGFs signal solely through a specific receptor (Table 4). The HS-mediated 
signalling process is carried out in a cascade manner and starts with the recruitment 
of the secreted signalling protein which next binds and induces the receptor 
dimerisation, causing the autophosphorylation of the TKs domain. These first steps 
trigger successive phosphorylation steps of intracellular substrates, constituting the 
intracellular transduction signal (Ornitz and Itoh 2015).  
As for their counterparts the FGFs, FGFRs have been thoroughly investigated in 
genetic studies (Eswarakumar et al. 2005). As for FGFs, the targeted disruption of 
specific receptor splice variants causes several phenotypes, ranging from lethality 
(Yamaguchi et al. 1994, Xu et al. 1998) to viable and normal individuals (Partanen et 
al. 1998). Mutations have also been shown to be involved in several human diseases 
(Ornitz and Itoh 2015), notably in Pfeiffer, Crouzon (Rutland et al. 1995) and Apert 
syndroms (Wilkie et al. 1995), but also dwarfism (Eswarakumar et al. 2002) and 
cancer (Jorgen et al. 2011). 
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  FGFR 
  1b 1c 2b 2c 3b 3c 4 
P
a
ra
cr
in
e 
FGF1 • • • • • • • 
FGF2 • •  •  • • 
FGF3 •  •     
FGF4  •  •  • • 
FGF5  •  •    
FGF6  •  •   • 
FGF7   •     
FGF8    •  • • 
FGF9  •  • • • • 
FGF10 •  •     
FGF16    • • • • 
FGF17  •  •  • • 
FGF18    •  • • 
FGF20  • • • • • • 
FGF22 •  •    • 
E
n
d
o
cr
in
e FGF19  •  •  • • 
FGF21  •  •  • • 
FGF23  •  •  • • 
 
Table 4: Ligand specificity of the FGF receptor family (Ornitz et al. 1996, 
Eswarakumar et al. 2005, Zhang et al. 2006).  
  
1.7.3. Role of HS in FGF signalling 
FGF signalling requires the involvement of many regulating cofactors. Paracrine 
FGFs display a relatively strong affinity towards Hp and HS, unlike endocrine FGFs 
and FHFs which display very low or no affinity (Asada et al. 2009). Endocrine FGFs 
require the action of protein cofactors to signal, all members of the Klotho protein 
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family (Kuro-o 2012) whereas FHFs do not interact with HS. Since the pioneering 
work of Klagsbrun and Baird (1991), Rapraeger et al. (1991) and Yayon et al. (1991) 
who established the role of HS as a cofactor, the complexes FGF1-FGFR2 and 
FGF2-FGFR1 have served as archetypes to determine the features inherent to the 
interactions between the signalling protein and its receptor. Despite two decades of 
investigation using biochemical and crystallographic studies, the exact mechanism is 
still debated (Pomin 2016).  
In the early nineties, Yayon et al. (1991) suggested that HS binding to FGF2 was 
leading to conformational changes of FGF2 into a receptor-compatible - therefore a 
biologically active - conformation of FGF2. Many studies conducted the following 
years did not yet corroborate this model (Roghani et al. 1994, Springer et al. 1994, 
Faham et al. 1996). Even though conformational changes occur upon interaction 
between the saccharides and FGF (as previously described in Section 1.6.1), other 
studies showed that HS must bind both FGF and FGFR (Guimond et al. 1993) to  
lead to their dimerisation/oligomerisation - the dimerisation of the receptor then 
triggering the signal transduction (Kan et al. 1993, Spivak-Kroizman, Lemmon, et al. 
1994, DiGabriele et al. 1998). These assumptions were later verified with the help of 
co-crystallography studies of the ternary complexes (Pellegrini et al. 2000, 
Schlessinger et al. 2000). These two studies concurrently led to two conflicting 
models to explain the molecular interactions between the three entities, even though 
other models have been proposed as well (Mohammadi et al. 2005).  
These models mainly differ in their architectures, the molecular assembly 
mechanism, the stoichiometry of the entities, the attributes of the molecular 
interactions and the role of the Hp/HS oligosaccharide. Schlessinger et al. (2000) 
described and studied the crystal structure resulting from the manual combination of 
the crystallographic data of the FGF2-FGFR1 complex with the ones of Hp 
oligosaccharides. Based on data previously collected (Plotnikov et al. 1999), they 
reasoned that Hp/HS oligosaccharides interact with FGF2 and FGFR1 through the 
positively charged canyon formed during the assembly of the signalling protein and 
its receptor. The authors therefore suggested that a stable but biologically inactive 1-
1-1 FGF2-FGFR1-Hp/HS ternary complex is first assembled. The recruitment of a 
second 1-1-1 complex follows this first step and results in the critical dimerisation of 
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the receptor, thus allowing the formation of the symmetric and biologically active 2-
2-2 entity (Figure 7). This symmetric model is characterised by the critical role 
played by the non-reducing ends of the oligosaccharides which tightly hold each 
FGF2-FGFR1 monomer together, as well as the physical contact between the two 
receptor Ig-II domains, unlike in the asymmetric model proposed by Pellegrini et al. 
(2000). Pellegrini et al. (2000) studied the crystal structures they obtained after co-
crystallisation of a 2-2-1 stoichiometric ratio mixture of FGF1-FGFR2c-Hp 
decasaccharide. The authors suggested in this case that, after encounter and assembly 
of the three entities, Hp induces the dimerisation of FGF1, thus leading to the 
formation of the biologically inactive 2-1-1 FGF1-FGFR2c-Hp complex. This 
complex next recruits a second FGFR2c, necessary for receptor dimerisation, to 
ultimately form the asymmetric 2-2-1 ternary complex (Figure 7). In this model and 
in the absence of any protein-protein interaction, the two monomeric halves of the 
complex are held together by the Hp/HS oligosaccharide only. Hp/HS thus plays the 
role of a “molecular bridge” between the two halves of the ternary complex and 
displays strong interactions with only the first monomer of the complex but none 
with the second receptor. The main architecture differences observed between these 
two models are due to the cis- or trans-conformation of the invariant proline of the 
Ig-II/Ig-III linker region of the receptors (Mohammadi et al. 2005). The orientation 
of the Ig-III domains - and thus their interactions with FGFs and Hp/HS - indeed 
depends on the conformation adopted by this proline residue. It should however be 
noted that these works were conducted using highly sulphated Hp oligosaccharides, 
and not with lower sulphated HS saccharides.  
Since the publication of these studies, many works have been carried out to identify 
which architecture is preferred in vivo. Each work, based on the combination of 
several experimental procedures (including analytical ultracentrifugation, bioassays, 
isothermal titration calorimetry, mass spectrometry, mutational studies, nuclear 
magnetic resonance, size-exclusion chromatography, three-dimensional cell 
microarray to name a few) has provided conflicting experimental evidence but most 
support the symmetric model (Harmer et al. 2004, Ibrahimi et al. 2005, Brown et al. 
2013, Nieto et al. 2013, Sterner et al. 2014). Harmer et al. (2004) and Goodger et al. 
(2008), however, suggested the existence of both models in solution. They suggested 
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that these findings might be relevant in vivo as well, and thus constitute proof of the 
existence of several FGF signalling states. 
 
 
Figure 7: Schematic representation of the formation of the two main FGF-
FGFR-HS ternary complexes in competition: (a) the 2-2-1 asymmetric 
model and (b) the 2-2-2 symmetric model.  
(a) The dimerisation of FGF occurs first and results in the formation of the 2 -1-
1 complex. The receptor dimerisation occurs next and results in the formation 
of the biologically complex 2-2-1. 
(b) The stable 1-1-1 complex is formed first. Both FGF and FGFR 
dimerisations result from the recruitment of another 1 -1-1 complex and lead to 
the formation of the biologically active 2 -2-2 complex. 
FGF: fibroblast growth factor; FGFR: fibroblast growth factor receptor; Hp: 
heparin; HS: heparan sulphate; Ig: immunoglobulin-like domain. 
 
1.7.4. HS specificity/selectivity in FGF-FGFR systems 
Owing to the architecture adopted by the protein complexes, FGF signalling requires 
oligosaccharides long and flexible enough to connect both the signalling proteins and 
the receptors. Ornitz et al. (1992) first showed that octasaccharides were the 
minimum size required to induce significant biological activity. These findings were 
(a) 
(b) 
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supported by studies carried out later (Mach et al. 1993, Fromm et al. 1997). 
However, other groups later showed that even shorter Hp oligosaccharides (down to 
disaccharides) may be able to induce FGF signalling, even though their mitogenic 
activities were relatively weak (Tyrrell et al. 1993, Ornitz et al. 1995, Delehedde et 
al. 2002, Ostrovsky et al. 2002, Guglieri et al. 2008, Zhang, Zhang, et al. 2009). 
Furthermore, they also showed that the results obtained were dependent on the FGF-
FGFR complex studied (Gambarini et al. 1993, Ornitz et al. 1995, Pye et al. 2000, 
Ye et al. 2001, Delehedde et al. 2002, Ostrovsky et al. 2002). Therefore, no 
consensus has yet been reached about the minimal size for FGF signalling.  
The structural characteristics of the saccharides that are required for optimal binding 
and biological activity also remain rather unclear. As for the majority of the proteins 
interacting with HS, the notion of specificity/selectivity in HS-FGF-FGFR 
interactions is a matter of extensive debate. Over the years, two major concepts have 
been developed to address the notion of specificity/selectivity in HS-FGF-FGFR 
interactions. The first concept suggests that there is indeed a link between the 
discrete and subtle structural properties of the HS polysaccharides and their ability to 
activate the protein complexes (Guimond and Turnbull 1999, Pye et al. 2000, Nakato 
and Kimata 2002). On the other hand, other groups have suggested that the 
interactions largely depend on the general structural layout of the glycans and not on 
their subtle structural differences (Kreuger et al. 2005, Jastrebova et al. 2006).  
Conflicting paradigms and views can be illustrated with the research surrounding the 
minimal FGF binding motif. Similarly to AT-III, the existence of binding domain, 
criterion of high-specificity interactions, was first being postulated. Turnbull et al. 
(1992) first reported the characterisation of the binding domain for FGF2 in the 
literature. The authors determined that the binding sequence was comprised of seven 
disaccharides and was enriched of the minimal Ido2S-GlcNS disaccharide unit – 
results supported by other studies (Maccarana et al. 1993, Ishihara 1994, Walker et 
al. 1994, Kreuger et al. 1999). They next exposed the dependence of FGF1 towards 
6-O-sulphate groups and the dependence of FGF2 towards 2-O-sulphate groups for 
binding. The latter results were also observed by other groups (Turnbull et al. 1992, 
Maccarana et al. 1993, Ashikari-Hada et al. 2004, Yuguchi et al. 2005). As for AT-
III and HSV 1 (see Section 1.6.2), 3-O-sulphate groups have been suggested to be of 
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critical importance for HS oligosaccharides to bind FGF7 and induce its signalling 
(Capila and Linhardt 2002, Luo et al. 2006a, 2006b). Ye et al. (2001) also showed 
that this type of sulphate groups is able to protect FGF7 from proteolysis as well, 
thus illustrating the importance of this unusual residue.  
All these studies helped reveal that specific structural determinants are required for 
each FGF-FGFR system, on both protein binding and FGF signalling levels 
(Guimond et al. 1993, Ishihara 1994, Pye et al. 2000, Ye et al. 2001, Allen and 
Rapraeger 2003, Ashikari-Hada et al. 2004, Luo et al. 2006a). The existence of this 
minimal FGF binding site is still discussed in light of other results reported in the 
literature. Other research groups indeed showed that distinct HS sequences may 
interact with a protein with comparable affinities, demonstrating that unique 
sequences are not always needed for protein-binding and biological activity 
(Ashikari-Hada et al. 2004, Zhang, Zhang, et al. 2009, Yu et al. 2014). Other groups 
also attempted the re-investigation of this binding domain and its structural 
characteristics. They came to the conclusion that other sequences may bind FGF with 
high-affinity and that FGF proteins share binding sites in HS oligosaccharides 
(Kreuger et al. 2001, 2005, Ye et al. 2001, Guerrini et al. 2002, Guglieri et al. 2008). 
These findings therefore challenge the notion of exquisite specificity of HS-FGF-
FGFR interactions.  
The two concepts described above mainly rely on the notion of spatial distribution of 
the ionic charges (sulphate and carboxylate groups) alongside the saccharide chain. 
However, despite the important role played by the sulphate groups in HS-FGF-FGFR 
interactions, low sulphated oligosaccharides have also been shown to be good 
activators (Guimond and Turnbull 1999, Powell et al. 2004, Ahmed 2010). Other 
parameters are now believed to be implicated in the process as well, such as the 
plasticity of both oligosaccharide chains and specific monosaccharide residues 
(particularly the L-iduronic residues) (Raman et al. 2003, Solari et al. 2015) or the 
nature of the coordinated ions (Rudd et al. 2007, Guimond et al. 2009). 
Unsurprisingly, the exclusive presence of flexible L-iduronic acid residues in Hp/HS 
oligosaccharides has then been shown to be important for high-affinity interactions 
between the oligosaccharides and FGF2 (Kovensky et al. 1996, 1999). Guglieri et al. 
(2008) suggested that the plasticity displayed by the L-iduronic acid residues may be 
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able to compensate the micro-changes induced by subtle modifications of the 
sulphation pattern. Later, Rudd and Yates (2010) showed that not all sulphate groups 
are equivalent in terms of effects on the linkage variations, so affect local chain 
conformation differently. Finally, it has been found that HS can play the role of both 
positive and negative regulators, with some saccharides identified in a screen either 
activating or inhibiting FGF2 signalling or showing neutral activity (Guimond and 
Turnbull 1999).  
1.8. Tools for HS-FGF-FGFR interactions studies 
In light of the importance of Hp and HS in biological events (Capila and Linhardt 
2002), it then quickly appeared necessary to develop biochemical and biophysical 
tools to study both these GAGs and their interactions with their ligands. Every tool 
can help to answer a specific biological question and presents its benefits and 
limitations (such as the cost, the rapidity to run experiments or the time needed to 
analyse the results, the biological relevance of the results, etc.). Each of these aspects 
must be taken into account in the process of selection. The combination of several 
methods offers a better overview of the biological problem. It must however be noted 
that the results obtained with in vitro and in vivo measurements may greatly differ. 
Reproducing the conditions found in vivo (which are often known in vague terms) is 
nearly impossible due to the complexity of the biological systems that are usually 
studied. In the case of the study of HS-FGF-FGFR interactions, the density, 
concentration and distribution of all interacting elements (the signalling proteins, the 
receptors and all other elements such as ions) found at the in vivo level can hardly be 
reproduced in vitro. Different techniques used to study the interactions between HS, 
FGF and FGFR are briefly discussed in the following sections. The tools used for the 
preparation of libraries of HS oligosaccharides are discussed first, followed by those 
used for the structural analysis and the characterisation of the oligosaccharides. The 
final section will consider the tools applied to the study of the interactions of the 
saccharides with their protein ligands at a biological level. 
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1.8.1. Library production methods: HS oligosaccharides from 
natural sources 
1.8.1.1. Extraction of HS from natural sources 
The relatively cheap and commercially available Hp has often been preferred over 
HS as a model for studying Hp/HS-protein interactions. The results obtained are then 
usually extrapolated to the case of HS. However, due to the structural differences 
between Hp and HS, the results may be biased. Access to HS oligosaccharide 
libraries thus appears to be of crucial importance. This has been made possible by the 
development of techniques of extraction of HS polysaccharide chains from natural 
sources, mainly from mammals (porcine or bovine origins) (Oduah et al. 2016). The 
extracted polysaccharide chains then usually undergo partial digestion - either by 
chemical (Shively and Conrad 1976) or enzymatic methods (Linhardt et al. 1990) - 
followed by purification steps and even chemical modifications in some cases 
(Kariya et al. 2000).  
Over the years, Hp and HS structures extracted from natural sources have been of 
great help in answering a multitude of important biological questions, notably the 
underlying characteristics regulating HS-protein interactions (Pellegrini et al. 2000, 
Petitou et al. 2003, Robinson et al. 2006) and the natural distribution of the 
saccharides in tissues (Maccarana et al. 1996, Cheng et al. 2001, Netelenbos et al. 
2001, Ledin et al. 2004). Extraction from natural sources ideally offers the possibility 
of accessing a large variety of structures from a single starting batch. However, the 
amounts of structures that are generally obtained are rather low (usually at the µg 
scale). The depolymerisation of the chains results in highly structurally 
heterogeneous mixtures, which then require intensive use of purification methods to 
obtain pure single structures. The purification steps also cause a significant loss of 
material. Besides, the full structural characterisation of isolated carbohydrates is only 
possible during the very last steps of the whole purification process, which makes the 
isolation of structures of interest, displaying specific sulphation patterns, virtually 
impossible. In addition, the purity of the material extracted from natural sources may 
be compromised and go unnoticed. For example, the “2008 Chinese heparin crisis”, 
which consisted of severe contamination of the Hp supplies by chemically-modified 
CS polysaccharides, resulted in acute allergic reactions of patients and ultimately led 
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to more than 200 deaths (Guerrini, Beccati, et al. 2008). The contamination went 
unnoticed because of the limitations of the screening tests that were being used at the 
time. The extraction from other sources such as invertebrates has since been 
suggested, even though these GAGs may differ from the mammalian ones on the 
structural level (Pomin 2015). 
1.8.1.2. Partial digestion of native HS polysaccharide chains 
The first step of the preparation of libraries of HS oligosaccharides consists of the 
degradation of native HS polysaccharide chains into fragments of smaller sizes. This 
step can be performed by enzymatic digestion, as described below. Other methods 
such as chemical digestion (Shively and Conrad 1976) or even radical degradation 
fragmentation are also possible (Kennett and Davies 2009, Higashi et al. 2012).  
Three different enzymes, expressed from Flavobacterium heparinum and named 
heparinase I-III (also known as heparin lyase I-III or even heparitinase III-I, 
respectively), are commonly used to enzymatically digest native Hp and HS chains. 
These enzymes cleave the glycosidic bond between uronic acid and glucosamine 
residues, as illustrated in Figure 8. The combination of the three enzymes can lead to 
the near-complete degradation of the chains into disaccharide residues. The 
enzymatic elimination reactions result in the formation of an intact D-glucosamine 
residue at the reducing end of the chain and an unsaturated uronic acid residue at the 
non-reducing end. This double bond which absorbs at λABS = 232 nm makes the 
detection of the oligosaccharides by chromatography relatively easy to perform. Each 
enzyme possesses its own substrate specificities, as described in Figure 8 (Linhardt et 
al. 1990). The partial digestion hence affords heterogeneous mixtures of 
oligosaccharides of different even-numbered length.  
1.8.1.3. Methods of purification of HS oligosaccharide mixtures 
Pure single Hp/HS structures are often considered the ultimate tools with which to 
study details of the biological processes. Nowadays, the access to these structures 
still remains hampered by diverse technical difficulties, such as the lack of selective 
and sensitive methods of purification for both isolation and analytical analyses.  
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Figure 8: Cleavage specificity of heparinases and resulting products from 
the cleavages. Enzymatic digestion of HS saccharides results in the formation 
of an unsaturated uronic acid residue and an intact glucosamine residue  at the 
non-reducing and the reducing end,  respectively. The cleavage specificities are 
described in the table. 
 
However, many have been developed over the years, mainly liquid chromatography-
based methods (Korir and Larive 2009). These methods are broadly categorised into 
two groups, according to the types of separation they allow to perform: either based 
on the size of the saccharides or on their charges.  
Size exclusion chromatography (SEC) - also called gel permeation chromatography 
or gel filtration - separates heterogeneous mixtures according to their size - or more 
specifically according to the hydrodynamic volume - of the compounds (Ziegler and 
Zaia 2006). The compounds are generally eluted with a volatile ammonium salt 
(isocratic elution), on a stationary phase, which is composed of a matrix beads of 
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varying pore sizes. The architecture of the matrix creates channels in which the 
analytes will be diffused. Molecules with a large hydrodynamic radius have limited 
access to the pores, unlike those with a small hydrodynamic radius, that have an 
unlimited access to the same pores. Therefore, large molecules have a shorter 
pathway through the column and are eluted first (Figure 9 (a)). In the case of HS 
oligosaccharide purification, it should be noted that size-uniform, but structurally 
heterogeneous mixtures of oligosaccharides are obtained. Same length 
oligosaccharides may indeed bear the same number of sulphate groups, but at 
different positions, resulting in equivalent hydrodynamic volumes and elution times. 
Furthermore, the rigorous separation of the analytes according to their length is 
unlikely to occur. Following the same reasoning, a low sulphated oligosaccharide 
may follow a similar path as a highly sulphated but smaller saccharide, resulting in 
the same elution time for both. Therefore, pure single fractions are unlikely to be 
obtained with this method of purification alone.  
Strong anion-exchange (SAX) chromatography is another commonly used technique 
in the field, usually to further purify the SEC fractions (Rice et al. 1985). SAX has 
historically been used for the quantification of the disaccharide composition of Hp 
and HS polysaccharides. This technique separates compounds according to their net 
charges. The saccharides are retained on a stationary phase composed of a matrix 
displaying many positively charged functional groups though ionic interactions (the 
matrix is usually derivatised with quaternary ammonium moieties). The strength of 
the interactions, therefore, depends of the content of sulphate and carboxylate groups 
of the analyte. Once the saccharides are bound to the matrix, the ionic strength of the 
mobile phase (generally a sodium chloride solution) is increased over a gradient in 
order to detach the analytes from the matrix (Figure 9 (b)). Therefore, low charged 
analytes will elute first, as they will require a low concentration of counter ion. 
However, as for SEC chromatography, the use of SAX alone, as a method of 
purification according to the charge of the saccharide, is usually insufficient. 
Structurally disparate oligosaccharides, but displaying the same number of sulphate 
and carboxylate groups, will be eluted with the same or very similar elution times. 
The use of concentrated solutions of sodium chloride also represents an obstacle to 
subsequent direct analysis by mass spectrometry (MS), so samples must be desalted 
prior to any analysis. Since its first use to purify Hp and HS oligosaccharides, SAX 
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chromatography, as well as other methods, has evolved and been refined. High 
resolution SAX chromatography on Propac PA1 columns has been described for HS 
library preparation (Guimond and Turnbull 1999, Powell et al. 2010). CTA-SAX 
chromatography – which has been developed on the model of reverse-phase ion-
pairing chromatography (RPIP) - can also be used in combination with SAX 
chromatography to give another degree of resolution to the separation techniques 
(Mourier and Viskov 2004). With CTA-SAX, the silica-based and largely 
hydrophobic matrix of the C18 column is derivatised with cetyltrimethylammonium 
(CTA) (Figure 9 (c)). The principle of elution is the same as for SAX 
chromatography (a gradient of salt buffer is used to detach the analytes from the 
matrix). Recently, a volatile salt-based CTA-SAX method has been described which 
simplifies oligosaccharide desalting and permits subsequent MS studies of samples 
(Miller et al. 2016). Comparatively, CTA-SAX offers a better resolution than SAX. 
Yet, the C18 column is less stable and needs to be re-derivatised every 3-4 months.  
Other methods such as porous graphitised carbon (PGC) chromatography (Karlsson 
et al. 2005), hydrophilic interaction liquid chromatography (HILIC) (Naimy et al. 
2008), capillary electrophoresis (CE) (Karamanos et al. 1996) and polyacrylamide 
gel electrophoresis (PAGE) (Turnbull and Gallagher 1990) are also used to perform 
the composition analysis/achieve the separation of HS oligosaccharides.  
The numerous methods of purification that have been developed the past decades and 
which are cited above make the isolation of single structures from natural sources 
possible. However, many difficulties still remain (i.e., the low quantity of compound 
that can be isolated and the lack of control over the structures which can be isolated), 
which encouraged the development of other methods of production. 
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Figure 9: Principle of the main chromatography techniques used to purify 
HS oligosaccharides: (a) SEC, (b) SAX and (c) CTA-SAX chromatography 
(a) For SEC, the compounds are eluted on stationary pha se composed of porous 
beads and are separated according to their hydrodynamic volumes: the large 
analytes (A) are eluted first and the smaller analytes (A) are eluted last.  
(b) For SAX, the negatively charged analytes (A
-
) are first retained on the 
positively charged matrix (B1) and are next eluted with a gradient of a 
positively charged buffer (B
+
) (B2). 
(c) For CTA-SAX, the negatively charged analytes (A
-
) are first retained on a 
CTA-derivatised C18 column (C1) and are next eluted with a gradient of a 
positively charged buffer (B
+
) (C2). 
 
1.8.2. Library production methods: synthetic and semi-synthetic 
methods 
Over recent decades, the possibility of preparing relatively complex carbohydrate 
oligosaccharides from simple and commercially available monosaccharide material 
has become a reality (Poletti and Lay 2003, Codée et al. 2004, Petitou and van 
Boeckel 2004, Dulaney and Huang 2012, Driguez et al. 2014). The relatively fast 
and recent developments of both organic carbohydrate and enzymatic synthesis 
methods are intimately linked to the growing demand for pure and well-characterised 
Hp/HS structures in large quantities. This appraisal can be explained for two 
(a) (b) (c) 
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essential reasons. First of all, unlike the preparation of Hp/HS oligosaccharides from 
biological sources, these methods allow the preparation of structures with specific 
structural and conformational properties (the structures are followed up at each 
synthetic step), which ultimately makes the meticulous investigation of the structure 
activity relationships (SAR) of these GAGs more accessible (Duchaussoy et al. 1991, 
Kovensky et al. 1996, De Paz and Martín-Lomas 2005). Secondly, obtaining large 
quantities of homogeneous batches of glycan oligosaccharides is possible with 
synthetic and semi-synthetic methods. However, carbohydrate synthesis remains 
challenging, as a few limitations remain to be overcome. First of all, the synthesis of 
a single Hp/HS oligosaccharide may be lengthy. A famous example, the chemical 
synthesis of Fondaparinux (Arixtra), requires more than 50 steps to be achieved 
(Petitou et al. 1989). In most cases, this kind of synthesis indeed requires the 
manipulation of specific hydroxyl groups in the presence of many others, as well as 
the manipulation of chemical moieties that must remain unaffected until they need to 
be modified in their turn. Secondly, the poor reliability of the glycosylation reactions 
also remains problematic. Another major issue is related to the intrinsic nature of the 
glycans themselves. Owing to the structural heterogeneity of Hp/HS saccharides, it is 
extremely complicated to set up a general method to prepare distinct structures. 
Every structure is hence often considered as the target of a whole project that may 
take months or even years to be carried out. Moreover, even the slightest 
modification of a glycan structure might require redesigning the whole synthetic 
route. 
Since the pioneering work by Sinaÿ, Petitou and others in the eighties who first 
synthesised the DEFGH pentasaccharide sequence that binds AT-III with high 
affinity (Sinaÿ et al. 1984), several approaches have been developed in order to 
synthetically prepare saccharides of various lengths. These approaches can be 
divided into three main categories. The first approach is the classical multi-step 
solution-phase synthesis, which is the most common way of synthesising saccharides 
and laid the foundations for most of the other approaches. In this case, orthogonally 
protected synthons are prepared in solution and then assembled in order to form 
oligosaccharides/polysaccharides of the desired length through chemical 
glycosylation reactions. This step is followed by further modifications of the glycan 
backbones (modification of the protecting groups (PGs), deprotection) and finally by 
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the functionalisation of the compounds (sulphation, acetylation). The strength of in-
solution synthesis lies in the fact that it has been extensively developed and a 
consequent number of synthons and PGs have already been described in the literature 
(Wuts and Greene 2006, Dulaney and Huang 2012, Mende et al. 2016). 
Nevertheless, this approach is material and time-consuming, as it requires a 
consequent number of manipulations and purifications at each stage of the synthesis. 
It also does not offer the possibility to develop an automated and high-throughput 
synthesis of oligosaccharides. This last point is a considerable disadvantage 
compared to the other methods that have been developed and which, therefore, offer 
the possibility of creating libraries of glycans presenting a broad range of structural 
differences in a relatively short period of time. 
The second category, the automated synthetic approach, includes both the one-pot 
multi-step synthesis and the solid-phase synthesis (also called polymer-supported 
synthesis). One-pot multi-step synthesis has known major advances (Polat and Wong 
2007, Wang et al. 2010, Wu and Wong 2015). In the late nineties, Zhang et al. 
(1999) even paved the way for programmable one-pot synthesis. On the other hand, 
solid-phase synthesis still remains a great challenge for chemists (Sears and Wong 
2001). Interest in solid-phase glycan synthesis has emerged after the success 
encountered by polymer-supported peptide synthesis. However, many issues arose 
while trying to adapt this strategy, mainly due to the lack of adapted materials 
(resins, linkers, PGs) and the absence of efficient glycosylation methods. 
Nevertheless, recent advances in chemistry have helped address some of those issues 
and the possibility of finding a solution for a routine and automated synthesis of 
oligosaccharides is getting closer (Sears and Wong 2001, De Paz et al. 2006, 
Lepenies et al. 2010, Czechura et al. 2011, Guedes et al. 2015). For both cases, 
selectively protected glycosyl donors and acceptors are prepared in advance in 
solution. Then, in the case of one-pot multi-step synthesis, the synthons are 
sequentially assembled in the same flask and then modified before functionalisation 
of the oligosaccharides. In the case of polymer-supported synthesis, a first synthon is 
attached to a resin which has been previously derivatised with a linker, followed by 
the elongation of the glycan through successive glycosylation reactions. Once the 
right size is obtained, the glycan is cleaved from the resin and then deprotected 
before its sulphation. Cleaving the glycan from the resin is carried out before the 
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deprotection step in order to facilitate the purification of the glycan at two levels. 
Firstly, the absorbance of the benzyl ether and benzoyl ester protecting groups 
greatly helps monitoring. Secondly, purifying the fully protected glycan from 
unwanted side-products, like glycans with a lower degree of polymerisation, is 
significantly easier than carrying out the purification at the stage of unprotected 
carbohydrates.  
As its name suggests, the automated approach would allow the rapid and high-
throughput production of glycan libraries for a relatively low number of 
manipulations, even though much remains to be done. One-pot multi-step synthesis 
still indeed requires researchers to progress in the elaboration of suitable building 
blocks, with the appropriate reactivity properties, as well as some progress in 
synthetic strategies. Regarding solid-phase synthesis, research is still focused on 
finding the appropriate conditions for each step that will be easily applicable to an 
automated version of this kind of synthesis. Other issues still need to be addressed 
such as the fact that a substantial amount of glycosyl donor is required to complete a 
single step of chemical glycosylation, or even the last steps for the linker 
functionalisation and PG modifications. 
The last category includes both the enzymatic and the chemoenzymatic approaches, 
which - as their name suggest - involves enzymes in order to introduce, modify or 
remove chemical functions or even sugar moieties to or from a maturing 
oligosaccharide chain (Wong 1995, Blixt and Razi 2006). Two main methods have 
been investigated, involving glycosyltransferases and reverse-activity glycosyl 
hydrolases, even though glycosynthases have also been introduced as new efficient 
tools (Mackenzie et al. 1998, Cobucci-Ponzano and Moracci 2012). Enzymatic and 
chemoenzymatic approaches are both powerful tools that can help shorten the 
synthetic routes, and, therefore, help save a considerable amount of time when 
preparing libraries of glycan oligosaccharides (Kuberan et al. 2003, Chappell and Liu 
2013, DeAngelis et al. 2013, Liu and Linhardt 2014). Unlike the first two 
approaches, this one does not rely on the use of PGs at all and the reactions are 
carried out in aqueous solutions at room temperature. Many sequences of interest 
have been synthesised, proving the efficacy/efficiency of these methods. Amongst 
those sequences, the well-known AT-III binding domain has been produced 
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(Kuberan et al. 2003). Examples of other works of interest are: 1) the syntheses of 
oligosaccharides concurrently displaying anti-factor Xa and IIa activities (Xu, 
Pempe, et al. 2012); 2) the syntheses of ultra low molecular weight heparins 
(ULMW) (Xu et al. 2011, Masuko and Linhardt 2012) and 3) the synthesis of HS 
oligosaccharides displaying a range of affinity towards FGF2 and which, therefore, 
allow the SAR of these GAGs (Xu, Wang, et al. 2012). Yet, many issues still need to 
be addressed, such as the substrate selectivity of the enzymes, which are not yet well 
characterised, the expense which also limits the number of usable building blocks, or 
even the lack of readily available glycotransferases and glucuronyl C-5 epimerase 
(converting glucuronyl residues into iduronyl residues), as well as the limited life-
time of those enzymes. Ultimately, both enzymatic and chemoenzymatic approaches 
will help develop another type of automated glycan synthesis. 
1.8.3. Tools for HS structures analysis 
Deciphering the SAR of HS with its ligands is intrinsically linked to the structural 
analysis of the saccharides. This latter is hampered by the lack of a unique, cheap, 
fast and consistent method to analyse any type of oligosaccharide. Many techniques 
have been developed, each allowing the study of specific structural characteristics of 
HS saccharides, such as their sequences, the exact nature and anomeric state of their 
monosaccharide components or their conformations. The combination of several 
methods is hence generally required to gather sufficient data to precisely sequence 
the saccharides. However, HS sequencing is hampered by a number of factors. First 
of all, the oligosaccharides must be sufficiently pure and clear of any contaminants 
such as salts. A rigorous and lengthy purification process of the glycans (as described 
in Section 1.8.1.3) is required, even though this involves significant losses of 
material. This, therefore, aggravates the fact that the access to consequent amounts of 
material is limited, mostly due to the intrinsic heterogeneity of HS. Some techniques, 
such as nuclear magnetic resonance (NMR), require large amounts of material 
(generally a few mg). Finally, HS is very sensitive to high and low pH conditions, its 
sulphate groups are prone to migration during ionisation processes (mass 
spectrometry (MS)), and it is insoluble in the common organic solvents (Drummond 
et al. 2001, Powell et al. 2004), which complicates its manipulation. It hence appears 
that developing fast, cheap, sensitive, consistent and reliable methods/methodologies 
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are required. All the problems mentioned above are not encountered during the 
production of HS oligosaccharides by both synthetic and semi-synthetic methods, as 
their structural properties are monitored throughout the synthesis.  
Two main approaches have been developed to determine the structures of the HS 
oligosaccharides. The first approach consists of enzymatic or chemical degradation 
of the HS oligosaccharides (labelled or not), the separation of the fragments (CE, 
PAGE or SAX), followed by their analysis by chromatography or MS (disaccharide 
composition quantification) (Turnbull et al. 1999, Vivès et al. 1999, Mourier and 
Viskov 2004, Skidmore et al. 2010, Leary et al. 2015). The second approach relies 
on the direct structural characterisation of the whole sequences by NMR (Yates et al. 
1996, Mulloy and Forster 2000) or MS (Miller 2011).  
NMR spectroscopy is based on the study of the behaviour of the atoms nuclei 
(mainly 
1
H, 
13
C, but also 
15
N, 
31
P isotopes) in a magnetic field and subjected to an 
electromagnetic pulse (Gerothanassis et al. 2002). Their behavioural variations are 
directly linked to their direct environment (neighbouring atoms). The energy 
accumulated (field on), then released during the relaxation by the nuclei (field off) is 
recorded as spectra for interpretation. Two types of spectra can be recorded: the one-
dimensional (1D) or two-dimensional (2D) spectra, which both give different 
insights at the structural organisation of the saccharides (Bubb 2003). 
1
H and 
13
C 
NMR spectra (both 1D NMR experiments) are used to have an overview of the 
structure of the saccharide, determine the number of residues, as well as the anomeric 
state of each one of them. However, 1D NMR techniques appear limited when it 
comes to the full characterisation of long saccharides, largely because of signal 
overlap. In this case, the combination of 2D NMR techniques allows the full 
assignment of the 
1
H and 
13
C NMR spectra (common 2D NMR techniques include 
COSY, TOCSY, HSQC, and NOESY) (Bubb 2003). Despite the advantages offered 
by this technique (fast, cheap, precise characterisation of the residues), NMR 
requires a relatively large amount of pure material (though reduced with recent cryo 
probes) and is not suitable for the study of structurally redundant oligosaccharides, 
even though it has been shown to be possible (Shriver et al. 2000).  
Chapter 1 – Background 
42 
 
MS is an analytical method which involves the ionisation of molecules and which 
affords charged molecules or molecular fragments. The mass-to-charge ratios (m/z) 
of the fragments are measured and recorded for interpretation. To sequence HS 
oligosaccharides, two main techniques are commonly used: electrospray ionisation 
(ESI) (Zhang and Linhardt 2009) and matrix-assisted laser desorption/ionisation 
(MALDI) which is often used in tandem with time of flight detection (TOF) 
(MALDI-TOF) (Tissot et al. 2007). Therefore, despite the challenging task that 
represents HS sequencing for MS, mainly due to the heterogeneity of the glycans, the 
presence of isomers, the loss of sulphate groups during ionisation (Strecker et al. 
1987) and the difficulty for HS oligosaccharides to fly (due to their highly charged 
properties), this technique has been intensively used in the field. MS has been mainly 
used for disaccharide composition quantification, either on its own (offline mode) or 
in tandem with CE or HPLC (online mode) (Linhardt et al. 1989, Chi et al. 2005, 
Doneanu et al. 2009, Zaia 2009). Many advances have been made, including the use 
of better and more appropriate matrixes or complexing cations (Tissot et al. 2007). 
Another breakthrough in the domain is the use of tandem MS (also called MS/MS or 
MS²) for HS sequencing (Saad and Leary 2003, Naggar et al. 2004, Zhang and 
Linhardt 2009, Miller 2011). Even more recently, Ion Mobility MS (IMMS) has also 
been shown to offer the possibility of distinguishing the uronic acid isomers (Leary 
et al. 2015). These recent advances make routine sequencing of HS by MS a 
possibility in the future. 
1.8.4. Tools for HS-FGF interactions studies 
Aberrant FGF signalling has been linked to many diseases (Belov and Mohammadi 
2013). Understanding the interactions between the saccharides and their protein 
ligands - in other words, identifying the structural determinants of HS-FGF-FGFR 
interactions – therefore, appears to be necessary to fully decipher these disease 
pathways and potentially develop HS saccharides-based therapeutics (Coombe and 
Kett 2005). Both aspects of these interactions - the binding and the functional 
activity interactions – have been thoroughly investigated over the last decades, as 
described in the following sections. The combination of both types of analyses is 
vital to understand the SAR of HS with FGF, as subtle structural changes may 
greatly affect the biological activity of the proteins (Rahmoune et al. 1998). 
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Numerous techniques and methods have been developed to have a better insight into 
the structural determinants of HS-FGF interactions. Depending on the 
method/technique used, the type of information obtained will vary, ranging from data 
about binding kinetics/thermodynamics to binding affinities and structural 
information. 
Surface plasmon resonance (SPR) is a powerful technique that allows binding events 
to be measured in real time and, therefore, makes the study of the kinetics of heparin-
protein interactions possible (Capila et al. 1999). Here, one of the interacting species 
(usually FGF) is flowed over the surface of a chip, onto which the other interacting 
species (usually the saccharides) has been immobilized. Upon interactions, the 
refractive index of the chip changes. This change is directly proportional to the 
amount of the species being bound, which gives a real-time measurement of the 
association and dissociation rate constants (ka and kd, respectively). The SPR 
technique can also be used to study the binding affinities between HS and its ligands 
(Cochran et al. 2009).  
Other methods to study binding affinities exist. Most of the techniques requires the 
immobilisation of one of the interacting elements (either the saccharide or the 
protein) onto a surface and allow the direct measure of binding parameters such as 
the equilibrium binding and dissociation constants (Ka and Kd respectively). Notably 
the binding affinities of HS for FGF and FGFR have mainly been studied with the 
help of affinity chromatography (Rapraeger et al. 1991, Jemth et al. 2002). This 
technique helps measuring the contribution of the ionic forces in the binding 
affinities. Other techniques such as affinity co-electrophoresis (ACE) (San Antonio 
et al. 1993) and ultracentrifugation (Harmer et al. 2004, Nieto et al. 2013) as well as 
optical/competition biosensors (Mach et al. 1993, Powell et al. 2002, Cochran et al. 
2009, Xu, Ori, et al. 2012) have also been intensively employed. Lately, Uniewicz et 
al. (2010) developed a method based on the principle of the differential scanning 
fluorimetry (DSF) technique to study binding affinities and which later helped 
unravel secondary binding sites in FGFs (Xu, Ori, et al. 2012). DSF is a powerful 
technique which is routinely used to evaluate the conformational changes that occur 
at the protein level, when the latter is put in the presence of a binding partner.  
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The thermodynamic parameters of HS-protein interactions can also be evaluated with 
the help of isothermal titration calorimetry (ITC), a technique which gives a better 
overview of the contribution of the non-ionic forces to the binding interactions 
(Pantoliano et al. 1994, Fromm et al. 1997, Leavitt and Freire 2001). This last 
technique, however, requires large amounts of material for both the saccharide and 
the binding protein (on the order of mgs).  
All the techniques that are cited above allow the direct measurements of the 
interactions. Performing such measurements requires the constant development of 
more robust, reliable platforms. Lately, the recent advances made in carbohydrate 
chemistry have provided the possibility of developing microarrays (Noti et al. 2006, 
Takada et al. 2013, Sterner et al. 2014) which could be used to carry out the 
quantitative and qualitative analyses of binding interactions in a high-throughput 
manner. Obtaining structural information, such as the contact points, is another vital 
element to better understand HS-protein interactions. Such information can routinely 
be obtained with the study of crystallographic structures of HS-FGF-FGFR 
complexes (Ye et al. 2001), the study of HS-FGF complexes by NMR (Nieto et al. 
2013) or the use of molecular modelling/molecular dynamics techniques to identify 
the residues involved in both the binding and functional interactions. Despite being 
very promising, these methodologies are not always well-suited because they require 
large amounts of material. Moreover, other types of limitations, such as having 
access to powerful computer clusters, or the time needed to run a simulation, often 
limit the use of these techniques. On the other hand, investigations into the structural 
changes that occur at both the protein and saccharide levels are of utmost 
importance, as saccharide-protein interactions are believed to induce conformational 
changes (Guimond et al. 2009). DSF and synchrotron radiation circular dichroism 
(SRCD) (Wallace and Janes 2010, Xu, Ori, et al. 2012), crystallographic studies 
(DiGabriele et al. 1998, Pellegrini 2001, Xu, Ori, et al. 2012), and others provide the 
possibility of carrying out such studies.  
As seen above, there is an extensive (but not exhaustive) list of techniques that can 
be used to study the binding interactions. Each has allowed the structural 
determinants of HS-FGF-FGFR interactions, as seen in Section 1.7.4, to be 
determined. In contrast, functional activity analysis of HS requires the use of cell-
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based assays. As most of the cells express endogenous HS, it is extremely difficult to 
work with any type of cells. Therefore, cell lines have been derived which lack 
endogenous HS (e.g. BaF3 cells (Ornitz et al. 1992, Zhang et al. 2006)). This can 
also be achieved by treating the cells with sodium chlorate for example. This leads to 
the inhibition of the enzyme synthesising the sulphate donor PAPS (Rapraeger et al. 
1994). PAPS is required for the biosynthesis of HS chains as described in Section 
1.5.1.3. Treating the cells in such a way hence leads to the synthesis of unsulphated 
(and therefore inactive) HS chains (e.g, the Swiss 3T3 fibroblasts (Rapraeger et al. 
1991) and Rama 27 (Rahmoune et al. 1998) cell lines). 
1.9. Aims 
The role played by HS in the regulation of FGF signalling has been well established 
throughout the years, as reviewed in this chapter. Despite the considerable effort put 
into the study of the SAR of HS, little is known about the determinants of the 
interactions between the saccharides and FGF and FGFR. This can be mainly 
explained by the limitations that are inherent to the methodologies and techniques 
that are commonly used in such studies. Access to both large amounts of material 
and broad libraries of saccharides are indeed impeded by the methods of production 
and extraction of the HS saccharides. In addition, only a few papers in the literature 
report the study of the saccharides SAR with the help of relatively similar structures. 
The majority of the HS oligosaccharide libraries used in most works published in the 
literature are structurally heterogeneous. This negates the possibility of studying the 
impact of subtle structural changes on the functional activity of the saccharides. The 
development of fast and robust synthetic routes should be able to overcome this 
problem.  
The aims of this thesis were therefore the following: 
 The preparation of a library of HS structures from porcine mucosal HS (PMHS) 
and their screening in BaF3-bioassays. 
 The development of a new synthetic strategy to aid the fast and efficient 
preparation of HS oligosaccharides and therefore the chemical synthesis of 
defined structures. 
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 The screening in BaF3-based bioassays of chemically and enzymatically 
prepared oligosaccharides displaying relatively similar structures (in 
collaboration with Prof. J. Liu (The University of North Carolina, Chapel Hill, 
NC, USA) and Prof. P. Tyler (Victoria University, Wellington, New Zealand)). 
 The evaluation of the impact of structural changes on FGF signalling. 
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2. Chapter 2 – Materials, methods, procedures and 
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2.1. Preparation of Hp/HS oligosaccharide libraries from 
natural sources 
2.1.1. Materials 
Porcine Mucosal HS (PMHS) was purchased from Celsus Laboratories (Cincinnati, 
Ohio, USA) and stored at -20 °C, until use. Recombinant heparinase III from 
Flavobacterium heparinum was purchased from IBEX (Montreal, Quebec, Canada) 
and stored at -80 °C, until use. Disaccharide standards were purchased from Dextra 
Laboratories (Reading, UK) and stored at -20 °C. All chemical and biochemical 
reagents were of analytical grade, used as received unless otherwise stated and were 
purchased from Sigma and VWR (UK). Milli-Q water was obtained from a ELGA 
purelab flex system (ELGA, Veolia Water, Marlow, UK). All reagents were stored as 
instructed by suppliers. Unless otherwise indicated, all experiments were performed 
in sterile and dry laboratory glassware/plasticware. 
2.1.2. Methods 
2.1.2.1. Enzymatic partial digestion 
Before performing the large-scale enzymatic partial digestion, a small-scale 
enzymatic digestion was carried out on a 1 mg trial batch, in order to determine the 
right conditions needed for successful partial digestion. Once the appropriate amount 
of enzyme and the reaction time were established, the partial digestion of 400 mg 
PMHS was carried out. Both small and large-scale experiments were performed in 1x 
lyase buffer (100 mM sodium acetate, 10 mM calcium acetate, (pH 7.0) at 37 °C 
(Powell et al. 2010)) and were monitored at several time points by small scale Size 
Exclusion Chromatography (SEC). For small-scale SEC, the isocratic elution of 100 
µg material was carried out using a Superdex™ peptide 7.5/300 small scale SEC 
column, at 0.2 mL/min (buffer: 0.5 M ammonium bicarbonate) and was monitored by 
absorbance at λABS = 232 nm. The digestion processes were stopped by boiling at 
100 °C for 2 minutes. The 400 mg PMHS were first digested with heparinase III at a 
concentration of 2 mU/mg PMHS (80 mU/mL) for 1 hour. At the end of the first 
hour of digestion, more heparinase III was added (at the rate of another 2 mU 
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enzyme/mg of PMHS) and the digestion was performed for 9 hours. All enzymatic 
partial digested saccharides were lyophilised and stored at -20 °C, until further use. 
2.1.2.2. PAGE oligosaccharide separation 
Polyacrylamide gel electrophoresis (PAGE) was used to analyse size fractionated 
digested PMHS oligosaccharides (Turnbull and Gallagher 1988). The running buffer 
used was 30 mM Tris, 20 mM MES (pH 8.0). The samples were first diluted with 
sample buffer (70% glycerol/30% running buffer, v/v), to which 10% phenol red 
(w/v) was added. The samples were next loaded into the wells of the loading gel 
(7.5% acrylamide, w/v). The electrophoresis was achieved at a constant voltage of 
200V for 4 hours, until the phenol red marker migrated to about 2/3 of the way down 
of the resolving gel (33% acrylamide, w/v). Oligosaccharides were stained with 
0.08% Azure A solution (w/v) for 1 hour. Excess dye was then removed by washing 
the gels several times (and overnight) with deionised water. Images of the gels were 
taken using a digital camera. 
2.1.2.3. SEC chromatography 
The partially digested samples were re-suspended in Milli Q water to obtain 
solutions at a concentration of 50 mg/mL. With the help of a Hamilton syringe, 1 mL 
of sample was loaded into the 5 mL loop of the AKTA purifier 10 (GE Healthcare), 
after verifying that the sample was free of air bubbles. The fractions were eluted 
through two Superdex™ 30 XK 16 columns connected in series, with 0.5 M 
ammonium bicarbonate NH4CO3 (isocratic buffer) at a constant flow rate of 0.5 
mL/min (Feyzi et al. 1997). The elution of the samples was monitored at λABS = 232 
nm (wavelength of absorption of the unsaturated double bond at the non-reducing 
end of the saccharides generated during the lyase enzymatic digestion). One mL 
fractions were collected between 130 and 330 mL of elution volume. Selected peak 
fractions were pooled, prior to desalting. 
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2.1.2.4. Desalting SEC fractions 
Pooled SEC fractions underwent several cycles of lyophilisation in order to remove 
volatile ammonium bicarbonate salt (Goodger et al. 2008). Samples were first diluted 
with Milli-Q water (up to a total volume of 5 mL), frozen at -80 °C for 30 minutes 
and then freeze-dried until complete evaporation of the solvent. The 
dilution/freezing/freeze-drying cycle was repeated until complete removal of 
ammonium bicarbonate salt (generally, 5 cycles were sufficient). 
2.1.2.5. SAX chromatography 
Further fractionation and purification of the partially digested PMHS 
oligosaccharides was performed based on their charges, applying strong anion-
exchange (SAX) chromatography (Turnbull et al. 1999), using Shimadzu LC-20AD 
HPLC equipped with a semi-preparative Propac-PA1 column (9 x 250 mm, Dionex). 
Prior to any run, the whole system was washed sequentially, at a flow rate of 1 
mL/min, with Milli-Q water (10 min), 2 M sodium chloride (10 min) and finally with 
Milli-Q water (10 min). The sample was re-suspended in Milli-Q water (maximum 5 
mg/0.5 mL), loaded onto the 1 mL injection loop and applied to the Propac PA1 
column at a constant temperature of 40 °C with Milli-Q water (1 mL/min). The flow 
rate was maintained at 1 mL/min, and the sample was eluted with a linear gradient of 
0-80% solvent B over 120 minutes (solvent A: Milli-Q water; solvent B: 2 M NaCl 
(HPLC grade), (Powell et al. 2010)). The elution was monitored by absorbance at 
λABS = 232 nm. The fractions were manually collected, after considering the short 
delay time between the UV/Vis detector unit (SPD-20A, Shimadzu) and the 
collector. Fractions corresponding to the same elution times were pooled and stored 
for further use. 
Further separations of selected fractions were performed on the same HPLC system, 
using a Propac PA1 analytical column (4 x 250 mm, Dionex). Prior to any run, the 
whole system was washed sequentially, at a flow rate of 1 mL/min, with Milli-Q 
water (10 min), 2 M NaCl (10 min) and finally with Milli-Q water (10 min). Each 
fraction was diluted with Milli-Q water (1/10 to 1/20, v/v) and individually loaded 
onto the column at a constant temperature of 40 °C with Milli-Q water (1 mL/min). 
Each sample was eluted with a suitable gradient of NaCl buffer (HPLC grade, 
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gradient details are given for each individual chromatogram, see Sections 3.2.3 and 
3.2.4). The elution was monitored by absorbance at 232 nm. Fractions were manually 
collected and stored for further use. The column was reconditioned in Milli-Q water 
prior to purification of the next sample. 
2.1.2.6. CTA-SAX chromatography 
Final fractionation and purification of the PMHS oligosaccharides was performed 
applying CTA-SAX chromatography (Mourier and Viskov 2004) and using a 
Shimadzu LC-20AD HPLC equipped with a C18 column (4.6 x 250 mm, 5 µm bead 
size, Supelco) derivatised with cetyltrimethylammonium (CTA). The derivatisation 
of the C18 column was performed in three stages. First, the column was pre-
conditioned by washing with pure methanol (MeOH) overnight. Secondly, the 
column was equilibrated overnight with a 1 nM CTA hydrogen sulphate in 
MeOH/water (50/50, v/v) solution. Finally, the whole system was washed 
sequentially, at 1 mL/min, with buffer A over 10 minutes (buffer A: Milli-Q water), 
buffer B over 10 minutes (buffer B: 2 M ammonium bicarbonate, HPLC grade) and 
finally with buffer A over 60 minutes. Each SAX sample was individually diluted 
with Milli-Q water (1/15, v/v), loaded onto the 1 mL injection loop and applied to the 
column with Milli-Q water (1 mL/min). The flow rate was maintained at 1 mL/min, 
and each sample was eluted with a 25-70% gradient over 60 min using 2 M NH4CO3 
(HPLC grade) as the elution buffer. The elution was monitored by absorbance at λABS 
= 232 nm. The fractions were manually collected, after considering the short delay 
time between the UV/Vis detector unit (SPD-20A, Shimadzu) and the collector. 
Fractions corresponding to the same elution times were pooled prior to desalting. The 
column was reconditioned in Milli-Q water prior to the separation of the next 
sample. 
2.1.2.7. Desalting CTA-SAX fractions 
CTA-SAX fractions underwent several cycles of desalting to remove the volatile 
ammonium bicarbonate salt using a Univapo 150 ECH vacuum concentrator 
(UniEquip) connected to a cold trap. Between each cycle, the samples were diluted 
with Milli-Q water (up to 800 µL maximum) and a total of 5 cycles were performed 
for complete desalting.  
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2.2. BaF3 bioassays 
2.2.1. Materials 
Chemoenzymatically prepared octasaccharides [Oct2S, Oct2,6S and Oct2,6+3S], 
decasaccharides [Dec2S, Dec2,6S and Dec2,6+3S], and dodecasaccharides [Dod2S, 
Dod2,6S and Dod2,6+3S] were a gift from Prof. J. Liu (The University of North 
Carolina, Chapel Hill, NC, USA).  Chemically prepared octasaccharides [Oct6SIdo, 
Oct6SIdo2S, Oct6SGlc and Oct6SGlc2S], decasaccharides [Dec6SIdo, Dec6SIdo2S, 
Dec6SGlc and Dec6SGlc2S], and dodecasaccharides [Dod6SIdo and Dod6SIdo2S] 
were a gift from Prof. P. Tyler (Victoria University of Wellington, New Zealand). 
All oligosaccharides were diluted in Milli-Q water and stored at -20 °C until use. 
Human recombinant (rh) Fibroblast Growth Factors (FGF) rhFGF1, rhFGF2, rhFGF7 
were purchased from R&D systems and stored as instructed by the supplier. All 
chemical and biochemical products were of analytical grade, purchased from Sigma, 
VWR, R&D, Invitrogen/Gibco (Spain) and used as supplied, unless otherwise stated. 
Milli-Q water was obtained from a water purifier. Unless otherwise indicated, all 
experiments were performed in sterile and dry laboratory glassware or plasticware. 
2.2.2. Method 
BaF3, a murine Interleukin-3 (IL-3) dependent pro-B cell line that does not express 
either endogenous HS or FGFR, was used in bioassays to investigate FGF signalling. 
These cells, which are transfected with cDNAs encoding specific FGF isomers, can 
be used as an HS-dependent assay for FGF signalling responses (Ornitz et al. 1992). 
The BaF3 cells used for this project have previously been transfected with specific 
FGFRs (FGFR1c and FGFR2b) (Ornitz et al. 1996), and were maintained in BaF3 
growth medium (RPMI 1640 medium, 10% (v/v) Foetal Bovine Serum (FBS), 1 mM 
L-glutamine, 1 mM penicillin G, 1 mM streptomycin), in the presence of mouse 
recombinant (rm) rmIL-3 (1 ng/mL) and G418 (600 µg/mL). Cells were routinely 
maintained at a density of 500,000 – 1,000,000 cells/mL, in the incubator at 37 °C, in 
5% CO2 (v/v).  
For testing signalling responses of different FGF-FGFR combinations to the presence 
of HS oligosaccharides, all solutions were prepared with BaF3 growth medium. The 
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combinations tested were: FGF1-FGFR1c, FGF1-FGFR2b, FGF2-FGFR1c and 
FGF7-FGFR2b. Prior to any bioassay, the cells were washed 3 times with BaF3 
growth medium. FGF (concentrations: 0.1 nM for FGF2, 1 nM for FGF1 and 3 nM for 
FGF7) was spotted on a 96 well plate, in the presence of selected HS 
oligosaccharides (concentration of 3 µg/mL for primary assays and concentrations 
ranging from 3 ng/mL to 10 μg/mL for titration assays, for a volume of 50 µL). Cells 
in culture medium were next added to the wells (10,000 cells per well, 50 µL per 
well). The plate was then incubated at 37 °C, in 5% CO2 (v/v) for 72 hours. Several 
controls were carried out. As positive controls, cells were incubated in BaF3 growth 
medium with 1 ng/mL IL-3 or in BaF3 growth medium with FGFs and heparin 
(concentrations ranging from 3 ng/mL to 10 µg/mL). As negative controls, cells were 
incubated in BaF3 growth medium only, in BaF3 growth medium and in the presence 
of FGF or in BaF3 growth medium and in the presence of the saccharides. Typical 
A570 values for controls in the MTT assays were: IL-3 controls (1.144±0.035, 
1.173±0.041, 1.076±0.003, 1.279±0.021), FGF plus heparin controls (0.546±0.011, 
0.515±0.008, 0.421±0.016, 0.459±0.026), background level controls with no added 
FGF, FGF alone or saccharides alone (0.156±0.003, 0.114±0.001, 0.098±0.001, 
0.124±0.002) for FGF2-FGFR1c, FGF1-FGFR1c, FGF1-FGFR2b and FGF7-
FGFR2b respectively. Each condition was tested as triplicate on the bioassay plate 
(for both primary bioassay and titration assay). In the case of primary assays, for 
each oligosaccharide-FGF-FGFR combination, the assays were carried out three 
times (for a total of 3 plates, 9 absorbance values for each oligosaccharide-FGF-
FGFR condition). In the case of dose response curve experiments, bioassays were 
carried out only once. 
After 72 hours, 10 μL 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT) (5 mg/mL in sterile PBS) was added to each well and the plate was incubated 
for 4 hours at 37 °C, in 5% CO2 (v/v). MTT is reduced by the mitochondrial 
reductase enzymes of viable cells to afford insoluble purple formazan. After 4 hours 
of incubation, 100 μL 10% (w/v) SDS/0.01 M HCl was added to each well (to 
dissolve formazan) and incubated overnight. Cell growth was determined by 
measuring the absorbance at λabs = 570 nm using a plate reader (the absorbance is 
proportional to the cell number).  
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2.2.3. Statistical analysis 
For primary bioassays, the average of activity was calculated for each plate and used 
for statistical evaluations. The compounds were tested using a one-sample t-test (one 
tailed) to determine whether their relative activities were significantly higher than the 
different reference values or not (reference values: 5%, 50% and 100% activity, 
relative to full-length Hp). 5% was designated as the value for minimal activity 
(comparatively to Hp). Selected compounds were also tested using a two-sided t-test. 
Statistical significance was reported if p<0.05*, p<0.01** and p<0.001***. Data 
analyses were performed with R statistical software v.3.3.0. 
2.3. Chemical synthesis of Hp/HS oligosaccharides 
2.3.1. Materials 
All chemicals were reagent grade, used as they were supplied unless described 
otherwise and purchased from Sigma, Acros and Biotage (Spain). All reagents were 
stored as instructed by suppliers. All solvents used for air and moisture-sensitive 
reactions were dried and stored over 4 Å molecular sieves under argon prior to use. 
Water was simply distilled prior to use. All anhydrous reactions were carried out in 
oven-dried glassware and under argon. All air and moisture-sensitive chemicals and 
anhydrous solvents were manipulated and transferred with oven-dried syringes or 
cannulae. 
2.3.2. Methods 
2.3.2.1. Microwave-assisted synthesis 
Microwave-assisted synthesis was performed using a Biotage Initiator Classic 
microwave monomode oven, equipped with a Robot Eight/Robot Sixty (Biotage). 
Samples were diluted with the appropriate solvent in a microwave vial (Biotage) 
equipped with a magnetic stir bar and placed onto the sample bed. The reaction 
conditions (irradiation time, stirring time, vial type, temperature) were set up on the 
fully integrated computer.  
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2.3.2.2. Flash chromatography 
Conventional flash chromatography was performed using silica gel 60 (63-200 µm). 
Automated flash chromatography was performed using Biotage SP, equipped with 
Biotage SNAP KP-Sil cartridges (50 μm silica particles with a surface area of 500 
m
2
.g
-1
). For both techniques, the sample was diluted in a minimum solvent (usually 
dichloromethane (DCM)) and loaded onto the column which had been 
preconditioned in the appropriate solvent mixture. 
2.3.2.3. Mass spectrometry 
Reaction monitoring and exact mass measurements were performed using either an 
Acquity UPLC (5 µL/min, MeOH) coupled to a LCT XE time-of-flight mass 
spectrometry detector with electrospray ionisation source (LC-ESI-TOF) or a Bruker 
UltrafleXtreme III MALDI tandem mass spectrometer (MALDI-TOF/TOF). 
Analyses were made in positive mode for both methods. 2,5-Dihydroxybenzoic acid 
(DHB) in MeOH was used as MALDI matrix.  
2.3.2.4. Specific rotation 
Specific rotation values α 
20  were measured with a PerkinElmer 341 polarimeter 
equipped with sodium lamp and wavelength filter (589 nm) and at a constant 
temperature of 20 °C. Prior to any measurement, pure chloroform was used for 
calibration. Samples were diluted in chloroform for measurements.  
2.3.2.5. NMR 
1
H, 
13
C, DQF-COSY and HSQC spectra were obtained at room temperature using a 
500 MHz NMR spectrometer equipped with a 
1
H/
19
F BBI 5 mm probe and a 
HRMAS (High Resolution Magic Angle Spinning) 4 mm probe. Samples were 
diluted with deuterated chloroform (CDCl3), methanol (CD3OD) or water (D2O) for 
recording of the NMR spectra, unless otherwise stated. 
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2.3.3. Procedures and characterisation data 
Copies of all NMR spectra can be accessed at: http://datacat.liverpool.ac.uk/ 
 
2.3.3.1. General procedures 
Procedure A: Prior to the reaction, the solvent was dried over freshly activated 4 Å 
molecular sieve beads for a minimum of 12 hours. Syringes and needles were dried 
under high vacuum for a minimum of 12 hours as well. The glycosyl acceptor and 
donor were dissolved together in dry solvent at the desired concentration under 
argon, in a flask containing freshly activated 4 Å molecular sieves powder. The 
mixture was cooled to the desired temperature and the activator was added. The 
reaction mixture was stirred at the desired temperature for a minimum of 15 min and 
a maximum of 2 hours. The reaction was quenched by addition of water (in the case 
of compounds bearing a Fmoc group) or Et3N. The reaction mixture was diluted with 
the corresponding solvent and filtered through a pad of celite. The concentrated 
crude reaction was then purified by silica gel chromatography.  
Procedure B: Prior to the reaction, the solvent was dried over freshly activated 4 Å 
molecular sieve beads for a minimum of 12 hours. Syringes, needles and canulae 
were dried under high vacuum for a minimum of 12 hours as well. The glycosyl 
acceptor and donor were separately dissolved in dry solvent at the desired 
concentrations, under argon, and in flasks containing freshly activated 4 Å molecular 
sieves powder. The activator was added to the glycosyl acceptor solution and the 
mixture was then cooled to the desired temperature. The donor solution was added 
dropwise via a canula to the acceptor solution. The reaction mixture was stirred at the 
desired temperature for a minimum of 15 min and a maximum of 2 hours. The 
reaction was quenched by addition of water (in the case of compounds bearing a 
Fmoc group) or Et3N. The reaction mixture was diluted with the corresponding 
solvent and filtered through a pad of celite. The concentrated crude reaction was then 
purified by silica gel chromatography.  
 
 
Chapter 2 – Materials, methods, procedures and characterisation data 
57 
 
2.3.3.2. Procedures and characterisation data 
2-Azido-6-O-benzoyl-3-O-benzyl-2-deoxy-4-O-(9-fluorenylmethoxycarbonyl)-
α/β-D-glucopyranosyl trichloroacetimidate (8) 
 
The hemiacetal 22 (1 g, 1.61 mmol) was dissolved in trichloroacetonitrile (30 mL) 
and sodium hydride (0.01 g, 0.161 mmol) was added. After stirring at room 
temperature for 15 min, the mixture was concentrated, and the residue was loaded 
onto a short pad of silica for flash chromatography purification (hexane/ethyl acetate 
7:3, 1% Et3N). The imidate 8 (1.17 g, 95%) was obtained as a mixture of anomers 
(α/β 1/2). Rf = 0.66 (hexane/ethyl acetate 7:3); 
1
H NMR (500 MHz, CDCl3) δ = 8.76 
(s, 0.35H, NHCCCl3), 8.74 (s, 0.65H, NHCCCl3), 8.09 – 7.15 (m, 18H, aromatic), 
6.45 (d, J = 3.5 Hz, 0.35H, H-1α), 5.68 (d, J = 8.5 Hz, 0.65H, H-1β), 5.16 – 5.02 (m, 
1H, H-4α, H-4β), 4.83 – 4.79 (m, 1H, CH2Ph), 4.75 – 4.68 (m, 1H, CH2Ph), 4.57 – 
4.29 (m, 4.35H, H-5α, H-6, CH2Fmoc), 4.17 – 4.12 (m, 1.35H, CHFmoc, H-3α), 3.93 
(dd, J = 8.3, 5.0 Hz, 0.65H, H-5β), 3.81 – 3.76 (m, 1H, H-2α, H-2β), 3.64 (t, J = 9.5 
Hz, 0.65H, H-3β). 13C NMR (126 MHz, CDCl3) δ = 166.14 - 166.11 (CqBz), 160.99 - 
160.59 (CqC=NH), 154.28 (CqFmoc), 143.31 - 143.08 (CqFmoc), 143.05 (CqFmoc), 141.44 
- 141.40 (CqFmoc), 137.19 - 137.03 (Cqaromatic), 133.33 - 119.88 (CHaromatic), 96.63 (C-
1β), 94.28 (C-1α), 80.24 (C-3β), 77.75 (C-3α), 75.58 (CH2Bn), 74.56 - 74.45 (C-4α, 
C-4β), 72.65 (C-5β), 70.55 - 70.43 (C-5α, CH2Fmoc), 65.37 (C-2β), 62.71 - 62.33 (C-
6, C-2α), 46.84 - 46.28 (CHFmoc); LRMS (ESI MS) m/z calcd for C37H31Cl3N4O8 [M 
+ H]
+
 765.1, found 765.2. 
2-Azido-3-O-benzyl-2-deoxy-4-O-(9-fluorenylmethoxycarbonyl)-6-O-levulinoyl-
α/β-D-glucopyranosyl trichloroacetimidate (9) 
 
The hemiacetal 23 (2.4 g, 3.9 mmol) was dissolved in trichloroacetonitrile (73 mL) 
under argon. Sodium hydride (0.16 g, 0.39 mmol) was added to the solution and 
complete consumption of the starting material was revealed by TLC analysis after 10 
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minutes. The solvent was evaporated and the crude was loaded on a short pad of 
silica for purification (hexane/ethyl acetate 7:3, 1% Et3N). The desired product 9 
(2.49 g, 85%) was obtained as a mixture of anomers (α/β 1/4). Rf = 0.66 
(hexane/ethyl acetate 1:1); 
1
H NMR (500 MHz, CDCl3) δ = 8.79 (s, 0.2H, 
NHCCCl3), 8.78 (s, 0.8H, NHCCCl3), 7.81 – 7.21 (m, 13H, aromatic), 6.42 (d, J = 
3.4 Hz, 0.2H, H-1α), 5.62 (d, J = 8.5 Hz, 0.8H, H-1β), 5.03 (t, J = 9.7 Hz, 0.2H, H-
4α), 4.96 (t, J = 9.7 Hz, 0.8H, H-4β), 4.83 – 4.75 (m, 1H, CH2Ph), 4.73 - 4.64 (m, J = 
10.9 Hz, 1H, CH2Ph), 4.52 (m, 1H, CH2Fmoc), 4.39 – 4.14 (m, 4.2H, CH2Fmoc, H-6, 
CHFmoc, H-5α), 4.08 (t, J = 9.7 Hz, 0.2H, H-3α), 3.81 – 3.72 (m, 1.8H, H-5β, H-2β, 
H-2α), 3.58 (t, J = 9.5 Hz, 0.8H, H-3β), 2.81 – 2.52 (m, 4H, CH2Lev), 2.16 (s, 3H, 
CH3Lev). 
13
C NMR (126 MHz, CDCl3) δ = 206.76 - 206.66 (CqLev), 172.38 (CqLev), 
160.87 - 160.46 (CqC=NH), 154.20 (CqFmoc), 143.29 - 142.92 (CqFmoc), 141.36 - 
141.30 (CqFmoc), 137.07 - 136.91 (Cqaromatic), 128.82 - 119.84 (CHaromatic), 96.45 (C-
1β), 94.12 (C-1α), 90.66 - 90.27 (CCl3), 79.94 (C-3β), 77.51 (C-3α), 75.40 (CH2Bn), 
73.94 - 73.64(C-4α, C-4β), 72.47 (C-5β), 70.48 - 70.32 (CH2Fmoc, C-5α), 65.20 (C-
2β), 62.40 (C-2α), 61.87 - 61.73 (C-6), 46.66 (CHFmoc), 38.02 - 37.84 (CH2Lev), 30.00 
- 29.80 (CH3Lev), 27.86 - 27.80 (CH2Lev); LRMS (ESI MS) m/z calcd for 
C35H33Cl3N4O9 [M + H]
+
 759.1, found 759.2. 
Methyl (Phenyl 2-O-benzoyl-3-O-benzyl-1-thio-α-L-idopyranoside) uronate (10) 
 
Compound 32 was first treated with a combination of 2,2,6,6-tetramethyl-1-
piperidinyloxyl (TEMPO) and a catalytic amount of [bis(acetoxy)-iodo]benzene 
(BAIB) to obtain the iduronic acid intermediate as described by Codée and 
colleagues. The spectral data was in good agreement with published values. (Codée 
et al. 2005).  
The L-iduronic acid intermediate (1 g, 2.08 mmol) was then dried in high vacuum. 
The crude was placed in a microwave vial equipped with a stirring bar and 
containing freshly activated molecular sieve beads. Dry MeOH (15 mL) and 
Amberlite IR-120 (H
+
) (0.5 g) were added. The solution was irradiated in a 
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microwave oven at 100 °C for 1h30 with pre-stirring for 30 s. The vial was cooled to 
room temperature and the solution filtered. The solvent was evaporated, the residual 
crude was purified by flash chromatography (hexane/ethyl acetate 7:3) to afford the 
desired product 10 (0.84 g, 82%). The structural data were in agreement with 
published values (Codée et al. 2005). 
Methyl (Phenyl 3-O-benzyl-2-O-levulinoyl-1-thio-α-L-idopyranoside) uronate 
(11) 
 
To a vigorously stirred solution of the diol 37 (100 mg, 0.22 mmol) in a mixture of 
DCM/H2O (0.3 M, 2:1), TEMPO (7 mg, 0.044 mmol) and BAIB (177 mg, 0.55 
mmol) were added. After 1 hour, analysis by TLC indicated complete conversion of 
the starting material. The mixture was co-evaporated with toluene, dried under high 
vacuum (minimum 3 hours) and used in the next reaction without further 
purification. Freshly activated 4 Å molecular sieve beads and dry Amberlite IR-120 
(H
+
) (50 mg) were added to a solution of the iduronic acid in dry MeOH (5 mL) in a 
microwave vial equipped with a magnetic stirring bar. The mixture was irradiated in 
the microwave oven for 1.5 hours at 95°C. The mixture was filtrated, concentrated 
and purified by column chromatography to yield 11 (82 mg, 76% in two steps). Rf = 
0.3 (hexane/ethyl acetate 3:7);   
20 = -56.1 (c = 0.65, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ = 7.55 – 7.22 (m, 10H, aromatic), 5.57 (s, 1H, H-1), 5.32 (d, J = 1.5 Hz, 
1H, H-5), 5.29 – 5.26 (m, 1H, H-2), 4.85 (d, J = 11.8 Hz, 1H, CH2Ph), 4.64 (d, J = 
11.8 Hz, 1H, CH2Ph), 4.10 (bs, 1H, H-4), 3.83 (s, 3H, CH3COOMe), 3.79 (t, J = 2.3 Hz, 
1H, H-3), 2.88 – 2.68 (m, 3H, 4-OH, CH2Lev), 2.64 – 2.53 (m, 2H, CH2Lev), 2.17 (s, 
3H, CH3Lev). 
13
C NMR (126 MHz, CDCl3) δ = 206.33 (CqLev), 171.21 (CqLev), 
169.68 (CqCOOMe), 137.10 (Cqaromatic), 135.71 (Cqaromatic), 131.57 – 127.35 
(CHaromatic), 86.64 (C-1), 73.39 (C-3), 72.50 (CH2Bn), 69.42 (C-2), 69.08 (C-5), 68.28 
(C-4), 52.52 (CH3COOMe), 37.88 (CH2Lev), 29.83 (CH3Lev), 28.06 (CH2Lev); HRMS 
(ESI-TOF MS) m/z calcd for C25H28O8S [M + Na]
+
 511.1397, found 511.1371. 
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tert-Butyldimethylsilyl 2-Azido-3-O-benzyl-2-deoxy-β-D-gluco-pyranoside (17) 
 
To a solution of compound 16 (10.3 g, 20.7 mmol) in dry DCM (207 mL), EtSH (8 
mL, 103.52 mmol) and a catalytic amount of BF3.O(Et)2 (255 µL, 2.07 mmol) were 
added sequentially. The solution was stirred for 3 hours under argon, and the solvent 
was next evaporated. The resulting crude was subsequently loaded onto a silica gel 
based column for purification (hexane/ethyl acetate 7:3) yielding of 17 (7.25g, 89%). 
The physical data was in good agreement with published values (Guedes et al. 2013). 
tert-Butyldimethylsilyl 2-Azido-6-O-benzoyl-3-O-benzyl-2-deoxy-β-D-gluco-
pyranoside (18) 
 
Compound 18 was prepared from compound 17 following the procedures described 
by Guedes and colleagues and the physical data was in good agreement with 
published values (Guedes et al. 2013). 
tert-Butyldimethylsilyl 2-Azido-3-O-benzyl-2-deoxy-6-O-levulinoyl-β-D-gluco-
pyranoside (19) 
 
Compound 17 (6 g, 14.71 mmol) was dissolved in dry DCM (221 mL) and LevOH 
(2.2 mL, 22.07 mmol) and CMPI (10.52 g, 41.19 mmol) were added subsequently . 
The reaction mixture was firstly stirred for 15 min then cooled to -20 °C. DABCO 
(6.6 g, 58.84 mmol) was added to the mixture and the reaction was slowly warmed to 
room temperature over 3 hours. The reaction mixture was diluted with DCM and 
washed with 1 M HCl, water, 1 M NaOH, water and brine. The organic layer was 
dried over MgSO4, filtered and concentrated. The crude product was purified by 
flash chromatography on silica gel (toluene/ethyl acetate 7:3) and the desired product 
19 was obtained (7.03 g, 94%). Rf = 0.37 (toluene/ethyl acetate 7:3);   
20 = -31.4 (c = 
0.5, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ = 7.41 – 7.28 (m, 5H, aromatic), 4.93 (d, 
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J = 11.4 Hz, 1H, CH2Ph), 4.74 (d, J = 11.4 Hz, 1H, CH2Ph), 4.53 (d, J = 7.6 Hz, 1H, 
H-1), 4.35 (dd, J = 12.0, 5.4 Hz, 1H, H-6a), 4.28 (dd, J = 12.0, 2.3 Hz, 1H, H-6b), 
3.52 – 3.44 (m, 1H, H-4), 3.43 – 3.37 (m, 1H, H-5), 3.31 (dd, J = 9.9, 7.7 Hz, 1H, H-
2), 3.20 (dd, J = 9.9, 8.7 Hz, 1H, H-3), 2.80 – 2.70 (m, 2H, CH2Lev), 2.64 (d, J = 3.3 
Hz, 1H, 4-OH), 2.61 – 2.56 (m, 2H, CH2Lev), 2.18 (s, 3H, CH3Lev), 0.93 (s, 9H, 
CH3TBS), 0.16 (d, J = 2.6 Hz, 6H, CH3TBS) ; 
13
C NMR (126 MHz, CDCl3) δ = 206.81 
(CqLev), 173.17 (CqLev), 138.21 (Cqaromatic), 130.10 – 126.78 (CHaromatic), 97.42 (C-1), 
82.16 (C-3), 75.20 (CH2Bn), 73.83 (C-5), 70.25 (C-4), 68.29 (C-2), 63.61 (C-6), 38.07 
(CH2Lev), 29.98 (CH3Lev), 27.97 (CH2Lev), 25.73 (CH3TBS), 18.13 (CqTBS), -4.20 
(CH3TBS), -5.07 (CH3TBS); HRMS (ESI-TOF MS) m/z calcd for C24H37N3O7Si [M + 
Na]
+
 530.2293, found 530.2294. 
tert-Butyldimethylsilyl 2-Azido-6-O-benzoyl-3-O-benzyl-2-deoxy-4-O-(9-
fluorenyl-methoxycarbonyl)-β-D-glucopyranoside (20) 
 
To a solution of 18 (1.9 g, 3.7 mmol) in DCM (75 mL) at 0 °C, pyridine (7.5 mL), 
FmocCl (2.4 g, 9.25 mmol) and a catalytic amount of DMAP (0.45 mg, 0.37 mmol) 
were added. The reaction was slowly warmed to room temperature and was stirred 
for 2h until completion was detected by TLC analysis. The mixture was diluted with 
DCM, washed consecutively with water, saturated CuSO4 aq. solution, water, and 
brine. The organic layer was dried over MgSO4 and concentrated. Flash column 
chromatography on silica gel (hexane/ethyl acetate 3:2) afforded the desired product 
20 (2.58 g, 96%). Rf = 0.50 (hexane/ethyl acetate 4:1);   
20 = -12 (c = 0.5, CHCl3); 
1
H 
NMR (500 MHz, CDCl3) δ = 8.08 – 7.18 (m, 18H, aromatic), 4.91 (dd, J = 10.0, 8.9 
Hz, 1H, H-4), 4.80 (d, J = 11.2 Hz, 1H, CH2Ph), 4.66 (d, J = 11.2 Hz, 1H, CH2Ph), 
4.59 (d, J = 7.3 Hz, 1H, H-1), 4.52 (dd, J = 12.0, 2.8 Hz, 1H, H-6a), 4.42 (dd, J = 
10.5, 7.0 Hz, 1H, CH2Fmoc), 4.37 – 4.30 (m, 2H, CH2Fmoc, H-6b), 4.15 (t, J = 7.1 Hz, 
1H, CHFmoc), 3.82 – 3.74 (m, 1H, H-5), 3.50 – 3.40 (m, 2H, H-3, H-2), 0.90 (s, 9H, 
CH3TBS), 0.13 (d, J = 3.3 Hz, 6H, CH3TBS) ; 
13
C NMR (126 MHz, CDCl3)  
δ = 166.14 (CqBz), 154.45 (CqFmoc), 143.30 - 143.19 (CqFmoc), 141.43 - 141.41 
(CqFmoc), 137.59 (Cqaromatic), 133.30 - 120.19 (CHaromatic), 97.36 (C-1), 79.95 (C-3), 
75.28 (CH2Bn), 75.08 (C-4), 71.93 (C-5), 70.34 (CH2Fmoc), 68.30 (C-2), 63.32 (C-6), 
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46.82 (CHFmoc), 25.66 (CH3TBS), 18.06 (CqTBS), -4.20 (CH3TBS), -5.11 (CH3TBS); 
HRMS (ESI-TOF MS) m/z calcd for C41H45N3O8Si [M + Na]
+
 758.2868, found 
758.2798. 
tert-Butyldimethylsilyl 2-Azido-3-O-benzyl-2-deoxy-4-O-(9-fluorenylmethoxy- 
carbonyl)-6-O-levulinoyl-β-D-glucopyranoside (21) 
 
To a solution of 19 (7.03 g, 13.85 mmol) in dry DCM (280 mL) at 0 °C, FmocCl (9 
g, 34.63 mmol) was added, along with DMAP (0.17 g, 1.39 mmol) and pyridine (28 
mL). The reaction mixture was slowly warmed to room temperature over 1 hour. The 
mixture was diluted with DCM and the organic phase was washed with water, 
saturated CuSO4 aq. solution, water and brine. The organic phase was dried over 
MgSO4, filtered and concentrated. Flash chromatography on silica column gel 
(toluene/ethyl acetate 9:1) afforded 21 (9.60 g, 95%). Rf = 0.36 (toluene/ethyl acetate 
9:1);   
20 = -13.7 (c = 0.65, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ = 7.80 – 7.20 (m, 
13H, aromatic), 4.85 – 4.75 (m, 2H, H-4, CH2Ph), 4.64 (d, J = 11.2 Hz, 1H, CH2Ph), 
4.55 (d, J = 7.3 Hz, 1H, H-1), 4.47 (dd, J = 10.5, 7.0 Hz, 1H, CH2Fmoc), 4.35 (dd, J = 
10.5, 7.3 Hz, 1H, CH2Fmoc), 4.24 – 4.15 (m, 3H, H-6a, H-6b, CHFmoc), 3.62 (dt, J = 
9.9, 4.4 Hz, 1H, H-5), 3.45 – 3.36 (m, 2H, H-3, H-2), 2.81 – 2.50 (m, 4H, CH2Lev), 
2.17 (s, 3H, CH3Lev), 0.94 (s, 9H, CH3TBS), 0.17 (d, J = 2.9 Hz, 6H, CH3TBS) ; 
13
C 
NMR (126 MHz, CDCl3) δ = 206.35 (CqLev), 172.33 (CqLev), 154.35 (CqFmoc), 
143.30 (CqFmoc), 143.17 (s), 141.37 (CqFmoc), 141.35 (CqFmoc), 137.57 (Cqaromatic), 
128.71 – 119.53 (CHaromatic), 97.23 (C-1), 79.82 (C-3), 75.10 (CH2Bn), 74.66 (C-4), 
71.74 (C-5), 70.31 (CH2Fmoc), 68.18 (C-2), 62.79 (C-6), 46.77 (CHFmoc), 37.86 
(CH2Lev), 29.88 (CH3Lev), 27.83 (CH2Lev), 25.65 (CH3TBS), 18.03 (CqTBS), -4.26 
(CH3TBS), -5.14 (CH3TBS); HRMS (ESI-TOF MS) m/z calcd for C39H47N3O9Si [M + 
Na]
+
 752.2974, found 752.2921. 
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2-Azido-6-O-benzoyl-3-O-benzyl-2-deoxy-4-O-(9-fluorenylmethoxycarbonyl)-
α/β-D-glucopyranose (22) 
 
To a solution of 20 (2 g, 2.72 mmol) in dry THF (32 mL) at 0 °C, HF.pyridine (70% 
solution, 7.2 mL) was added. The reaction was stirred at room temperature over night 
and quenched with a saturated NaHCO3 aq. solution. The mixture was diluted with 
ethyl acetate and consequently washed with water, saturated CuSO4 aq. solution, 
water and brine. After being dried over MgSO4 and filtered, the organic layer was 
concentrated. The resulting residue was then loaded onto a silica gel based column 
for purification (hexane/ethyl acetate 3:7). The desired hemiacetal 22 was obtained 
(1.37 g, 81%) as a mixture of anomers (α/β 2/1). Rf = 0.20 (hexane/ethyl acetate 1:4); 
1
H NMR (500 MHz, CDCl3) δ = 8.11 – 7.19 (m, 18H, aromatic), 5.34 (t, J = 3.2 Hz, 
0.65H, H-1α), 5.10 – 5.03 (m, 0.65H, H-4α), 5.03 – 4.97 (m, 0.35H, H-4β), 4.85 – 
4.76 (m, J = 10.0 Hz, 1H, CH2Ph), 4.73 – 4.63 (m, 1.35H, CH2Ph, H-1β), 4.58 (ddd, 
J = 11.1, 8.3, 2.7 Hz, 1H, H-6), 4.45 (dt, J = 10.5, 7.2 Hz, 1H, CH2Fmoc), 4.39 – 4.26 
(m, 3H, H-5α, CH2Fmoc, H-6), 4.20 – 4.06 (m, 1.65H, CHFmoc, H-3α), 3.79 (ddd, J = 
10.0, 4.7, 2.9 Hz, 0.35H, H-5β), 3.63 (bs, 0.35H, 1-OHβ), 3.57 – 3.43 (m, 1.35H, H-
3β, H-2α, H-2β), 3.12 (d, J = 2.7 Hz, 0.65H, 1-OHα). 13C NMR (126 MHz, CDCl3) δ 
= 166.49 - 166.41 (CqBz), 154.45 - 154.41 (CqFmoc), 143.32 - 143.28 (CqFmoc), 143.16 
- 143.10 (CqFmoc), 141.44 - 141.40 (CqFmoc), 137.32 - 137.23 (Cqaromatic), 133.44 - 
120.19 (CHaromatic), 96.51 (C-1β), 92.04 (C-1α), 80.29 (C-3β), 77.70 (C-3α), 75.54 
(CH2Bn), 75.20 (C-4α), 74.59 (C-4β), 71.98 (C-5β), 70.38 - 70.33 (CH2Fmoc), 67.94 
(C-5α), 67.08 (C-2β), 63.58 (C-2α), 62.81 - 62.66 (C-6), 46.83 (CHFmoc); LRMS (ESI 
MS) m/z calcd for C35H31N3O8 [M + H]
+
 622.2, found 622.3. 
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2-Azido-3-O-benzyl-2-deoxy-4-O-(9-fluorenylmethoxycarbonyl)-6-O-levulinoyl-
α/β-D-glucopyranose (23) 
 
To a solution of compound 21 (3 g, 4.11 mmol) in dry THF (41 mL) at 0 °C, 
HF.pyridine (70% solution, 2.7 mL) was added. The reaction was stirred at room 
temperature overnight and was quenched with a saturated NaHCO3 aq. solution. The 
mixture was diluted in ethyl acetate and washed with water, saturated CuSO4 aq. 
solution, water and brine. The organic phase was dried over MgSO4, filtered and 
concentrated. The residue was purified by flash chromatography on silica gel 
(toluene/ethyl acetate, 7:3) and delivered 1.97 g (78%) of 23 as a mixture of anomers 
(α/β 2/1). Rf = 0.3 (toluene/ethyl acetate 7:3); 
1
H NMR (500 MHz, CDCl3) δ = 7.82 – 
7.15 (m, 13H, aromatic), 5.34 (t, J = 2.9 Hz, 0.65H, H-1α), 4.89 – 4.76 (m, 2H, H-4α, 
H-4β, CH2Ph), 4.72 – 4.60 (m, 1.35H, CH2Ph, H-1β), 4.53 – 4.45 (m, 1H, CH2Fmoc), 
4.39 – 4.14 (m, 5H, CH2Fmoc, H-5α, H-6a, CHFmoc, 1-OHβ), 4.11 – 4.05 (m, 0.65H, 
H-3α), 3.86 (d, J = 1.7 Hz, 0.65H, 1-OHα), 3.66 (ddd, J = 10.1, 4.9, 3.2 Hz, 0.35H, 
H-5β), 3.53 – 3.42 (m, 1.35H, H-3β, H-2α, H-2β), 2.84 – 2.69 (m, 2H, CH2Lev), 2.66 
– 2.51 (m, 2H, CH2Lev), 2.18 (s, 3H, CH3Lev); 
13
C NMR (126 MHz, CDCl3)  
δ = 207.78 - 207.38 (CqLev), 172.51 - 172.47 (CqLev), 154.54 - 154.40 (CqFmoc), 
143.35 - 143.21 (CqFmoc), 141.44 - 141.40 (CqFmoc), 137.43 - 137.37 (Cqaromatic), 
128.50 - 120.23 (CHaromatic), 96.39 (C-1β), 92.01 (C-1α), 80.24 (C-3β), 77.73 (C-3α), 
75.43 - 74.51 (CH2Bn, C-4β, C-4α), 71.86 (C-5β), 70.45 (CH2Fmoc), 67.58 (C-5α), 
67.08 (C-2β), 63.61 (C-2α), 62.61 - 62.43 (C-6), 46.80 (CHFmoc), 38.29 -38.03 
(CH2Lev), 30.00 - 29.97 (CH3Lev), 28.15 - 28.02 (CH2Lev); HRMS (ESI-TOF MS) m/z 
calcd for C33H33N3O9 [M + Na]
+
 638.2109, found 638.2089. 
Phenyl 2-O-benzoyl-3-O-benzyl-1-thio-α-L-idopyranoside (32) 
 
Compound 32 was prepared from compound 30 following the procedures described 
by Guedes and colleagues and the physical data was in good agreement with 
published values (Guedes et al. 2013). 
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Phenyl 3-O-benzyl-2-O-levulinoyl-1-thio-α-L-idopyranoside (37) 
 
To a solution of 30 (2 g, 7.93 mmol) in dry DCM (31 mL), 
trimethyl(phenylthio)silane (4.6 mL, 24 mmol) and zinc iodide ZnI2 (5.77 g, 16 
mmol, protected from light and dried under high vacuum) were added. The mixture 
was stirred at room temperature for 4 hours and filtered through a pad of Celite. The 
filtrate was diluted with DCM, after a solution of 4 M HCl in dioxane (20 mL, 1 
equivalent) and 20 mL water were added. The mixture was stirred at room 
temperature for 15 min until complete conversion was detected by TLC analysis. The 
mixture was washed with 1 M HCl aq. solution, saturated NaHCO3 aq. solution, water 
and brine, filtered, concentrated and dried under high vacuum. The resulting triol was 
dissolved in dry pyridine (10 mL) and acetic anhydride (5 mL) was added at 0 ºC. 
The mixture was stirred at room temperature overnight, and the reaction was hence 
quenched with ethanol. The mixture was diluted with DCM, washed with saturated 
NaHCO3 aq. solution, water, saturated CuSO4 aq. solution, water and brine. The 
aqueous phase was extracted with DCM. The organic layers were dried over MgSO4 
and concentrated. The residue was purified by column chromatography (hexane/ethyl 
acetate 8:1) to afford the peracetylated intermediate (3.25 g, 85% over two steps). 
The structural data were in good agreement with published data (Tatai et al. 2008). 
To a solution of the peracetylated intermediate (293 mg, 0.60 mmol) in dry MeOH (4 
mL), a catalytic amount of NaOMe (200 µL of a 0.5 M solution) was added. The 
mixture was stirred for 3 hours at room temperature, neutralized with Amberlite IR 
120 (H+) resin, filtered, and concentrated to give the corresponding triol 34 (202  
mg, 93%). The structural data was in good agreement with published data (Tatai et 
al. 2008). 
The intermediate triol (150 mg, 0.42 mmol) was dissolved in dry acetonitrile (1.5 
mL), and benzaldehyde dimethyl acetal (120 µL, 0.84 mmol) and a catalytic amount 
of CSA (3 mg) were added (until an acid pH was obtained). After 1.5 hours of 
stirring, the mixture was neutralized with Et3N and concentrated. The residue was 
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purified by silica gel column chromatography (hexane/ethyl acetate 4:1) and afforded 
the desired compound 35 (140 mg, 75%) as a mixture of anomers (α/β 3/1). The 
anomers were separated by flash chromatography. The structural data was in 
agreement with published data (Tatai et al. 2008). 
A suspension of EDC.HCl (127 mg, 0.66 mmol) and DMAP (36 mg, 0.30 mmol) in 
DCM (10 mL) was added to a solution of the 4,6-O-benzylidene protected 
intermediate α-35 (0.20 g, 0.44 mmol) and levulinic acid (77 mg, 0.66 mmol) in 
DCM (4 mL). After stirring for 2 hours at ambient temperature, two more 
equivalents of EDC.HCl and of levulinic acid were added. The reaction was stirred 
overnight. The reaction mixture was diluted with DCM, washed with 1 M HCl aq. 
solution, saturated NaHCO3 aq. solution, water and brine. The organic layer was 
dried and concentrated. The product was purified by column chromatography to 
afford the fully protected intermediate 36 (0.222 g, 92%). Structural data was in 
agreement with published data (Dhamale et al. 2014). 
A solution of the fully protected intermediate (200 mg, 0.365 mmol) in a mixture of 
DCM/TFA/H2O (0.06M, 10:1:0.1, v/v/v) was stirred at 0ºC for 3 hours. The reaction 
mixture was quenched with solid NaHCO3, washed with 1 M HCl aq. solution, 
saturated NaHCO3 aq. solution and water. The residue was purified by flash column 
chromatography (DCM/MeOH 99:1) to give pure product 37 (126 mg, 75%). Rf = 
0.3 (hexane/ethyl acetate 7:3);   
20 = -59.5 (c = 0.5, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ = 7.56 – 7.24 (m, 10H, aromatic), 5.49 (s, 1H, H-1), 5.31 – 5.26 (m, 1H, H-
2), 4.85 (d, J = 11.8 Hz, 1H, CH2Ph), 4.70 (t, J = 4.7 Hz, 1H, H-5), 4.60 (d, J = 11.8 
Hz, 1H, CH2Ph), 4.00 – 3.77 (m, J = 25.7, 21.6, 11.8, 6.3 Hz, 3H, H-6a, H-6b, H-4), 
3.74 – 3.69 (m, J = 2.9, 1.2 Hz, 1H, H-3), 2.85 (d, J = 9.6 Hz, 1H, 4-OH), 2.82 – 2.71 
(m, 2H, CH2Lev), 2.62 – 2.56 (m, 2H, CH2Lev), 2.19 (s, 3H, CH3Lev), 2.11 (dd, J = 8.3, 
4.2 Hz, 1H, 6-OH).
 13
C NMR (126 MHz, CDCl3) δ = 206.72 (CqLev), 171.35 (CqLev), 
137.36 (Cqaromatic), 135.83 (Cqaromatic), 132.41 – 126.73 (CHaromatic), 86.49 (C-1), 
73.80 (C-3), 72.41 (CH2Bn), 69.71 (C-2), 68.33 (C-4), 68.27 (C-5), 63.36 (C-6), 38.04 
(CH2Lev), 29.84 (CH3Lev), 28.16 (CH2Lev); HRMS (ESI-TOF MS) m/z calcd for 
C24H28O7S [M+Na]
+
 483.1448, found 483.1411. 
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Methyl (Phenyl [2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-4-O-(9-fluorenyl-
methoxycarbonyl)-α-D-glucopyranosyl]-3-O-benzyl-2-O-levulinoyl-1-thio-α-L-
idopyranoside) uronate (38) 
 
The reaction was carried out following procedure A using glycosyl acceptor 11 (50 
mg, 0.102 mmol) and glycosyl donor 8 (117 mg, 0.153 mmol). TMSOTf (0.1 
equivalents, 2 µL, 0.01 mmol) was added at -30 °C. The reaction was quenched by 
the addition of water (10 µL), and the mixture was filtered and concentrated. The 
flash chromatography purification of the crude (hexane/ethyl acetate 4:1) gave the 
desired disaccharide 38 (36 mg, 32%). Rf = 0.40 (hexane/ethyl acetate 3:1);   
20 = 
+4.4 (c = 0.85, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ = 8.09 – 7.17 (m, 28H, 
aromatic), 5.65 (s, 1H, H-1), 5.34 (d, J = 2.2 Hz, 1H, H-5), 5.20 (t, 1H, H-2), 5.09 – 
4.98 (m, 2H, H-4’, H-1’), 4.85 (d, J = 11.6 Hz, 1H, CH2Ph), 4.76 (d, J = 10.8 Hz, 
1H, CH2Ph), 4.64 (dd, J = 11.3, 2.8 Hz, 2H, CH2Ph), 4.57 (dd, J = 12.4, 2.5 Hz, 1H, 
H-6’), 4.42 (dd, J = 10.5, 6.9 Hz, 1H, CH2Fmoc), 4.31 – 4.24 (m, 2H, CH2Fmoc, H-6’), 
4.20 – 4.11 (m, 3H, H-4, H-5’, CHFmoc), 4.01 (t, J = 2.7 Hz, 1H, H-3), 3.98 – 3.92 
(m, 1H, H-3’), 3.81 (s, 3H, CH3COOMe), 3.45 (dd, J = 10.2, 3.5 Hz, 1H, H-2’), 2.82 – 
2.53 (m, 4H, CH2Lev), 2.13 (s, 3H, CH3Lev). 
13
C NMR (126 MHz, CDCl3) δ = 206.24 
(CqLev), 172.23 (CqLev), 169.43 (CqCOOMe), 166.19 (CqBz), 154.30 (CqFmoc), 143.28 
(CqFmoc), 143.17 (CqFmoc), 141.38 (CqFmoc), 137.30 - 136.99 (Cqaromatic), 135.34 
(Cqaromatic), 133.25 - 120.18 (CHaromatic), 96.88 (C-1’), 86.33 (C-1), 77.92 (C-3’), 
75.32 (CH2Bn), 74.80 (C-4’), 72.95 (C-4, CH2Bn), 71.30 (C-3), 70.25 (CH2Fmoc), 68.97 
(C-2), 68.65 (C-5’), 68.52 (C-5), 63.14 (C-2’), 62.43 (C-6’), 52.52 (CH3COOMe), 
46.79 (CHFmoc), 37.88 (CH2Lev), 29.85 (CH3Lev), 27.92 (CH2Lev); HRMS (MALDI-
TOF MS) m/z calcd for C60H57N3O15S [M + Na]
+
 1114.3403, found 1114.3444. 
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Methyl (Phenyl [2-azido-3-O-benzyl-2-deoxy-4-O-(9-fluorenylmethoxy-
carbonyl)-6-O-levulinoyl-α-D-glucopyranosyl]-2-O-benzoyl-3-O-benzyl-1-thio-α-
L-idopyranoside) uronate (39) 
 
The reaction was carried out following procedure A or procedure B using glycosyl 
acceptor 10 and glycosyl donor 9.  
Procedure A: To a solution of 10 (50 mg, 0.101 mmol) and 9 (115 mg, 0.152 mmol) 
in DCM (2 mL), TMSOTf (0.1 equivalents, 2 µL, 0.01 mmol) was added at -20 °C. 
The reaction was quenched by the addition of water (30 µL), and the mixture was 
filtered and concentrated. The flash chromatography purification of the crude 
(hexane/ethyl acetate 3:2) gave the desired disaccharide 39 (56 mg, 51%).  
Procedure B: To a solution of 10 (100 mg, 0.202 mmol) and TMSOTf (0.1 
equivalents, 4 µL, 0.02 mmol) in DCM (1 mL), a solution of 9 (230 mg, 0.304 
mmol) in DCM (0.5 mL) at -30 °C was slowly added. The reaction was quenched by 
the addition of water (20 µL), and the mixture was filtered and concentrated. The 
flash chromatography purification of the crude (hexane/ethyl acetate 3:2) gave the 
desired disaccharide 39 (42 mg, 19%).  
Procedure B: To a solution of 10 (100 mg, 0.202 mmol) and TBSOTf (0.1 
equivalents, 5 µL, 0.02 mmol) in DCM (1 mL), a solution of 9 (230 mg, 0.304 
mmol) in DCM (0.5 mL) at -30 °C was slowly added. The reaction was quenched by 
the addition of water (20 µL), and the mixture was filtered and concentrated. The 
flash chromatography purification of the crude (hexane/ethyl acetate 3:2) gave the 
desired disaccharide 39 (55 mg, 25%). 
Structural data: Rf = 0.40 (hexane/ethyl acetate 3:1);   
20 = -21.7 (c = 0.5, CHCl3); 
1
H 
NMR (500 MHz, CDCl3) δ = 8.14 - 6.95 (m, 28H, aromatic), 5.78 (s, 1H, H-1), 5.44 
(s, 1H, H-2), 5.40 (d, J = 1.7 Hz, 1H, H-5), 5.01 (d, J = 11.7 Hz, 1H, CH2Ph), 4.82 – 
4.74 (m, 3H, H-4’, CH2Ph, H-1’), 4.55 (dd, J = 10.5, 6.4 Hz, 1H, CH2Fmoc), 4.32 (dd, 
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J = 10.5, 6.9 Hz, 1H, CH2Fmoc), 4.26 – 4.16 (m, J = 12.7, 2.6 Hz, 4H, H-3, H-6’, 
CHFmoc), 4.14 – 4.07 (m, 2H, H-5’, H-4), 3.82 (s, 3H, CH3COOMe), 3.77 (d, J = 10.8 
Hz, 1H, CH2Ph), 3.70 (d, J = 10.8 Hz, 1H, CH2Ph), 3.45 (t, J = 9.7 Hz, 1H, H-3’), 
3.26 (dd, J = 10.2, 3.5 Hz, 1H, H-2’), 2.78 – 2.52 (m, 4H, CH2Lev), 2.14 (s, 3H, 
CH3Lev). 
13
C NMR (126 MHz, CDCl3) δ = 206.57 (CqLev), 172.44 (CqLev), 169.27 
(CqCOOMe), 165.47 (CqBz), 154.32 (CqFmoc), 143.40 - 143.28 (CqFmoc), 141.52 
(CqFmoc), 141.40 (Cqaromatic), 137.32 - 137.13 (Cqaromatic), 135.46 (Cqaromatic), 133.68 - 
120.23 (CHaromatic), 100.38 (C-1’), 87.31 (C-1), 78.01 (C-3’), 77.52 (C-4), 74.66 
(CH2Bn), 74.11 (C-4’), 72.86 (CH2Bn), 72.37 (C-3), 70.06 (CH2Fmoc), 69.26 (C-2), 
68.85 (C-5’), 68.16 (C-5), 63.38 (C-2’), 61.53 (C-6’), 52.62 (CH3COOMe), 46.89 
(CHFmoc), 37.97 (CH2Lev), 29.92 (CH3Lev), 27.97 (CH2Lev); HRMS (MALDI-TOF 
MS) m/z calcd for C60H57N3O15S [M + Na]
+
 1114.3403, found 1114.3455. 
Methyl (Phenyl [2-azido-6-O-benzoyl-3-O-benzyl-2-deoxy-4-O-(9-fluorenyl-
methoxycarbonyl)-α-D-glucopyranosyl]-2-O-benzoyl-3-O-benzyl-1-thio-α-L-
idopyranoside) uronate (40) 
 
The reaction was carried out following procedure A using glycosyl acceptor 10 and 
glycosyl donor 8. To a solution of 10 (90 mg, 0.174 mmol) and 8 (200 mg, 0.261 
mmol) in DCM (3.5 mL), TMSOTf (0.1 equivalents, 3 µL, 0.017 mmol) was added 
at -20 °C. The reaction was quenched by the addition of water (30 µL) , and the 
mixture was filtered and concentrated. The flash chromatography purification of the 
crude (hexane/ethyl acetate 6:1) gave the desired disaccharide 40 (56 mg, 40%). Rf = 
0.61 (hexane/ethyl acetate 3:1).   
20 = -14.6 (c = 0.5, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ = 8.10 - 6.96 (m, 33H, aromatic), 5.80 (s, 1H, H-1), 5.44 (s, 1H, H-2), 5.41 
(s, 1H, H-5), 5.03 – 4.94 (m, J = 20.5, 10.7 Hz, 2H, CH2Ph, H-4’), 4.80 – 4.73 (m, 
2H, CH2Ph, H-1’), 4.68 (d, J = 10.8 Hz, 1H, H-6’), 4.50 (dd, J = 10.5, 6.4 Hz, 1H, 
CH2Fmoc), 4.32 (dd, J = 10.5, 6.8 Hz, 1H, CH2Fmoc), 4.25 – 4.08 (m, 5H, H-3, H-5’, H-
6’, CHFmoc, H-4), 3.82 (s, 3H, CH3COOMe), 3.78 (d, J = 10.6 Hz, 1H, CH2Ph), 3.72 (d, 
J = 10.6 Hz, 1H, CH2Ph), 3.49 (t, J = 9.7 Hz, 1H, H-3’), 3.27 (dd, J = 10.2, 3.3 Hz, 
1H, H-2’). 13C NMR (126 MHz, CDCl3) δ = 169.33 (CqCOOMe), 166.15 (CqBz), 
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165.49 (CqBz), 154.30 (CqFmoc), 143.28 (CqFmoc), 141.51 (CqFmoc), 141.42 (CqFmoc), 
137.22 (Cqaromatic), 137.11 (Cqaromatic), 135.49 (Cqaromatic), 133.70 - 120.21 (CHaromatic), 
100.39 (C-1’), 87.30 (C-1), 78.14 (C-3’), 77.55 (C-4), 74.83 (CH2Bn), 74.46 (C-4’), 
72.86 (CH2Bn), 72.31 (C-3), 69.94 (CH2Fmoc), 69.29 (C-2), 68.87 (C-5’), 68.21 (C-5), 
63.45 (C-2’), 61.85 (C-6’), 52.68 (CH3COOMe), 46.92 (CHFmoc); HRMS (MALDI-TOF 
MS) m/z calcd for C62H55N3O14S [M + Na]
+
 1120.3297, found 1120.3262. 
2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α/β-D-glucopyranosyl trichloro-
acetimidate (41) 
 
Compound 33 was prepared from compound 12 following the procedures described 
by de Paz and colleagues (De Paz et al. 2003) and the physical data was in good 
agreement with published values (La Ferla et al. 1999). 
Methyl (Dimethylthexylsilyl 3-O-benzyl-β-L-idopyranoside) uronate (42) 
 
Compound 42 was prepared from compound 24 following the described procedures 
(Ojeda et al. 1999, Lohman et al. 2003) and the physical data was in good agreement 
with published values (Ojeda et al. 1999). 
Methyl (Dimethylthexylsilyl 4-O-[2-Azido-6-O-benzoyl-3-O-benzyl-2-deoxy-4-O-
(9-fluorenylmethoxycarbonyl)-α-D-glucopyranosyl]-3-O-benzyl-β-L-
idopyranoside) uronate (47) 
 
The reaction was carried out following procedure B. To a solution of glycosyl 
acceptor 42 (114 mg, 0.26 mmol) and the Lewis acid TBSOTf, (0.2 equivalents, 125 
µL of a 0.26 M solution, 0.032 mmol) in dry DCM (4 mL) at 0 °C, a solution of 
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glycosyl donor 8 (122 mg, 0.16 mmol) in dry DCM (1.5 mL) was slowly added. The 
reaction was quenched by the addition of water (30 µL). A small aliquot of the 
reaction was dried with an air stream and analysed by LC-MS. 
Methyl (Dimethylthexylsilyl 4-O-[2-Azido-3-O-benzyl-2-deoxy-4-O-(9-fluorenyl-
methoxycarbonyl)-6-O-levulinoyl-α-D-glucopyranosyl]-3-O-benzyl-β-L-ido-
pyranoside) uronate (48) 
 
The reaction was carried out following the procedure B. To a solution of glycosyl 
acceptor 42 (100 mg, 0.231 mmol) and TMSOTf (0.2 equivalents, 5 µL, 0.028 
mmol) in dry DCM (3.5 mL) at 0 °C, a solution of glycosyl donor 9 (0.106 mg, 0.14 
mmol) in dry DCM (1.5 mL) was slowly added. The reaction was quenched by the 
addition of Et3N, and the mixture was filtered and concentrated. Flash 
chromatography (hexane/ethyl acetate 4:1) gave 48 (65 mg, 45%). Rf = 0.38 
(hexane/ethyl acetate 7:3); 
1
H NMR (500 MHz, CDCl3) δ = 7.76  – 7.16 (m, 18H, 
aromatic), 5.06 (s, 1H, H-1), 5.03 (d, J = 3.5 Hz, 1H, H-1’), 4.88 (t, J = 9.8 Hz, 1H, 
H-4’), 4.79 (d, J = 10.8 Hz, 1H, CH2Ph), 4.69 – 4.61 (m, 3H, CH2Ph), 4.58 (d, J = 
1.2 Hz, 1H, H-5), 4.45 (dd, J = 10.0, 6.6 Hz, 1H, CH2Fmoc), 4.28 – 4.16 (m, 4H, 
CH2Fmoc, H-6’, CHFmoc), 4.10 (s, 1H, H-4), 4.08 – 4.03 (m, 1H, H-3), 3.94 – 3.86 (m, 
2H, H-3’, H-5’), 3.80 (s, 3H, CH3COOMe), 3.67 (d, J = 8.8 Hz, 1H, H-2), 3.55 (dd, J = 
10.1, 3.5 Hz, 1H, H-2’), 2.91 (d, J = 9.2 Hz, 1H, 2-OH), 2.79 – 2.53 (m, 4H, CH2Lev), 
2.14 (s, 3H, CH3Lev), 1.72 – 1.67 (m, 1H, CH(CH3)2), 0.97 – 0.87 (m, 12H, C(CH3)2 
and CH(CH3)2), 0.25 (d, J = 27.5 Hz, 6H, Si(CH3)2). 
13
C NMR (from HSQC) (500 
MHz, CDCl3) δ = 129.1- 120.1 (Caromatic), 95.4 (C-1’), 94.9 (C-1), 78.1 (C-3’), 75.5 
(CH2Bn), 74.2 (C-4’), 73.7 (C-5), 73.6 (C-3), 72.8 (CH2Bn), 71.7 (C-4), 70.4 
(CH2Fmoc), 68.6 (C-5’), 68.5 (C-2), 63.2 (C-2’), 61.8 (C-6’), 52.3 (CH3COOMe), 46.8 
(CHFmoc), 37.8 (CH2Lev), 34.1 (CH(CH3)2), 29.9 (CH3Lev),  28.1 (CH2Lev), 19.5 
(C(CH3)2 and CH(CH3)2), -2.9 (Si(CH3)2); LRMS (ESI MS) m/z calcd for 
C55H67N3O15Si [M + H]
+
 1038.4, found 1038.6. 
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Methyl (Dimethylthexylsilyl 4-O-[2-Azido-3-O-benzyl-4,6-O-benzylidene-2-
deoxy-4-O-(9-fluorenyl-methoxycarbonyl)-α-D-glucopyranosyl]-3-O-benzyl-β-L-
idopyranoside) uronate (49) 
 
The reaction was carried out following procedure A and procedure B.  
Procedure A: To a solution of glycosyl acceptor 42 (55 mg, 0.125 mmol) and 
glycosyl donor 41 (40 mg, 0.076 mmol) in dry DCM (2.2 mL), TMSOTf (0.2 
equivalents, 3 µL, 0.0152 mmol) at -10 °C was added. The reaction was quenched by 
the addition of Et3N, and the mixture was filtered and concentrated. Flash 
chromatography (toluene/ethyl acetate 15:1) afforded the desired disaccharide 49 (19 
mg, 32%). 
Procedure B: To a solution of glycosyl acceptor 42 (1.5 g, 3.4 mmol) and TMSOTf 
(0.2 equivalents, 72 µL, 0.4 mmol) in dry DCM (26 mL) at 0 °C, a solution of 
glycosyl donor 41 (1.06 g, 2 mmol) in dry DCM (9 mL) was slowly added. The 
reaction was quenched by the addition of Et3N, and the mixture was filtered and 
concentrated. Flash chromatography (toluene/ethyl acetate 15:1) afforded the desired 
disaccharide 49 (0.95 g, 59%). 
Physical data was in good agreement with published values (De Paz et al. 2003). 
Methyl (4-O-[2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-D-gluco-
pyranosyl]-2-O-benzoyl-3-O-benzyl-α/β-L-idopyranosyluronate) 
trichloroacetimidate (50) 
 
Compound 50 was prepared from the disaccharide 49 following the procedures 
described by Lucas and colleagues. The physical data of the intermediates 52 and 54 
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and of the final product 50 were in good agreement with published values (Lucas et 
al. 2003). 
Methyl (4-O-[2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-D-gluco-
pyranosyl]-3-O-benzyl-2-O-levulinoyl-α/β-L-idopyranosyluronate) 
trichloroacetimidate (51) 
 
Compound 51 was prepared from the disaccharide 49 following the procedures 
described by De Paz and colleagues. The physical data of the intermediates 53 and 
55, and the final product 51, were in good agreement with published values (De Paz 
and Martín-Lomas 2005). 
N-(Benzyl)-benzyloxycarbonyl-5-aminopentyl 2-Azido-3-O-benzyl-4,6-O-
benzylidene-2-deoxy-α/β-D-glucopyranoside (56) 
 
The reaction was carried out according to procedure A. To a solution of glycosyl 
acceptor 6 (0.5 g, 1.52 mmol) and glycosyl donor 41 (1.21 g, 2.29 mmol) in dry Et2O 
(15 mL), TMSOTf (0.1 equivalents, 30 µL, 0.15 mmol) was added at 0 °C. The 
reaction was quenched by the addition of Et3N, and the mixture was filtered and 
concentrated. The flash chromatography purification of the crude (hexane/ethyl 
acetate 4:1) gave the desired product 56 (0.75 g, 72%) as a mixture of anomers (α/β 
2/1). The structural data was in good agreement with published data (Arungundram 
et al. 2009). 
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N-(Benzyl)-benzyloxycarbonyl-5-aminopentyl 2-Azido-3-O-benzyl-2-deoxy-α-D-
glucopyranoside (57) 
 
Compound α-56 (0.693g, 1 mmol) was diluted with dry DCM (10 mL) and EtSH 
(360 µL, 5 mmol) and a catalytic amount of BF3.O(Et)2 (12 µL, 0.5 mmol) were 
added. The reaction was stirred at room temperature for 1 hour and quenched by the 
addition of Et3N. The crude was concentrated and loaded onto a silica gel-based 
column for purification. Flash chromatography (hexane/ethyl acetate 1:1) afforded 
the desired product 57 (0.554 g, 92%). The structural data was in good agreement 
with published data (Arungundram et al. 2009). 
N-(Benzyl)-benzyloxycarbonyl-5-aminopentyl 2-Azido-6-O-benzoyl-3-O-benzyl-
2-deoxy-α-D-glucopyranoside (58) 
 
To a solution of compound 57 (0.78 g, 1.29 mmol) in dry acetonitrile (28 mL), Et3N 
(36 µL, 0.258 mmol) was added. The solution was cooled to -30 °C and a 0.9 M 
benzoyl cyanide BzCN solution in dry acetonitrile (1 equivalent, 1.43 mL, 1.29 
mmol) was added dropwise over 1 hour at -30 °C. The reaction was monitored by 
TLC analysis (hexane/ethyl acetate 1:1) to avoid the formation of the di-benzoylated 
by-product. At the end of the addition of the BzCN solution, the reaction was 
quenched by the addition of methanol. The reaction crude was concentrated and 
purified by flash column chromatography (hexane/ethyl acetate 4:1) to afford the 
desired mono-benzoylated product 58 (0.809 g, 89%). Rf = 0.31 (hexane/ethyl 
acetate 4:1);    
20 = +25.5 (c = 0.5, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ = 8.04 – 
7.06 (m, 18H, aromatic), 5.19 (d, J = 20.2 Hz, 2H, OCH2PhCbz), 4.98 – 4.79 (m, 3H, 
CH2Ph, H-1), 4.72 (d, J = 11.9 Hz, 1H, H-6), 4.60 – 4.39 (m, 3H, H-6, NCH2Ph), 
3.99 – 3.80 (m, 2H, H-5, H-3), 3.78 – 3.55 (m, 2H, OCH2linker, H-4), 3.52 – 3.36 (m, 
1H, OCH2linker), 3.34 – 3.14 (m, 3H, NCH2linker, H-2), 2.95 (bs, 1H, 4-OH), 1.74– 
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1.24 (m, 6H, CH2linker); 
13
C NMR (126 MHz, CDCl3) δ = 167.10 (CqBz), 156.40 
(CqCbz), 138.12 - 137.95 (Cqaromatic), 133.45 - 127.34 (CHaromatic), 98.02 (C-1), 79.75 
(C-3), 75.41 (CH2Bn), 71.28 (C-4), 70.41 (C-5), 68.26 (OCH2linker), 67.38 
(OCH2PhCbz), 63.66 (C-6), 63.01 (C-2), 50.50 (NCH2Ph), 47.46 - 46.19 (NCH2linker), 
29.14 - 23.42 (CH2linker); HRMS (ESI-TOF MS) m/z calcd for C40H44N4O8 [M + Na]
+
 
731.3051, found 731.2989. 
N-(Benzyl)-benzyloxycarbonyl-5-aminopentyl (2-azido-3-O-benzyl-4,6-O-
benzylidene-2-deoxy-α-D-glucopyranosyl)-(1→4)-(methyl 2-O-benzoyl-3-O-
benzyl-α-L-idopyranosyluronate)-(1→4)-2-azido-3-O-benzyl-6-O-benzoyl-2-
deoxy-α-D-glucopyranoside (59) 
 
The reaction was carried out according to procedure A. To a solution of glycosyl 
acceptor 58 (230 mg, 0.325 mmol) and glycosyl donor 50 (444 mg, 0.487 mmol) in 
dry DCM (3.3 mL), TMSOTf (0.1 equivalents, 6 µL, 0.032 mmol) was added at -20 
°C. The reaction was quenched by the addition of Et3N, and the mixture was filtered 
and concentrated. The flash chromatography purification of the crude (toluene/ethyl 
acetate 7:1) gave the desired product 59 (452 mg, 95%). Rf = 0.43 (toluene/ethyl 
acetate 6:1);   
20 = +1.3 (c = 0.5, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ = 8.09 – 
7.15 (m, 40H, aromatic), 5.58 (d, J = 3.0 Hz, 1H, H-1’), 5.53 (s, 1H, Ph-CH), 5.23 – 
5.12 (m, 3H, H-2’, OCH2PhCbz), 4.95 (d, J = 10.3 Hz, 1H, CH2Ph), 4.87 – 4.71 (m, 
6H, CH2Ph, H-1, H-5’, H-1’’), 4.66 (dd, J = 12.0, 1.9 Hz, 1H, H-6), 4.58 – 4.41 (m, 
4H, CH2Ph, NCH2Ph, H-6), 4.28 (dd, J = 10.2, 4.9 Hz, 1H, H-6’’), 4.21 – 4.10 (m, 
2H, H-3’, CH2Ph), 4.08 – 3.99 (m, 2H, H-4’, H-4), 3.98 – 3.88 (m, 3H, H-5’’, H-3, 
H-5), 3.69 – 3.54 (m, 4H, H-6’’, OCH2linker, H-3’’, H-4’’), 3.46 (s, 3H, CH3COOMe), 
3.43 – 3.15 (m, 5H, OCH2linker, H-2, NCH2linker, H-2’’), 1.69  – 1.20 (m, 6H, 
CH2linker); 
13
C NMR (126 MHz, CDCl3) δ = 169.25 (CqCOOMe), 166.15 (CqBz), 165.47 
(CqBz), 163.53 (CqCbz), 137.99 -137.35 (Cqaromatic), 133.44 - 126.20 (CHaromatic), 
101.46 (Ph-CH), 99.72 (C-1’’), 98.70 (C1’), 97.59 (C-1), 82.48 (C-4’’), 78.70 (C-3), 
76.32 (C-3’’), 75.97 (C-4), 75.32 (C-4’), 75.09 (CH2Bn), 74.80 (C-3 ‘), 73.60 
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(CH2Bn), 69.33 (C-2’, C-5’, C-5), 68.59 (C-6’’), 68.30 (OCH2linker), 67.29 
(OCH2PhCbz), 63.51 (C-5’’, C-2), 63.11 (C-2’’), 62.82 (C-6), 52.00 (CH3COOMe), 
50.67 – 50.34 (NCH2Ph), 46.28 (NCH2linker), 29.09 - 23.34 (CH2linker); HRMS 
(MALDI-TOF MS) m/z calcd for C81H83N7O19 [M + Na]
+
 1480.5636, found 
1480.5663. 
N-(Benzyl)-benzyloxycarbonyl-5-aminopentyl (2-acetamido-3-O-benzyl-4,6-O-
benzylidene-2-deoxy-α-D-glucopyranosyl)-(1→4)-(methyl 2-O-benzoyl-3-O-
benzyl-α-L-idopyranosyluronate)-(1→4)-2-acetamido-3-O-benzyl-6-O-benzoyl-
2-deoxy-α-D-glucopyranoside (60) 
 
To a solution of 59 (150 mg, 0.103 mmol) in THF/H2O (10.1 mL, 8 mL:2.1 mL), a 1 
M PMe3 solution in THF (10 equivalents per azido group, 2.1 mL, 2.06 mmol) was 
added, followed by the addition of a 1 M sodium hydroxide NaOH solution (1 
equivalent per azido group, 206 µL, 0.206 mmol). The solution was vigorously 
stirred at room temperature for 3 hours and another amount of PMe3 solution (1 mL, 
1.03 mmol) and 1 M NaOH solution (103 µL, 0.103 mmol) were added to the 
reaction mixture. After another 2 hours of vigorous stirring at room temperature, 
MALDI-TOF analysis of a small aliquot revealed the completion of the reaction 
(detection of the mass of the intermediate 61 only was detected). The reaction was 
quenched by the addition of 1 M HCl solution (309 µL, 0.309 mmol). The solution 
was evaporated and the resulting crude was dried overnight under high vacuum to 
obtain the crude diamino residue 61.  
The crude of the diamino intermediate 61 was dissolved in dry Et3N (2.8 mL, 8 
mL/0.3 mmol) and dry acetic anhydride Ac2O (1.4 mL, 4 mL/0.3 mmol) was added 
to the solution under argon at 0 °C. The progress of the reaction was monitored by 
MALDI-TOF analysis. After 1 hour of stirring at room temperature, ethanol EtOH 
was added to quench the reaction. The solvent was evaporated and dried under high 
vacuum. The resulting crude was dissolved in a minimum volume of methanol 
MeOH and loaded onto a Sephadex LH-20 for purification (MeOH). The desired 
Chapter 2 – Materials, methods, procedures and characterisation data 
77 
 
bisacetamide product 60 was obtained (106 mg, 69% over two steps). Rf = 0.29 
(hexane/ethyl acetate 2:3);   
20 = +13.0 (c = 0.56, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ = 8.04 –7.10 (m, 40H, aromatic), 5.77 (d, J = 9.0 Hz, 1H, NHAc), 5.53 (s, 
1H, Ph-CH), 5.47 – 5.39 (m, 2H, NHAc’’, H-1’), 5.23 – 5.08 (m, 3H, H-2’, 
OCH2PhCbz), 4.93 – 4.83 (m, 3H, H-1’’, CH2Ph, H-5’), 4.76 – 4.68 (m, 3H, CH2Ph, 
H-1), 4.65 – 4.47 (m, 6H, CH2Ph, NCH2Ph, H-6), 4.32 – 4.17 (m, 4H, CH2Ph, H-2, 
H-6’’, H-2’’), 4.07 – 3.96 (m, 3H, H-3’, H-4, H-4’), 3.88 – 3.80 (m, 1H, H-5), 3.78 – 
3.54 (m, 5H, H-5’’, H-6’’, H-3, H-4’’, OCH2linker), 3.53 – 3.37 (m, 4H, H-3’’, 
CH3COOMe), 3.31 – 3.13 (m, 3H, OCH2linker, NCH2linker), 1.80 (s, 3H, CH3Ac), 1.60 – 
1.44 (m, 4H, CH2linker), 1.41 (s, 3H, CH3Ac), 1.26 (s, 2H, CH2linker); 
13
C NMR (126 
MHz, CDCl3) δ = 170.19, 169.00, 166.24, 165.55, 138.48 - 136.96 (Cqaromatic), 
133.80 - 126.17 (CHaromatic), 101.43 (Ph-CH), 99.23 (C-1’’), 98.61 (C-1’), 97.44 (C-
1), 82.38 (C-4’’), 78.74 (C-3), 76.54 (C-3’’), 76.08 (C-4), 74.44 (C-4’, CH2Bn), 74.08 
(C-3’, CH2Bn), 73.56 (CH2Bn), 70.38 (C-2’), 69.38 (C-5’, C-5), 68.71 (C-6’’), 68.24 
(OCH2linker), 67.31 (OCH2PhCbz), 63.83 (C-5’’), 62.85 (C-6), 52.59 (C-2, C-2’’), 
52.05 (CH3COOMe), 50.38 (NCH2Ph), 47.20 (NCH2linker), 30.42 - 23.88 (CH2linker), 
23.34 - 22.82 (CH3Ac); HRMS (MALDI-TOF MS) m/z calcd for C85H91N3O21 [M + 
Na]
+
 1512.6037, found 1512.6014. 
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Figure 10: Monitoring the progress of the synthesis of the trisaccharide 60 
by MALDI-TOF mass spectrometry. 
(a) MALDI-TOF mass spectrum of the starting material 59. Calcd for 
C81H83N7O19: 1458.6 [M], found m/z 1481.0 [M+Na]
+
, 1453.0 [M-N2+Na]
+
; 
(b) MALDI-TOF mass spectrum of the reaction crude after 5 hours stirring at 
R.T. Calcd for C81H87N3O19: 1405.6 [M], found m/z 1429.2 [M+Na]
+
: 
trisaccharide intermediate 61;  
(c) MALDI-TOF mass spectrum of the reaction crude after 1 hour stirring at 
R.T. Calcd for C85H91N3O21: 1489.6 [M], found 1513.2 [M+Na]
+
: trisaccharide 
60. 
 
N-(Benzyl)-benzyloxycarbonyl-5-aminopentyl (2-acetamido-6-O-benzoyl-3-O-
benzyl-2-deoxy-α-D-glucopyranosyl)-(1→4)-(methyl 2-O-benzoyl-3-O-benzyl-α-
L-idopyranosyluronate)-(1→4)-2-acetamido-3-O-benzyl-6-O-benzoyl-2-deoxy-α-
D-glucopyranoside (63) 
 
Compound 60 (90 mg, 0.06 mmol) was diluted with dry DCM (600 µL) and EtSH 
(222 µL, 3 mmol) was added, followed by the addition of a catalytic amount of 
TMSOTf (0.2 equivalents, 2 µL, 0.012 mmol). After 12 hour stirring at room 
temperature, TLC analysis (Rf = 0.12, hexane/ethyl acetate 3:7) and MALDI-TOF 
analysis showed a complete conversion of the starting material. The reaction was 
(a) 
(b) 
(c) 
[59+Na]
+
 
[59-N2+Na]
+
 
[61+Na]
+
 
[60+Na]
+
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quenched by the addition of Et3N. The solvent was evaporated and the crude eluted 
on a Sephadex column to remove salts and excess of reagents. The resulting residue 
was then dried under high vacuum overnight to afford the crude intermediate 62. 
The diol intermediate was dissolved in dry acetonitrile ACN (1.2 mL) and a catalytic 
amount of Et3N was added. The solution was cooled to -30 °C and a 0.9 M benzoyl 
cyanide BzCN solution in dry acetonitrile (1 equivalent, 67 µL, 0.06 mmol) was 
added dropwise at -30 °C. The reaction was monitored by TLC analysis 
(toluene/ethyl acetate 7:3) and MALDI-TOF analysis to avoid the formation of the 
di-benzoylated by-product. At the end of the addition of the BzCN solution, the 
reaction was quenched by addition of methanol. The solvent was evaporated and the 
crude was eluted from a Sephadex LH-20 for purification (MeOH). The desired 
monobenzoylated compound 63 was obtained (63 mg, 70% over two steps). Rf = 
0.65 (toluene/ethyl acetate 7:3);   
20 = +21.4 (c = 0.5, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) δ = 8.05 – 7.13 (m, 40H, aromatic), 5.76 (d, J = 9.4 Hz, 1H, NHAc), 5.57 (d, 
J = 9.4 Hz, 1H, NHAc’’), 5.42 (s, 1H, H-1’), 5.23 – 5.09 (m, 3H, H-2’, OCH2PhCbz), 
4.96 (s, 1H, H-1’’), 4.91 (s, 1H, H-5’), 4.84 (d, J = 11.5 Hz, 1H, CH2Ph), 4.78 – 4.69 
(m, 3H, CH2Ph, H-1, H-6’’), 4.67 – 4.54 (m, 5H, CH2Ph, H-6), 4.50 (s, 2H, 
NCH2Ph), 4.40 (d, J = 12.2 Hz, 2H, CH2Ph, H-6’’), 4.36 – 4.24 (m, 1H, H-2), 4.19 
(td, J = 10.1, 3.5 Hz, 1H, H-2’’), 4.10 – 4.03 (m, 3H, H-3’, H-4, H-4’), 3.92 – 3.82 
(m, 1H, H-5), 3.79 (d, J = 9.3 Hz, 1H, H-5’’), 3.75 – 3.55 (m, 3H, H-3, H-4’’, 
OCH2linker), 3.48 – 3.40 (m, 3H, CH3COOMe), 3.36 – 3.15 (m, 4H, H-3’’, OCH2linker, 
NCH2linker), 2.96 (bs, 1H, 4-OH’’), 1.78 (d, J = 16.5 Hz, 3H, CH3Ac), 1.61 – 1.45 (m, 
4H, CH2linker), 1.40 (s, 3H, CH3Ac), 1.34 – 1.26 (m, 2H, CH2linker); 
13
C NMR (126 
MHz, CDCl3) δ = 170.17, 169.13, 167.29, 166.31, 165.71, 138.31 - 136.96 
(Cqaromatic), 133.85 - 127.31 (CHaromatic), 98.46 (C-1’), 98.14 (C-1’’), 97.50 (C-1), 
79.77 (C-3’’), 78.65 (C-3), 75.90 (C-4), 74.31 (CH2Bn), 73.33 (C-4’, C-3’, CH2Bn), 
71.52 (C-5’’), 70.49 (C-2’), 69.86 (C-4’’), 69.43 (C-5, C-5’), 68.25 (OCH2linker), 
67.32 (OCH2PhCbz), 63.05 - 62.93 (C-6, C-6’’), 52.49 (C-2), 52.13 (C-2’’, 
CH3COOMe), 50.38 (NCH2Ph), 47.22 - 46.10 (NCH2linker), 29.80 - 27.32 (CH2linker), 
23.87 (CH2linker), 23.36 - 22.93 (CH3Ac); HRMS (MALDI-TOF MS) m/z calcd for 
C85H91N3O22 [M + Na]
+
 1528.5986, found 1528.5992. 
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Figure 11: Monitoring of the progress of the synthesis of the trisaccharide 
63 by MALDI-TOF mass spectrometry. 
(a) MALDI-TOF mass spectrum of the starting material 60. Calcd for 
C85H91N3O21: 1489.6 [M], found 1513.2 [M+Na]
+
; 
(b) MALDI-TOF mass spectrum of the reaction crude a fter 12 hours stirring at 
R.T. Calcd for C78H87N3O21: 1401.6 [M], found m/z 1425.1 [M+Na]
+
: 
trisaccharide intermediate 62;  
(c) MALDI-TOF mass spectrum of the reaction crude after 1 hour stirring at -
30°C. Calcd for C85H91N3O22: 1505.6 [M], found 1528.9 [M+Na]
+
, 1544.9 
[M+K]
+
: trisaccharide 63. 
 
N-(Benzyl)-benzyloxycarbonyl-5-aminopentyl (2-azido-3-O-benzyl-4,6-O-
benzylidene-2-deoxy-α-D-glucopyranosyl)-(1→4)-(methyl 2-O-benzoyl-3-O-
benzyl-α-L-idopyranosyluronate)-(1→4)-(2-acetamido-6-O-benzoyl-3-O-benzyl-
2-deoxy-α-D-glucopyranosyl)-(1→4)-(methyl 2-O-benzoyl-3-O-benzyl-α-L-ido-
pyranosyluronate)-(1→4)-2-acetamido-3-O-benzyl-6-O-benzoyl-2-deoxy-α-D-
glucopyranoside (64) 
 
The reaction was carried out according to procedure A. To a solution of glycosyl 
acceptor 63 (5 mg, 0.0033 mmol) and glycosyl donor 50 (0.015 mg, 0.016 mmol) in 
dry DCM (50 µL), TMSOTf (0.2 equivalents, 0.0007 mmol) was added at -20 °C. 
(a) 
(b) 
(c) 
[60+Na]
+
 
[62+Na]
+
 
[63+Na]
+
 
[63+K]
+
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The reaction was quenched by the addition of Et3N, and the mixture was filtered and 
concentrated. A small aliquot of the reaction was dried with an air stream and 
analysed by LC-MS. 
 
 
 
 
Figure 12: LC-MS spectra obtained for the synthesis of pentasaccharide 64. 
Retention times: 12.75 min (calcd for C85H91N3O22: 1505.6 [M], found m/z 
1506.8 [M+NH4]
+
, 1528.9 [M+Na]
+
): acceptor 63; retention time: 14.43 min 
(calcd for C88H99N3O22Si: 1578.8 [M], found m/z 1601.8 [M+Na]
+
): silylated 
acceptor 64a; retention time: 15.71 min (calcd for C126H130N6O33: 2254.9, 
found m/z 1128.7 [M+2H]
2+
, 1140.2 [M+H+Na]
2+
): product 64. 
(a) Conditions: 1.5 equiv. of donor, 0.2 equiv. of activator (TfOH), -20°C, 
0.01 M; peak areas: 63 (100%); 
(b) Conditions: 1.5 equiv. of donor, 0.2 equiv. of activator (TMSOTf), 0°C,  
 0.5 M; peak areas: 63 (57.13%), 64a (15.97%), 64(26.90%); 
(c) Conditions: 1.5 equiv. of donor, 0.2 equiv. of activator (TMSOTf), -80°C, 
0.01 M; 63 (65.21%), 64a (19.51%), 64(15.28%); 
(d) Conditions: 1.5 equiv. of donor, 0.2 equiv. of activator (TMSOTf), -20°C, 
0.01 M; 63 (62.13%), 64a (5.19%), 64(32.68%) 
 
 
 
 
 
(a) 
(b) 
(c) 
(d) 
63 
64a 
64 
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N-(Benzyl)-benzyloxycarbonyl-5-aminopentyl (3-O-benzyl-4,6-O-benzylidene-2-
deoxy-2-trichloroacetamido-α-D-glucopyranosyl)-(1→4)-(methyl 2-O-benzoyl-3-
O-benzyl-α-L-idopyranosyluronate)-(1→4)-6-O-benzoyl-3-O-benzyl-2-deoxy-2-
trichloroacetamido-α-D-glucopyranoside (65) 
 
To a solution of 59 (102 mg, 0.07 mmol) in THF/H2O (6.72 mL, 5.5 mL:1.22 mL), a 
1 M solution of trimethylphosphine PMe3 in THF (10 equivalents per azido group, 
1.4 mL, 1.4 mmol) was added, followed by the addition of a 1 M NaOH solution (1 
equivalent per azido group, 140 µL, 0.14 mmol). The solution was stirred at room 
temperature for 3 hours and another aliquot of PMe3 solution (0.7 mL, 0.7 mmol) and 
1 M NaOH solution (70 µL, 0.070 mmol) were added to the reaction mixture. After 
another 2 hours of stirring at room temperature, MALDI-TOF analysis of a reaction 
sample revealed the completion of the reaction (detection of the mass of the 
intermediate 61 only). The reaction was quenched by the addition of 1 M HCl 
solution (210 µL, 0.21 mmol). The solution was evaporated and dried overnight 
under high vacuum to afford the crude diamino intermediate 61.  
The crude intermediate 61 was dissolved in dry Et3N (700 µL) and the solution was 
cooled to 0 °C. Trichloroacetyl chloride CCl3COCl (1.5 equivalents per amino group, 
24 µL, 0.21 mmol) was added to the solution under argon. The reaction was 
monitored by TLC analysis (toluene/acetone 9:1) and stopped when the starting 
material was all consumed. The reaction solution was diluted with DCM and washed 
with water. The organic phase was dried over MgSO4, filtered and concentrated. The 
resulting crude was dissolved in a minimum volume of methanol MeOH and loaded 
onto a Sephadex LH-20 for purification (MeOH). The desired ditrichlorocetamido 
product 65 was obtained (65 mg, 55% over two steps). Rf = 0.50 (toluene/acetone 
9:1);   
20 = +5.6 (c = 0.5, CHCl3); 
1
H NMR (500 MHz, CDCl3) δ = 8.00 – 6.97 (m, 
40H, aromatic), 6.92 – 6.80 (dd, J = 8.6 Hz, 1H, NHCCl3), 6.48 (d, J = 8.3 Hz, 1H, 
NHCCl3’’), 5.56 (s, 1H, Ph-CH), 5.49 (d, J = 1.9 Hz, 1H, H-1’), 5.20 – 5.13 (m, 3H, 
H-2’, OCH2PhCbz), 5.05 (s, 1H, H-1’’), 4.93 – 4.82 (m, 2H, H-5’, CH2Ph), 4.82 – 
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4.72 (m, J = 11.7 Hz, 2H, CH2Ph, H-1), 4.71 – 4.57 (m, 3H, CH2Ph, H-6), 4.54 – 
4.39 (m, 5H, CH2Ph, NCH2Ph, H-6, H-6’’), 4.30 – 4.23 (m, 1H, H-2), 4.18 – 3.85 
(m, 7H, CH2Ph, H-4’, H-3’, H-4, H-2’’, H-5’’, H-5), 3.82 – 3.75 (m, 1H, H-3), 3.72 – 
3.60 (m, 3H, H-4’’, H-6’’, OCH2linker), 3.45 – 3.32 (m, 4H, CH3COOMe, H-3’’), 3.21 
(d, J = 39.8 Hz, 2H, NCH2linker), 1.57 – 1.41 (m, 4H, CH2linker), 1.38 – 1.27 (m, J = 
47.4 Hz, 2H, CH2linker); 
13
C NMR (126 MHz, CDCl3) δ = 168.70, 166.19, 165.29, 
161.69, 148.38, 138.88 - 137.06 (Cqaromatic), 133.78 - 126.24 (CHaromatic), 101.33 (Ph-
CH), 99.25 (C-1’’), 98.79 (C-1’), 96.78 (C-1), 82.22 (C-4’’), 79.33 (C-3), 76.57 (C-
3’’), 75.97 - 75.16 (C-4, C-4’, C-3’, CH2Bn), 74.56 (CH2Bn), 73.40 (CH2Bn), 69.45 (C-
5), 68.50 (C-2’, C-6’’, OCH2linker, C-5’), 67.38 (OCH2PhCbz), 63.77 (C-5’’), 62.83 (C-
6), 54.93 (C-2, C-2’’), 52.00 (CH3COOMe), 50.43 (NCH2Ph), 47.11 - 46.20 
(NCH2linker), 29.02 - 23.58 (CH2linker); HRMS (MALDI-TOF MS) m/z calcd for 
C85H85Cl6N3O21 [M + Na]
+
 1716.3699, found 1716.3761. 
N-(Benzyl)-benzyloxycarbonyl-5-aminopentyl (6-O-benzoyl-3-O-benzyl-2-deoxy-
2-trichloroacetamido-α-D-glucopyranosyl)-(1→4)-(methyl 2-O-benzoyl-3-O-
benzyl-α-L-idopyranosyluronate)]-(1→4)-6-O-benzoyl-3-O-benzyl-2-deoxy-2-
trichloroacetamido-α-D-glucopyranoside (67) 
 
Compound 65 (50 mg, 0.03 mmol) was diluted with dry DCM (500 µL) and EtSH 
(111 µL, 1.5 mmol) was added, followed by the addition of a catalytic amount of 
TMSOTf (0.2 equivalents, 1 µL, 0.006 mmol). After 1 hour stirring, TLC analysis 
(Rf = 0.41, toluene/ethyl acetate 3:2) and MALDI-TOF analysis showed a complete 
conversion of the SM. The reaction was then quenched by addition of Et3N. The 
solvent was evaporated and the residue was loaded onto a Sephadex LH-20 column 
to remove the majority of the salts and the excess of the reagent. The resulting 
residue was hence dried under high vacuum overnight to afford the crude 
intermediate 66. 
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The diol intermediate 66 was dissolved in dry acetonitrile ACN (600 µL) and a 
catalytic amount of Et3N was added. The solution was cooled to -30 °C and a 0.9 M 
benzoyl cyanide BzCN solution in dry acetonitrile (1 equivalent, 33 µL, 0.03 mmol) 
was added dropwise at -30 °C. The reaction was monitored by TLC analysis 
(toluene/ethyl acetate 7:3) and MALDI-TOF analysis to avoid the formation of the 
di-benzoylated by-product. At the end of the addition of the BzCN solution, the 
reaction was quenched by addition of methanol. The solvent was evaporated and the 
crude was eluted from a Sephadex LH-20 for purification (MeOH). The desired 
monobenzoylated compound 67 was obtained (26 mg, 51%). Rf = 0.65 (toluene/ethyl 
acetate 7:3); 
1
H NMR (500 MHz, CDCl3) δ = 8.00 – 7.03 (m, 40H, aromatic), 6.92 
(d, J = 8.2 Hz, 1H, NHCCl3), 6.80 (bs, 1H, NHCCl3), 6.53 (d, J = 8.2 Hz, 1H, 
NHCCl3’’), 5.45 (s, 1H, H-1’), 5.20 – 5.14 (m, J = 2.9 Hz, 3H, H-2’, OCH2PhCbz), 
5.06 (s, 1H, H-1’’), 4.92 – 4.85 (m, 2H, CH2Ph, H-5’), 4.84 – 4.76 (m, 3H, H-6’’, 
CH2Ph, H-1), 4.69 – 4.61 (m, J = 18.8 Hz, 3H, CH2Ph, H-6), 4.49 (bs, 3H, NCH2Ph, 
H-6), 4.43 – 4.36 (m, J = 10.7 Hz, 2H, H-6’’, NCH2Ph), 4.29 (bs, 1H, H-2), 4.12 – 
3.98 (m, 4H, H-4’, H-3’, H-4, CH2Ph), 3.97 – 3.87 (m, J = 10.6 Hz, 3H, H-5, H-5’’, 
H-2’’), 3.79 (bs, 1H, H-3), 3.60 (s, 1H, OCH2linker), 3.55 – 3.46 (m, 4H, CH3COOMe, 
H-4’’), 3.34 – 3.13 (m, 4H, OCH2linker, H-3’’, NCH2linker), 1.60 – 1.18 (m, 6H, 
CH2linker); 
13
C NMR (from HSQC) (500 MHz, CDCl3) δ = 133.3 – 126.5 (Caromatic), 
98.7 (C-1’), 98.6 (C-1’’), 96.6 (C-1), 79.2 (C-3’’), 78.9 (C-3), 75.4 (C-4’), 74.9 
(CH2Bn), 74.8 (C-4, C-3’, CH2Bn), 73.1 (CH2Bn), 71.7 (C-5’’), 70.0 (C-4’’), 69.4 (C-
5), 68.9 (C-2’), 68.2 (C-5’), 68.0 (OCH2linker), 67.2 (OCH2PhCbz), 62.9 (C-6), 62.6 (C-
6’’), 54.9 (C-2), 54.6 (C-2’’), 52.1 (CH3COOMe), 50.4 (NCH2Ph), 46.9 - 46.3 
(NCH2linker), 30.2 – 23.3 (CH2linker); LRMS (ESI MS) m/z calcd for C85H85Cl6N3O22 
[M + H]
+
 1710.4, found 1710.6. 
 
 
 
 
Chapter 2 – Materials, methods, procedures and characterisation data 
85 
 
N-(Benzyl)-benzyloxycarbonyl-5-aminopentyl (2-azido-3-O-benzyl-4,6-O-
benzylidene-2-deoxy-α-D-glucopyranosyl)-(1→4)-(methyl 2-O-benzoyl-3-O-
benzyl-α-L-idopyranosyluronate)-(1→4)-(6-O-benzoyl-3-O-benzyl-2-deoxy-2-
trichloroacetamido-α-D-glucopyranosyl)-(1→4)-(methyl 2-O-benzoyl-3-O-
benzyl-α-L-idopyranosyluronate)]-(1→4)-6-O-benzoyl-3-O-benzyl-2-deoxy-2-
trichloroacetamido-α-D-glucopyranoside (68) 
 
The reaction was carried out according to procedure A. To a solution of glycosyl 
acceptor 67 (13 mg, 0.008 mmol) and glycosyl donor 50 (11 mg, 0.012 mmol) in dry 
DCM (160 µL), TMSOTf (0.2 equivalents, 0.016 mmol) was added at  
-20 °C. The reaction was quenched by the addition of Et3N, and the mixture was 
filtered and concentrated. A small aliquot of the reaction was dried with an air stream 
and analysed by LC-MS. 
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Figure 13: LC-MS spectra obtained for the synthesis of pentasaccharide 68. 
Retention time: 14.97 min (calcd for C85H85Cl6N3O22: 1713.3 [M], found m/z 
1714.4 [M+H]
+
, 1731.4 [M+NH4]
+
, 1736.3 [M+Na]
+
): acceptor 67; retention 
time: 16.15 min (calcd for C88H93Cl6N3O22Si: 1785.5 [M], found m/z 1786.5 
[M+NH4]
+
,1803.5 [M+H]
+
,1809.5 [M+Na]
+
): silylated acceptor 68a (by-
product); retention time: 16.90 min (calcd for C 126H124Cl6N6O33: 2463.1, found 
m/z 1254.4 [M+2Na]
2+
): product 68. 
(a) Conditions: 1.5 equiv. of donor, 0.2 equiv. of activator (TMSOTf), -20°C, 
0.05 M; peak areas: 67 (67.87%), 68a (17.05%), 68(15.07%); 
(b) Conditions: 1.5 equiv. of donor, 0.2 equiv. of activator (TMSOTf), -20°C, 
0.05 M; peak areas: 67 (34.00%), 68a (13.82%), 68(52.18%). 
(a) 
(b) 
67 
68b 68 
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3.1. Introduction 
3.1.1. Aims 
Libraries of HS oligosaccharides from different sources (notably from natural 
sources) have been used to assess a number of biological problems, such as the 
minimum size for functional activity (Ornitz et al. 1992, Gambarini et al. 1993, 
Ostrovsky et al. 2002), the existence of specific protein-binding sequences (Cardin 
and Weintraub 1989, Sobel et al. 1992, Hileman, Fromm, et al. 1998) and the 
specificity of the saccharides in their interactions with proteins (Xu and Esko 2014). 
Using such short saccharides decreases the complexity of studies as it greatly reduces 
the number of possible epitopes in a single structure. Therefore, in order to 
investigate the specificity of HS in FGF signalling, the preparation of a library of HS 
oligosaccharides from natural sources was attempted in this chapter. 
3.1.2. Strategy 
The strategy adopted for this chapter relied on the preparation/isolation of HS 
oligosaccharides from natural sources. The enzymatic digestion of porcine mucosal 
HS (PMHS) was carried out, followed by the purification of the resulting saccharide 
mixtures by different chromatographic techniques to isolate pure HS hexa-, octa- and 
deca-saccharides. Pure compounds are required to perform the sequencing of HS 
saccharides by MS and MS/MS and, therefore, requires the use of several techniques 
of purification. The general strategy adopted for the study of SAR of HS in FGF 
signalling is described in Figure 14.  
3.1.3. Methods 
This section describes briefly the techniques and methods used for the isolation of 
PMHS oligosaccharides (for further detail about the principles of the different 
methods, see Section 1.8.1). 
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Figure 14: Strategy adopted for the creation of libraries of HS 
oligosaccharides from natural sources and the study of HS SAR in FGF 
signalling. 
 
The preparation of the first set of HS oligosaccharides was performed following the 
protocol described by Powell et al. (2010). Native PMHS was first enzymatically 
digested with heparinase III which selectively cleaves the glycosidic bond D-
GlcNR(± 6S) α(1→4) D-GlcA (with R = N-acetyl or N-sulphate). The two other 
glycosidic bonds are D-GlcNS(± 6S) α(1→4) L-IdoA(2S) and D-GlcNR(± 6S) 
α(1→4) D-GlcA/L-IdoA(± 2S), which are cleaved by heparinase I and heparinase II, 
respectively (Linhardt et al. 1990). The enzymatic elimination reactions resulted in 
the formation of an intact D-glucosamine residue at the reducing end of the chain and 
an unsaturated uronic acid residue at the non-reducing end. This double bond absorbs 
at 232 nm which makes the detection of the oligosaccharides by UV relatively easy 
to perform. The resulting saccharide mixtures were next partitioned first according to 
their sizes and second according to their charges. 
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SEC helps separating heterogeneous mixtures according to the hydrodynamic 
volume of the compounds (Ziegler and Zaia 2006). The saccharides were eluted 
through two Superdex™ 30 XK 16 columns connected in series, with 0.5 M 
ammonium bicarbonate NH4CO3 (isocratic buffer), and the elution was monitored at 
λABS = 232 nm. SAX chromatography is a common technique used to further purify 
the SEC fractions (Rice et al. 1985, Powell et al. 2010). This technique separated the 
compounds according to their net charges and often requires several runs to afford 
pure fractions (here, two runs were necessary). The saccharides were first eluted 
through a Propac PA1 column (semi-preparative column: 9 x 250 mm) with a linear 
gradient of 0-50% 2 M NaCl over 120 minutes. An additional run was carried out 
using a Propac PA1 analytical column (analytical column: 4 x 250 mm) with a 
gradient of NaCl solution suited to every individual sample. As for SEC, the 
saccharides were monitored by detection at 232 nm.  
In order to ensure the effective isolation of pure single structures, CTA-SAX 
chromatography was used to complement the SAX-Propac chromatography. The 
development of the CTA-SAX chromatography technique by Mourier and Viskov 
(2004) was inspired by the reverse-phase ion pairing (RPIP) chromatography, a 
robust technique, which efficiently separates highly sulphated oligosaccharides such 
as HS and Hp (Zhang, Xie, et al. 2009, Yang et al. 2011, Du et al. 2016). However, 
until the work published by Mourier and Viskov (2004), many problems were 
encountered with this technique. The ion pairing agents (mainly quaternary amines) 
were often not adapted to mass spectrometry, as they caused a severe loss of 
sensitivity and a reduced signal-to-noise ratio (Doneanu et al. 2009). Therefore, 
Mourier and Viskov (2004) coated a C18 column with cetyltrimethylammonium 
(CTA) instead of using the ion-pairing agent in the mobile phase. This technique 
permitted the separation of saccharides displaying up to 20 sulphate groups, which 
perfectly suited this project. The buffer used here was ammonium bicarbonate 
NH4CO3, which is volatile and is not corrosive, thus granting a longer life-time to the 
column (Miller et al. 2016). 
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To broadly determine the size of the oligosaccharides, PAGE was used to 
complement the small-scale SEC technique. PAGE is a routine technique that 
separates molecules based on their sizes, charges and conformations. The electric 
field applied across the gel will cause the migration of the compounds from the 
negative electrode (cathode) to the positive electrode (anode) through a gel (30% 
polyacrylamide gels (w/v) are generally used for separation of HS saccharides). The 
gels were stained with a 0.08% Azure A solution (w/v), which interacts with the 
negatively charged groups of the saccharides.  
3.2. HS oligosaccharide library preparation: from natural 
sources 
3.2.1. Partial enzymatic digestion of PMHS 
A small-scale enzymatic digestion was first carried out to determine the appropriate 
ratio of enzyme/PMHS. From this trial digestion, it was determined that the most 
suitable ratio to use was 2 mU/mg PMHS for the first hour of the digestion, followed 
by the addition of another 2 mU/mg PMHS of heparinase III at the end of the first 
hour. A total of 400 mg of PMHS was digested for a total digestion time of 9 hours. 
The evolution of the digestion was monitored by small-scale SEC (Figure 15).  
The enzymatic digestion of the native PMHS led to the consequent formation of 
saccharides of small sizes (represented by the peaks at 25-35 mins) in comparison to 
the formation of longer saccharides (represented by the peaks at 15-25 mins).  
3.2.2. SEC of digested PMHS 
The oligosaccharide mixtures resulting from the enzymatic digestion were separated 
according to their hydrodynamic volumes using large-scale SEC chromatography 
(buffer: 0.5 M NH4HCO3). Batches of 50 mg were fractionated separately to optimise 
the separation and avoid overloading the column. Similar chromatograms were 
obtained for each batch, therefore demonstrating that the technique is consistent 
between each run (data not shown). In all cases, there was no base line resolution, 
therefore confirming the incomplete fractionation of the saccharides. The sizes of the 
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Figure 15: Monitoring the evolution of PMHS partial enzymatic diges tion 
by heparinase III using small-scale SEC. In black is represented the profile 
obtained for the starting material (digestion time point t 0h). In blue is 
represented the profile obtained for the partially digested PMHS (digestion 
time point t9h). For small-scale SEC, the isocratic elution of 100 µg material 
was carried out using a Superdex™ peptide 7.5/300 small scale SEC column, at 
0.2 mL/min (buffer: 0.5 M ammonium bicarbonate) and was monitored by 
absorbance at λABS = 232 nm. 
 
saccharides were assigned by reference to standard Hp saccharides of known size 
with the help of the results obtained from the PAGE analysis of the pooled fractions 
from SEC chromatography (Figure 16). However, owing to the lack of sensitivity 
of Azure A for low sulphated oligosaccharides, the sizes could only be estimated 
approximately. Moreover, even though the degree of polymerisation (dp) of the 
oligosaccharide chain could be expected to increase by two units (peak(n): dp(2n)) 
between each peak, this was not apparent for the complex mixture shown in Figure 
16. This was due to the mode of separation of SEC chromatography, as the 
saccharides were fractionated according to their hydrodynamic volumes and not 
according to their number of disaccharide units only. This mode of separation led to 
pooled fractions that contained heterogeneous mixtures of saccharides of varying 
sizes and sulphation, which explains why the bands did not appear to be sharp on the 
PAGE gel. However, for this project, oligosaccharides ranging from hexa- to deca-
saccharides were desired. Therefore, such mixtures of saccharides of different sizes 
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were not considered to be a major drawback. The SEC fraction corresponding to the 
SEC chromatography profile peak n° 10 (Figure 16) was selected for further work. 
Prior to further purification, fraction 10 was desalted by means of several cycles of 
lyophilisation (ammonium bicarbonate is a volatile salt, easily removable by 
lyophilisation) and stored for further use. In total, five cycles were necessary to 
achieve complete desalting. 
 
 
Figure 16: Estimation of the degree of polymerisation of the partially 
digested PMHS saccharides: comparison of the large-scale SEC profile and 
the PAGE analysis of the resulting SEC fractions.  
(a) Typical SEC profile of PMHS partially digested by heparinase III . The 
isocratic elution was made using a solution of 0.5 M NH4HCO3 over 900 min at 
a flow rate of 0.5 mL/min. The peaks (and thus pooled fractions) were 
numbered 1 - 12, starting from the right hand side of the profile (for details 
about large-scale SEC run conditions, see Section 2.1.2.3).  
(b) PAGE analysis of the pooled SEC fractions. The numbers 2 - 12 correspond 
to the SEC fraction numbers. Fraction number 10 (underlined) was selected for 
further work. 
 
(a) 
(b) 
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3.2.3. SAX chromatography of digested PMHS: 1st run 
SEC fraction 10 was next purified using SAX chromatography with a semi-
preparative ProPac PA1 column (9 x 250 mm), which allows the purification of a 
maximum of 5 mg material per run. The saccharides were eluted with a gradient of 
0-80% 2 M NaCl over 120 min and the resulting SAX profile is shown in Figure 17. 
The chromatogram showed a spread of peaks across the gradient, confirming the 
structural heterogeneity of the compounds of the SEC fraction. There was no base 
line resolution, suggesting that the multiple peaks in the complex mixture were 
overlapping and that no complete separation of the saccharides was accomplished. 
This was also confirmed by the different shapes of the peaks (sharp or broad, single 
or double peaks). However, it must be noted that SAX chromatography can provide 
separation of anomers of a single structure (Skidmore et al. 2010). Therefore, the 
apparent structural heterogeneity suggested by such type of profile may not be as 
high as predicted. The two sets of peaks 10-A (59-63 min) and 10-B (68-73 min) 
were selected for an additional step of SAX-HPLC, as they were assumed to grant a 
high diversity of structures.  
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Figure 17: Semi-prep SAX-HPLC profile for SEC fraction 10. The 
saccharides were eluted with a 0-80% gradient over 120 min (buffer: 2 M NaCl) 
at a flow rate of 1 mL/min. The conditions for SAX-HPLC purification of SEC 
fractions are described in more detail  in Section 2.1.2.5. 
(a) Shows the complete SAX-HPLC profile.  
(b) Shows a region of the SAX-HPLC profile (56-74 min). Peaks representing 
the fractions that have been selected for further work have been assigned the 
labels 10-A (59-63 min) and 10-B (68-73 min). 
 
 
(a) 
(b) 
10-A 10-B 
Chapter 3 –HS oligosaccharide library production from natural sources 
96 
 
3.2.4. SAX chromatography of digested PMHS: 2nd and 3rd runs 
Further separation of the fractions 10-A and 10-B was performed using an analytical 
Propac PA1 column (4 x 250 mm). Fractions were not desalted and were simply 
diluted with water (1/15 dilution) prior to loading and absorption onto the column. 
Each sample was eluted with an appropriate gradient of NaCl solution (gradient 
details are given for each individual chromatogram in Figure 18). As expected, the 
chromatograms showed a spread of peaks across the gradient. No base line resolution 
was detected, again suggesting that the multiple peaks in the complex mixture were 
overlapping, despite very shallow gradients being used for this second step. This, 
therefore, demonstrated the limitation of SAX chromatography for the separation of 
oligosaccharides bearing similar levels of anionic moieties. However, it should be 
noted that using less steep gradients resulted in a better separation of the peaks. 
Three sets of peaks (10-A1, 10-A2 and 10-B1, Figure 18) were selected for further 
work. Prior to the last step of purification by CTA-SAX chromatography (see 
Section 3.2.5 below), selected peaks were purified for a third and last time with 
SAX-HPLC on Propac PA1 column, with an even shallower gradient. However, no 
improved purification was observed (see Figure 19). Even though complete 
separation of the peaks was not achieved using standard SAX chromatography, it 
assisted in the further purification of the saccharides according to their charge. 
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Figure 18: SAX-HPLC profiles for fractions 10-A and 10-B. The conditions 
for the improved separation of the SAX -HPLC fractions are described in more 
detail in Section 2.1.2.5. 
(a) Shows the SAX-HPLC profile obtained for the purification of fraction 10-
A. The saccharides were eluted with a 30 -38% gradient over 40 min (buffer: 2 
M NaCl) at a flow rate of 1 mL/min. The peaks representing the fractions that 
were selected for further work were assigned the labels 10-A1 (46-49 min) and 
10-A2 (57-60 min).  
(b) Shows the SAX-HPLC profile obtained for the purification of fraction 10-
B. The saccharides were eluted with a 35-45% gradient over 40 min (buffer: 2 
M NaCl) at a flow rate of 1 mL/min. The peak representing the fraction that 
was selected for further work was assigned the label 10-B1 (47-50 min). 
 
10-B1 
10-A1 
(a) 
(b) 
10-A2 
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Figure 19: SAX-HPLC profiles for fractions 10-A1, 10-A2 and 10-B1.The 
fractions were eluted at a flow rate of 1 mL/min (buffer: 2 M NaCl). 
(a) Shows the SAX-HPLC profile obtained for the purification of fraction 
10-A1. The saccharides were eluted with a 32-34% gradient over 40 min.   
(b) Shows the SAX-HPLC profile obtained for the purification of fraction 
10-A2. The saccharides were eluted with a 35-45% gradient over 40 min.  
( c) Shows the SAX-HPLC profile obtained for the purification of fraction 
10-B1. The saccharides were eluted with a 32-34% gradient over 40 min.   
  
(a) 
(b) 
(c) 
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3.2.5. CTA-SAX chromatography of digested PMHS 
3.2.5.1. Column preparation  
CTA-SAX chromatography was next used to further purify structures, as originally 
described by Mourier and Viskov (2004). Prior to any purification of the SAX 
fractions, the derivatisation of the C18 column with CTA was performed. This was 
done by eluting a 1 nM CTA solution in methanol/water (MeOH/H2O). The 
appropriate coating of the column was assessed by fractionating a mixture of the 
eight common naturally occurring disaccharide standards with the freshly derivatised 
column. The ratio (MeOH/H2O 50/50, v/v) offered both ideal resolution and 
retention times for the disaccharide standards, as seen in Figure 20 (Std 6 (ΔUA2S-
GlcNS,6S) should not be eluted at more than 0.6 - 0.8 M NH4CO3). Ammonium 
bicarbonate was chosen as solvent for the elution (2 M solution) in order to 
simplify/reduce the loss of material during the desalting process (Miller et al. 2016).   
 
Figure 20: Confirming the derivatisation of the C18 silica column by CTA: 
CTA-SAX profile obtained for the separation of the eight common 
naturally occurring disaccharides standards. Profile obtained for 
derivatisation with a 1 nM CTA solution of MeOH/H2O (50/50, v/v). The 
conditions for the column coating are described in detail  in Section 2.1.2.6. 
The disaccharide standards were eluted with a 0 -50% gradient over 45 min 
(buffer: 2 M NH4CO3) at a flow rate of 1 mL/min.  The peak labels refer to the 
reference numbers assigned to the disaccharide standards: 1. ΔUA-GlcNAc; 2. 
ΔUA-GlcNAc(6S); 3. ΔUA-GlcNS; 4. ΔUA-GlcNS(6S); 5. ΔUA(2S) -GlcNS; 6. 
ΔUA(2S)-GlcNS(6S); 7. ΔUA(2S) -GlcNAc; 8. ΔUA (2S)-GlcNAc(6S). 
1 
2 
3 
4 
5 
6 
7 
8 
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3.2.5.2. CTA-SAX of compounds 10-A1 and 10-A2 
SAX fractions 10-A1 and 10-A2 were not desalted and were simply diluted with 
water (1/15 dilution) prior to absorption onto a freshly derivatised C18 column. Each 
sample was eluted with a 25-70% gradient over 60 min (elution buffer: 2 M 
NH4CO3). As shown by the chromatogram in Figure 21 (a), CTA-SAX allowed the 
separation of the double peak for the fraction 10-A1 - separation which could not be 
achieved by standard SAX chromatography (Figure 19). For fraction 10-A2, the 
separation of the minor and major peaks was also achieved. Therefore, the CTA-
SAX technique appeared to offer a better resolution than regular SAX. However, it 
should be noted that CTA-SAX has also been shown to allow the separation of the 
anomers of a same structure (Mourier and Viskov 2004). In order to verify the purity 
of the structures and to sequence them by MS/MS, the collected fractions were 
desalted and dried using a vacuum concentrator for a total of 5 cycles (the material 
loss is generally limited with a vacuum concentrator compared to a freeze-dryer). 
However, at the end of the drying process, a fine white powder - soluble in DMSO 
but not in water - was observed in the Eppendorf tubes. It was concluded that this 
powder was organic material and was neither a saccharide nor a salt (the latter are 
both soluble in water). In order to determine the nature of the contaminant, the pH of 
the buffer used for both runs was measured (expected value: 7.6, read value: 9.25). 
According to the supplier (Supelco HPLC Column - Selection Guide, Sigma 
Aldrich), the C18 column used is stable for pH ranging between 2 and 8. The white 
powder was therefore thought to be some CTA-derivatised silica that became 
detached from the column and was eluted along with the compounds. The high pH 
obtained for the buffer may be explained by the decomposition of the hydrogen 
bicarbonate in water to form both volatile carbon dioxide and soluble ammonia. A 
high concentration of ammonia would have, therefore, led to a higher pH. This 
assumption was confirmed by the fact that the column could not be used at all after 
running the fractions 10-A1 and 10-A2 as the pressure of the system was above the 
threshold value (4000 psi), advised by the manufacturer for normal elution 
conditions (1 mL/min, water). No further purification was conducted as it would 
have resulted in yields of the compounds (approximately a few µg) that were too low 
to allow further work (bioassays and structural analysis). 
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Figure 21: CTA-SAX profiles for fractions 10-A1 and 10-A2. Each sample 
was eluted with a 25-70% gradient over 60 min (elution buffer: 2 M NH4CO3) at 
a flow rate of 1 mL/min. The conditions for CTA-SAX purification are 
described in detail  in Section 2.1.2.6.  
(a) SAX-HPLC profile obtained for the  purification of fraction 10-A1. Peaks 
representing the fractions that were selected for further work were assigned the 
labels 10-A1a (52.6-54 min) and 10-A1b (54-55 min).  
(b) SAX-HPLC profile obtained for the purification of fraction 10 -A2. Peaks 
representing the fractions that were selected for further work were assigned the 
labels 10-A2a (59-60 min) and 10-A2b (61.5-63.5 min).  
 
 
10-A1a 
10-A1b 
10-A2b 10-A2a 
(a) 
(b) 
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3.3. Conclusions 
Establishing the structural determinants underpinning the interactions of HS with 
FGF and FGFR requires the preparation of oligosaccharide libraries. For this project, 
one approach attempted was the preparation of a library of HS oligosaccharides, 
ranging from octa- to dodeca-saccharides, by partial enzymatic digestion of native 
PMHS. The preparation of the oligosaccharide was initially carried out following the 
protocol developed by Powell et al. (2010). The first step of the process consisted of 
the degradation of native PMHS polysaccharide chains by heparinase III to afford 
resistant sulphated saccharides. The PMHS digests were sequentially purified by 
chromatographic fractionation. Several fractions (10-A1, 10-A2 and 10-B1) were 
successfully isolated according to their sizes and partially according to their charges, 
by SEC and subsequent SAX-HPLC. The last purification step (by means of CTA-
SAX chromatography) was, however, unsuccessful and resulted in low amounts of 
contaminated compounds. The degradation of the column - and therefore the elution 
of CTA-coated silica along with the analytes – was observed during the last step of 
purification of the digested PMHS samples, caused by the decomposition of the salt 
into soluble ammonia. The high pH of the buffer may have also altered the structures 
of the saccharides, as HS and Hp are known to be sensitive to extreme pH (Skidmore 
et al. 2009). Developing more appropriate buffers is clearly required to overcome 
this problem (such as non-volatile ammonium methane sulphonate, sodium methane 
sulphonate, or even the volatile ammonium acetate). Alternatively, other methods of 
purification including reverse-phase ion-pairing chromatography (Ponnusamy 2013), 
porous graphitised carbon chromatography (Karlsson et al. 2005) and hydrophilic 
interaction liquid chromatography (Naimy et al. 2008) could also be used instead of 
CTA-SAX. 
The partially successful purification exposed some of the limitations of the 
preparation of HS oligosaccharides from natural sources. Firstly, even though it has 
been shown to afford access to a certain number of structures in a relatively short 
amount of time, working with tissue-derived HS structures rarely allows the isolation 
of highly pure saccharides. Moreover, their structures are unknown and require 
difficult analytical procedures to be determined, therefore limiting the rigorous study 
of the SAR of HS. Secondly, the isolation of PMHS oligosaccharides greatly relies 
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on an extensive range of orthogonal purification methods. This leads to a substantial 
loss of material, meaning that preparation of HS oligosaccharides derived from 
tissues generally results in access to very restricted amounts of final material (of the 
order of low µg amounts). Such low amounts seriously hamper the further analysis 
and SAR studies. For example, BaF3 bioassays, as used in Chapter 5 to study the 
SAR of HS in FGF signalling, require a minimum of a few µg of compound 
(Guimond et al. 2009). Similar amounts are likely to be needed to permit sequencing 
using recently developed MS methods (Jones et al. 2011, Yang et al. 2011, Du et al. 
2016). Thus, the amounts of material are just on the limit of the minimum needed to 
tackle such studies. In contrast, chemical and enzymatic/chemoenzymatic syntheses 
could be seen as potential alternative to the extraction of the saccharides from tissues 
for the study of the SAR of HS as these methods permit the preparation of relatively 
large amounts of well-defined structures. It was thus decided to continue work using 
compounds derived by these approaches as a more productive line of research. 
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4. Chapter 4 – Chemical synthesis of HS oligosaccharide 
structures 
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4.1. Introduction 
Several approaches - namely the multi-step and one-pot solution-phase syntheses, the 
solid-phase synthesis, and finally the enzymatic/chemoenzymatic syntheses - have 
been developed for the preparation of HS oligosaccharide libraries, as mentioned in 
Section 1.8.2. However, given the difficulties still encountered with the high-
throughput methods, the traditional multi-step solution-phase synthesis generally 
seems like the most convenient alternative for the preparation of such compounds. 
The wealth of glycosylating agents, synthetic routes and the fairly good 
understanding of its mechanisms indeed make it appear the most reliable and 
efficient approach. Thus, to meet the requirements and expectations of this project - 
the production of several octasaccharide targets in a relatively short period of time - 
it was decided to resort to the development of a multi-step solution-phase method. In 
the following sections, a general overview of the chemical synthesis of carbohydrates 
(and more specifically of Hp/HS), but also an overview of the advances that have 
been made in the field of Hp/HS oligosaccharide synthesis and the challenges that 
remain will be addressed. 
4.1.1. Chemical synthesis of Hp/HS oligosaccharides 
4.1.1.1. Protecting groups 
Owing to the intrinsic polyfunctional nature of the Hp/HS carbohydrates, their 
synthesis requires the extensive use of protecting groups (PGs) to appropriately and 
temporarily mask the different hydroxyl, carboxyl and amino groups. A broad variety 
of PGs is available (Wuts and Greene 2006), which therefore permits the precise 
control of the availability of each functional moiety at each step of the synthetic 
process. To be considered suitable for such lengthy and complex syntheses, the PGs 
must fulfil a certain number of conditions. First of all, ideally, the environment and 
user friendly reagents used to install and remove a PG must be relatively easy to 
access. Secondly, the installation and cleavage reactions themselves must preferably 
be carried out in mild conditions and not affect any other PG (the ability to 
add/remove PGs in the presence of others is termed orthogonality). Thirdly, the 
groups must also remain stable throughout the synthesis, as well as during the work-
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up and purification steps. Ideally, the installation of a PG will afford a final product 
that will be more hydrophobic than the starting material. Hydrophobic compounds 
are indeed easier to handle during work-up steps and may also be crystallised for 
more convenient purification. Finally, the starting material, the final product and the 
reagents must be easily separated from one another during the work-up and 
purification steps. The timing of the introduction of the different PGs is determined 
by the relative reactivity of the hydroxyl groups. Primary hydroxyl groups are known 
to be more reactive than secondary ones. In addition, the anomeric hydroxyl group is 
the most reactive of the secondary hydroxyl groups. Finally, to a first approximation, 
the reactivity of the hydroxyl groups generally decreases as they get further away 
from the anomeric position. It is however to be noted that this rule of thumb is not 
valid in the presence of both axial/equatorial hydroxyl groups (axial hydroxyl groups 
are far less reactive than equatorial ones (Orgueira et al. 2002, Pedersen et al. 2011)).  
PGs can be classified into two distinct categories. Permanent groups will be used to 
mask the hydroxyl groups that will ultimately be exposed at the very last step of the 
synthesis. Benzyl, benzyl-derivative and benzoate ester groups are widely used as 
permanent groups. Unlike permanent groups, temporary groups will be subjected to 
manipulations, thus selectively installed and removed according as required. Various 
acetyl-derivative, silyl, ester, ether, carbonate and acetal groups are often used as 
temporary groups. In the case of Hp/HS carbohydrates, chemists need to resort to 
numerous orthogonal permanent/temporary groups that can be selectively installed 
and removed to obtain compounds that display discrete sulphation and acetylation 
patterns (Figure 22). 
4.1.1.2. Glycosylation: keystone of carbohydrate synthesis 
Chemical synthesis of carbohydrate oligo- and poly-saccharides mainly relies on the 
formation of a covalent bond - glycosidic linkage - between two sugar units or 
between a sugar unit and an aglycon in a reaction termed chemical glycosylation. 
Although several types of glycosidic linkages can be formed, such a linkage 
generally consists of an acetal connecting two sugar residues and has been formed 
between the hemiacetal of one of the residues and a hydroxyl group of the other.  
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Figure 22: Some of the major protecting groups used for Hp/HS 
oligosaccharide synthesis.  R = carbohydrate. 
 
The glycosylation reaction has been thoroughly studied since it was first reported by 
different groups (Fischer 1893, 1895, Koenigs and Knorr 1901). It has since been 
extensively modified, essentially introducing new types of promoters, mainly 
mercury and silver salts (Boullanger et al. 1987, Fürstner et al. 2000, Mastelić et al. 
2004). The impact of the type and polarity of the solvent has been investigated as 
well (Bills and Green 1967). All the efforts involved in improving the Koenigs-Knorr 
and Fisher methods paved the way for the development of new methods to form 
glycosidic bonds (Nicolaou and Mitchell 2001, Zhu and Schmidt 2009). 
A chemical glycosylation commonly requires three main components to be 
performed: a glycosyl donor, a glycosyl acceptor and a promoter. The glycosyl donor 
is the sugar residue bearing the leaving group (LG) at its anomeric centre 
(electrophilic entity) and the glycosyl acceptor is the residue presenting a free 
hydroxyl group (nucleophilic entity). The first step consists of the activation of the 
glycosyl donor by the activator. This first step results in the departure of the leaving 
group and the creation of a glycosyl cation intermediate, called an oxocarbenium ion 
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(Scheme 1). This transient entity can hence be attacked by the free hydroxyl group of 
the glycosyl acceptor from either the top face or the bottom face of the ring plane, 
which will finally result in the formation of the new glycosidic bond, with one or the 
other configuration at C1.  
 
Scheme 1: General mechanism of the chemical O-glycosylation. 
 
Several parameters must be taken into account and controlled to perform a high-yield 
chemical glycosylation that will ultimately afford the desired glycoside. First of all, 
completely anhydrous conditions must be maintained to avoid the hydrolysis of the 
activated glycosyl donor that can occur in some cases. The participation of water as a 
competitive nucleophile can be circumvented by scavenging the water molecules 
with the addition of molecular sieves to the reaction mixture. However, due to the 
alkaline nature of the molecular sieves, higher amounts of activator may be necessary 
to achieve full activation of the donor. This may compromise the stability of the PGs 
of the building blocks and lead to other side reactions. Secondly, secondary hydroxyl 
groups are less reactive nucleophiles, leading to lower glycosylation yields. Finally, 
measures have to be taken to ensure the stereoselectivity of the glycosylation 
reaction as two different isomers may be formed during the reaction depending on 
the conformation of the new glycosidic linkage formed: either 1,2-cis or 1,2-trans 
linkage.  
In theory, a glycosylation reaction could lead to the formation of both 1,2-cis and 
1,2-trans glycosides. The resulting stereoselectivity of a glycosylation reaction is 
governed by many parameters including the stereochemistry of the donor, the 
reaction temperature, the solvent/anomeric/remote PG effects, the monosaccharide 
type, the promoter used, the steric hindrance/accessibility and nucleophilicity of the 
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acceptor. The exclusive formation of one type of glycosidic linkage can be achieved 
by controlling some of these parameters. The formation of 1,2-trans glycosidic 
linkages can easily be performed using the participating effect of an acyl group 
installed at position 2 of the glycosylating donor (Scheme 2). The presence of this 
electron donating moiety stabilises the oxocarbenium cation and leads to the 
formation of an acetoxonium ion (also called acyloxonium ion). Since one of the 
faces of the ring plane is blocked, the nucleophilic attack will only be performed 
from the other side of the plane. Ultimately, this generally leads to the exclusive 
formation of the 1,2-trans glycoside, even though some traces of the 1,2-cis 
glycoside may be detected. 
 
Scheme 2: Synthesis of 1,2-trans glycoside via neighbouring group 
participation. 
 
The formation of 1,2-cis glycosidic linkages is much more challenging. Even though 
the absence of a participating neighbouring group and the anomeric effect 
(Nishimura et al. 1972, Cumpstey 2012) should guarantee the exclusive formation of 
the 1,2-cis-linked glycoside, the stereoselectivity of the glycosylation may be poor. 
The impact of several parameters on the glycosylation outcome, such as the type of 
solvent or the structural characteristics of the glycosyl agents, has hence been 
examined. For instance, the polarity of the solvent has a direct impact on the 
conformation of the newly formed glycosidic bond. A non-polar solvent such as 
diethyl ether tends to favour the 1,2-cis linkage formation when a polar solvent, such 
as acetonitrile which stabilises the oxocarbenium ion, favours the formation of the 
1,2-trans glycoside (Nishimura et al. 1972, Fraser-Reid et al. 1988). In the case of 
the synthesis of β-D-mannopyranosides, a very interesting example, it has also been 
discovered that the challenging β-D-mannosylation reaction could be directly 
performed using a 4,6-O-benzylidene-protected mannosyl sulphoxide (Crich and Sun 
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1996). In this case, the presence of the acetal leads to the formation of the β-D-
mannoside with high yield and selectivity. Before finding this specificity, the 
synthesis of this type of glycoside could only be obtained through indirect methods, 
such as the synthesis of β-D-mannoside from β-D-glucoside by intramolecular 
nucleophilic substitution followed by inversion of configuration. (Kunz and Günther 
1988) or the intramolecular aglycon delivery method, which gives access to the 
desired β-glycoside from the α-glycoside using N-iodosuccinimide (Barresi and 
Hindsgaul 1991). As for the β-D-mannosides, many important direct and indirect 
methods have been developed in recent years to overcome all the technical 
limitations to the synthesis of 1,2-cis glycosides. For example, Lemieux et al. (1975) 
successfully prepared α-linked disaccharide in a highly stereoselective manner by 
coupling per-O-benzylated α-glycosyl bromide with suitably protected glycosides. 
Tokimoto et al. (2005) demonstrated that the formation of 1,2-cis glycosidic linkages 
can be performed using the long-range effect of bulky 6-O-protecting groups. Using 
suitably protected and activated glycosyl acceptor can also lead to highly 
stereoselective glycosylations, as shown by Nakagawa et al. (2015) who used 
glycosyl acceptor-derived boronic ester catalyst. 
Moreover, even though is it widely agreed that the general mechanism of a chemical 
glycosylation can be described as depicted in Scheme 1, the exact mechanism is still 
not fully understood. Several studies have been carried out and several methods, 
(including the use of the primary 
13
C kinetic isotope effect (Huang et al. 2012), using 
the low-temperature NMR technique (Frihed et al. 2015) or the isolation and study of 
the glycosyl cation by NMR (Martin et al. 2015)) have been used recently to have a 
better overview of its characteristics. A better understanding of the reaction 
mechanism, as well as having a better overview of the impact of all the 
parameters/components on its outcome, will help in finding appropriate solutions to 
overcome the difficulties still encountered for the synthesis of problematic sugars. 
4.1.1.3. Glycosyl donors 
One of the most important aspects to take into account for oligosaccharide assembly 
is the choice of the anomeric leaving group of the glycosyl donor. Ideally, the 
leaving group should be easily installed, but should also be cleaved in preferably 
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mild conditions, that will not affect any of the other PGs. It should remain stable for 
the time between its preparation and use, but also during the glycosylation reaction 
itself. Many glycosylating agents (Figure 23) have been designed such as glycosyl 
halides (Lemieux et al. 1975, Mukaiyama et al. 1981, Toshima 2008), glycosyl 
trichloroacetimidates (Schmidt and Michel 1980), glycosyl N-
phenyltrifluoroacetimidates (Yu and Tao 2001), glycosyl sulphoxides(Kahne et al. 
1989), glycosyl phosphates (Palmacci et al. 2002), thioglycosides (Ferrier et al. 
1973), n-pentenyl glycosides (Fraser-Reid et al. 1992) or even glycals (Thiem et al. 
1978). However, despite the wealth of glycosyl donors, there is a need to develop 
new donors to overcome the issues encountered with the available ones, such as a 
lack of stability at room temperature, a lack of reactivity during the glycosylation 
reactions or even difficult and lengthy syntheses. 
 
Figure 23: The major types of glycosyl donors . 
 
Amongst all the glycosyl donors listed above, trichloroacetimidates are the most 
widely used. This can be explained for several reasons. First of all, the methods to 
prepare these are relatively easy and fast to perform. In addition, they can be stored 
at low temperatures. They are freshly prepared just before being used in 
glycosylation reactions and turn out to be very reactive. Moreover, they are rapidly 
activated with only a catalytic amount of a Lewis acid such as trimethylsilyl 
trifluoromethanesulphonate (TMSOTf), which does not compromise the stability of 
the other PGs during glycosylations. However, obtaining this kind of compound 
usually requires lengthy synthetic routes, with considerable amounts of PG 
manipulation. Owing to the instability of these types of glycosides in acidic 
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conditions, their purification with routine silica-based flash chromatography turns 
out to be rather delicate. The use of only a short pad of silica is hence required, as 
well as the use of a base such as triethylamine (Et3N) or pyridine to counter the 
acidity of the silica. This base must be fully eliminated during the drying process, 
under high vacuum, prior to glycosylation in order to avoid quenching the Lewis acid 
used to initiate the reaction. In addition, the high reactivity of these compounds may 
become a major drawback as well, as they may undergo hydrolysis or rearrangement 
into trichloroacetamides in acidic conditions (Scheme 3). It should be noted that the 
Overman rearrangement has been used in certain cases as a powerful tool for the 
synthesis of nitrogen-containing residues (Overman 1974, Nishikawa et al. 1998, 
Larsen et al. 2008). Thus, glycosylation reactions performed with 
trichloroacetimidate glycosides as glycoside donors must be performed in perfectly 
anhydrous conditions to avoid these undesirable reactions that will have a 
considerable impact on the reaction yield.  
 
Scheme 3: Trichloroacetimidate glycoside rearrangement , also known as 
Overman rearrangement.  
 
4.1.2. In solution synthesis of Hp/HS oligosaccharides: a brief 
historical review and remaining issues 
Even though the role of Hp/HS in disease mechanisms is still not fully understood, 
they remain potential carbohydrate-based drugs. Some groups have evaluated their 
potential as therapeutics (Petitou et al. 1989, Schwӧrer et al. 2013), emphasising the 
necessity to develop methodologies to prepare these carbohydrates. In the early 
1980s, motivated by the rigorous structural elucidation of the minimal heparin 
structure required to bind and activate AT-III (Lindahl et al. 1984, Atha et al. 1985), 
Petitou, Jacquinet and colleagues carried out the first reported syntheses of fragments 
of this pentasaccharide (Jacquinet et al. 1984, Sinaÿ et al. 1984, Petitou et al. 1986). 
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Other crucial work was later published, describing the preparation of AT-binding site 
analogues to establish if the entire pentasaccharide sequence is required to observe 
high affinity binding, but also to overcome the complications inherent to the 
synthesis of its exact structure (Beetz and Van Boeckel 1986, Petitou et al. 1987, 
1999, Walenga et al. 1988).  
These pioneering studies have paved the way for the development of the chemical 
synthesis of a wider range of these types of GAGs and their mimetics. Over the last 
three decades, three major strategies have emerged. On the one hand, the convergent 
modular synthesis is based on the sequential assembly of fully differentiated building 
blocks, until the desired length is reached. This final precursor is then intensively 
modified to attain the desired functionalised oligosaccharide. Convergent modular 
synthesis of Hp/HS is nevertheless known for requiring extensive and lengthy 
synthetic pathways and is more suitable for the preparation of structurally 
homogenous types of oligosaccharides (de Paz et al. 2001, Haller and Boons 2001, 
Ojeda et al. 2002, Lucas et al. 2003, Orgueira et al. 2003, Arungundram et al. 2009, 
Cole et al. 2010, Hu et al. 2011, Zong et al. 2013, Miller et al. 2013, Baráth et al. 
2015). On the other hand, the divergent synthesis requires the synthesis of one or 
several common precursors which will undergo structural modifications of their 
backbone prior to further elongation until the desired size is obtained (Tiruchinapally 
et al. 2011, Schwӧrer et al. 2013, Dulaney et al. 2015). The divergent type of 
synthesis allows easier preparation of a wider range of structures, unlike the 
convergent modular one. Finally, over the last decade, for the sake of developing 
concise and more efficient synthetic pathways, much effort has been put into the 
development of versatile syntheses, which can be defined as an astute combination of 
both divergent and modular syntheses (Poletti et al. 2001, Lubineau et al. 2004, 
Zulueta et al. 2012). Despite the differences that can be listed between those 
synthetic strategies, they all rely on diverse glycosylating agents, which thus appear 
to be one of the keystones of carbohydrate chemical synthesis.  
In general, the synthetic approaches reported in the literature mainly differ in the 
degree of modulation: monomeric (Codée et al. 2005), dimeric (De Paz et al. 2003, 
Arungundram et al. 2009), trimeric (Orgueira et al. 2003) or even tetrameric (Hansen 
et al. 2015) residues have been used as elongation blocks in modular glycosylation 
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strategies. They also differ in the type of building blocks used, in the timing of the 
oxidation of the hydroxyl group at position 6 to obtain the uronic acid and finally in 
the glycosylation procedures. In the case of Hp/HS, a dimeric glycosylation strategy 
is often preferred for practical reasons (good to very good coupling reaction yields, 
greater freedom of modulation, etc.). On this basis, 48 different disaccharide units 
can theoretically be found in native Hp/HS. These calculations take into account the 
potential presence of unusual residues bearing uncommon sulphation pattern as well 
as the presence of both L-iduronic acid and D-glucuronic acid residues. However, 
only 23 different disaccharides have yet been found to occur in nature (Esko and 
Selleck 2002). Synthetic routes to attain these 48 disaccharides have been reported in 
the literature. Lu et al. (2006) were the first to report the full synthesis of the first set 
of 48 fully and orthogonally protected disaccharide precursors that can be used as 
building blocks for the modular synthesis of Hp/HS oligosaccharides. Later on, Hu et 
al. (2012) also prepared these building blocks in order to investigate the interactions 
between the sugars and FGF1. A multitude of different size building block precursors 
have been designed throughout the years (Haller and Boons 2002, Saito et al. 2010). 
The differences between the blocks are essentially based on the type of PGs used, but 
also on the structural configurations of the building blocks to constrain the exclusive 
formation of the 1,2-cis-linked products (Orgueira et al. 2002), or even the use of 
either a glucosamine or a uronic acid monomeric building blocks as glycosyl donor 
(Tabeur et al. 1996). Using uronic acid residues as glycosyl donors could help 
prevent the formation of a mixture of anomers during the formation of the glycosidic 
bond thanks to the neighbouring group participation principle, in contrast to the 
glucosamine residue. Recently, Dhamale et al. (2014) reported the synthesis of 
modular disaccharide building blocks containing glucuronic acid residues. They 
demonstrated that astutely protected glucuronic acids may be used as glycosyl donors 
to prepare dimeric precursors with high yields, avoiding the late-stage oxidation step 
at the very end of the synthetic process. 
All the efforts put into the development of new synthetic routes have made possible 
the preparation of well-defined oligosaccharides of different sizes, first on a 
milligram-scale, then, more recently, on a gram-scale (Hansen et al. 2012). Recently, 
the total synthesis of a 40-mer heparin-related polysaccharide has also been 
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performed by Hansen et al. (2015), hence proving the feasibility of the synthesis of 
such lengthy polysaccharides.  
Theoretically, carbohydrate chemistry allows the preparation of all sorts of Hp/HS 
structures, presenting specific sulphation/acetylation patterns and conformational 
characteristics. However, many limitations remain to be overcome. More 
specifically, the poor reliability of the glycosylation reactions remains a major issue. 
As previously mentioned, the exclusive stereoselective formation of α-glycosidic 
linkages in the absence of a participating neighbouring group is nearly impossible. In 
addition, uronic acids are known for being poor glycosylating agents and for their 
poor coupling efficacy due to their lack of reactivity. This is due to the electron 
withdrawing effect of the carboxyl group at position 5 of the residue which 
dramatically decreases the nucleophilicity of the neighbouring hydroxyl groups. 
Work recently published by Hansen et al. (2012) yet showed that uronic acids can 
lead to high yield reactions in some conditions. Idoside and glucoside residues have 
hence been extensively used as glycosylating agents (Haller and Boons 2001). 
Performing the selective late-stage oxidations of the hydroxyl groups at position 6 of 
the idoside and glucoside residues thus affords the desired corresponding uronic acid 
counterparts as well as helping to circumvent the problematic step of epimerisation 
of the uronic acid residues at the end of the process. However, high-yielded 
oxidations become more difficult to achieve as the size of the oligosaccharide 
increases (Huang and Huang 2007). As an alternative, oxidations are often realised at 
the mono-, di- or even tri-saccharide stage, thus avoiding the late-stage oxidation of 
larger and more valuable oligosaccharides. Moreover, due the major difficulties 
encountered during both the synthesis of the building blocks and their assemblies, 
fewer efforts have been put in the study of the deprotection and sulphation of the 
synthesised oligosaccharide precursors. Thus, the effective compatibility/ 
orthogonality of the PGs remains to be assessed, as well as the general stability of the 
partially deprotected compounds. Finally, despite the wealth of glycosylating agents 
and procedures at disposal of chemists, no general and systematic procedure that 
could accommodate all the characteristics of Hp/HS saccharides has yet been 
generated. 
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4.2. Objectives and design of general synthetic strategy 
4.2.1. Objectives 
The correlation between monosaccharide sequence sulphation pattern of Hp/HS and 
the biological activities of these GAGs is still under intense investigation. 
Deciphering the interactions between Hp/HS and FGF-FGFR complexes requires 
access to well-defined oligosaccharides. Despite some remarkable works reported in 
the literature (Ornitz et al. 1995, Tabeur et al. 1999, de Paz et al. 2001, Poletti et al. 
2001, De Paz et al. 2006, Noti et al. 2006, de Paz et al. 2007, Cole et al. 2010, 
Sterner et al. 2014) which relate to the preparation of structurally well-defined 
Hp/HS structures or analogues on different supports and dedicated to the study of 
these interactions, room for improvements in this domain still exists. As previously 
mentioned in Section 1.8.1, the isolation of structures presenting specific structural 
characteristics from natural sources is remarkably difficult, making it an unattractive 
method. For these reasons, it was decided to resort to chemical synthesis to attempt 
the synthesis of target molecules. In doing so, setting up a new convenient and short 
synthetic route, as well as setting up a library of new glycosylating agents, one of the 
main objectives of this project, was attempted. These new building blocks were 
evaluated as glycosyl donors and acceptors in glycosylation reactions. 
It is generally understood and accepted that the automated synthesis of 
oligosaccharides will be, in the future, the key to an in-depth study of the SAR of 
glycans. However, unlike oligonucleotides and oligopeptides (Merrifield 1985) that 
are generated on a daily basis with the help of solid-phase methods, no general 
method has yet been set up to generate oligosaccharides. Much progress remains to 
be made, despite some encouraging results obtained by Seeberger and colleagues in 
this domain, who successfully prepared both branched and linear oligosaccharides 
(Plante et al. 2001, Eller et al. 2013). Studying and setting up new glycosylating 
agents and glycosylation procedures are keys to improve the automated synthesis of 
oligosaccharides. Therefore, another objective of this project will be the transfer of 
the chemistry developed during the in solution-phase synthesis to the solid-phase 
synthesis. To do so, some parameters required for the solid-phase synthesis such as 
the type of PGs used or the use of a linker to derivatise the reducing end residue will 
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have to be taken into account during the multi-step solution synthesis. Guedes and 
colleagues have recently reported the preparation of similar compounds, derivatised 
with a carbamate-type linker, proving that such a transfer of chemistry between the 
two methods is feasible (Czechura et al. 2011, Guedes et al. 2013). The work 
reported here was motivated by these promising results and will hopefully contribute 
to a better understanding of the close relationship between sequence specificities and 
biological activities of these types of compounds. 
4.2.2. General strategy  
The strategy that has been adopted for this project is based on the assembly of 
advanced disaccharide building blocks, yet the assembly of monosaccharide building 
blocks is also another alternative (Codée et al. 2005, Tatai and Fügedi 2008). Even 
though a monomeric residue iteration-based strategy would have afforded a greater 
degree of flexibility, the assembly of dimeric building blocks has been preferred over 
the assembly of monomeric building blocks for several reasons. First of all, the 
elongation process of the oligosaccharide backbone is undoubtedly considerably 
shortened. In the case of Hp/HS oligosaccharides synthesis, this quickly appears to 
be a major advantage, as no less than 8
3
=512 possible hexasaccharide structures can 
theoretically be synthesised, 8
4
=4,096 and 8
5
=32,768 structures for octasaccharides 
and decasaccharides respectively (8 structurally different disaccharide units may 
constitute the oligosaccharides, see Figure 24). However, these calculations are 
rather simplified, as the possible presence of unusual residues (such as D-
glucosamine residues presenting a free amine at C-2 or a sulphate group at C-3, or 
even the presence of D-glucuronic acid residues) is not included. Moreover, the 
diversification of the building blocks is done at a very early stage of the process, thus 
providing the synthesis of oligosaccharides with a broad variety of possible 
structures in a relatively short time. Secondly, using dimeric building blocks will 
require fewer glycosylations to reach the desired backbone size, which is another 
appreciable advantage due to the intrinsic unreliability of glycosylation reactions in 
most cases. Finally, only a limited number of building blocks are required to afford a 
wide range of structural motifs. Moreover, despite the fact that modifying the 
building blocks might appear laborious to achieve at first sight, this is not actually 
the case as the synthetic routes can be redesigned and modulated relatively easily. 
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This is due to the extensive and diversified library of PGs and to the multitude of 
methods available to researchers – library and new methods that are constantly being 
expanded as chemists develop new ones or redesign existing ones (Jarowicki and 
Kocienski 2001, Prabhu et al. 2003, Wuts and Greene 2006, Codee et al. 2011). In 
addition, many synthetic routes and synthons have already been developed and 
evaluated as building blocks over recent decades, granting researchers many 
possibilities to redesign the synthetic routes for their projects. 
 
Figure 24: Structures of the disaccharide units constituting Hp/HS 
oligosaccharides. The basic disaccharide structure can be differentiated at 
three different positions, labelled R
1
 and R
2
. This representation is limited to a 
single type of uronic acid (L-iduronic acid here) and does not include unusual 
structural features (3-O-sulphate/unsubstituted amino groups)  R
1
 = H or SO3
-
;  
R
2
 = Ac or SO3
-
.  
 
In the case of the preparation of a library of Hp/HS oligosaccharides, the desired 
structures will be prepared in four main stages (Scheme 4). The first stage consists of 
the derivatisation with a linker at the anomeric position of the first glycosyl residue, 
also called the seeding block. The choice of derivatising the seeding block with this 
particular linker has been motivated for two reasons. On the one hand, the 
derivatisation with a linker was favoured over the use of a permanent protective 
group in order for a potential transfer of the chemistry developed in this case to the 
solid-phase synthesis of Hp/HS oligosaccharides. On the other hand, as mentioned in 
Section 4.2.1, this particular linker and similar ones had already been described in 
the literature and their reactivity assessed. Moreover, two seeding blocks will be used 
to prepare a total of four different linker-seeding precursors during this first step. 
This is explained by the use of D-glucosamine residues as seeding blocks. 
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Scheme 4: General strategy for Hp/HS octasaccharide synthesis. 
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These residues indeed present two sites at which substitutions can be performed: a 
hydroxyl or sulphate group can be found at position 6 and an N-acetyl or N-sulphate 
group can also be found at position 2.  
In the second stage, called the elongation process, disaccharide glycosyl synthons are 
used to elongate the oligosaccharide backbone through a couple of elongation cycles. 
The elongation building blocks will be composed of 1-4 linked D-glucosamine and L-
iduronic acid residues. In theory, a total of 8 disaccharide building blocks must be 
synthesised to prepare all possible oligosaccharide structures. However, the 
backbone can be modified between two elongation cycles, thus allowing a possible 
reduction of the total number of disaccharide building blocks to be synthesised. The 
third step consists of terminating the elongation of the backbone with a 
monosaccharide building block, often termed capping block. Two different capping 
blocks might be used, thus allowing either a hydroxyl or a sulphate group at position 
2 of the L-iduronic acid residue at the non-reducing end of the oligosaccharide. 
Finally, the ultimate steps consist of the deprotection and selective 
sulphation/acetylation of the oligosaccharide precursor, thus affording the targeted 
oligosaccharide.  
All through the process, several parameters will need to be monitored and closely 
controlled, such as the stability of the PGs, the conformations of the different 
residues, the nature and conformation of the glycosidic bonds (regio- and 
stereoselectivity of the glycosidic bond formation). Moreover, in order to make the 
synthetic route viable and attractive, the best conditions to obtain high-yield 
glycosylations, deprotection and sulphation reactions will need to be established. 
The targeted oligosaccharides will all share the same general structural features. 
Their sequences - which will essentially consist of 1-4 linked α-L-iduronic acids 
(IdoA) and α-D-glucosamines – will start with a D-glucosamine residue which is 
derivatised with a linker at the reducing end and be terminated with an L-iduronic 
acid residue at the non-reducing end. L-iduronic acid residues represent 
approximately 30-80% of the total of the uronic acid residues in native Hp/HS 
oligosaccharides and are required for protein binding (see Section 1.6.2). This 
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thereby explains why the targeted oligosaccharides will solely contain L-iduronic 
acid residues.  
Ultimately, the only difference between two targets will lie in their sulphation and 
acetylation patterns. To make the selective modification of the positions of interest 
possible, all seeding, elongation and capping blocks have been designed in such a 
way that appropriate PGs will be introduced at specific positions of the residues. 
These PGs have been chosen according to the type of modifications that will be 
carried out during subsequent steps of the process. In addition, the building blocks 
and oligosaccharide precursors must be orthogonally protected, so that all the other 
PGs will remain stable whilst a group or chemical moiety is being introduced, 
modified or removed. With all these conditions in mind, three categories of PGs will 
be used. The first category includes the groups that will not be modified during both 
the assembly and sulphation of the building blocks and oligosaccharide precursors 
(the permanent PGs): the benzyl ether (Bn) and benzoate ester (Bz) groups to 
permanently protect hydroxyl moieties, the acetamido (Ac) group for the amine 
moieties and the methyl ester (Me) for masking the carboxylic acid moiety of the 
uronic acid residues. The second category includes the groups that will be used to 
temporarily protect the sites that will undergo sulphation at a later stage (the 
temporary PGs): the azido moiety (N3) to mask the amines and the levulinoyl ester 
group (Lev) to protect the hydroxyl groups. Finally, the 9-
fluorenylmethyloxycarbonyl carbonate (Fmoc) group, which belongs to the third and 
last category, will be used to protect the acceptor sites of the building blocks and 
oligosaccharide precursors. The cleavage of the Fmoc group is possible using a 
hindered base such as triethylamine (Et3N), which does not affect the other PGs, 
particularly the Lev ester group. 
In addition to all the conditions mentioned above, other requirements have motivated 
the selection of the protective groups. For instance, on the one hand, the use of a non-
participating group such as N3 at the position 2 of the D-glucosamine residue usually 
leads to the introduction of 1,2-cis glycosidic linkages only. However, under specific 
conditions, the formation of 1,2-trans glycosidic linkages might take place as well, 
indicating that the non-participatory character of this moiety alone does not 
guarantee the selectivity of the bond formation (Tsuda et al. 2003, Lohman and 
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Seeberger 2004). Yet, in the case of the synthesis of Hp/HS oligosaccharides, it is 
now well known that assembling a D-glucosamine derivative bearing a non-
participating group at C-2, such as an azido group, and an L-idose/L-iduronic 
derivative preferably leads to the formation of the α-linked product (Van Boom et al. 
1996, Kovensky et al. 2002, Orgueira et al. 2002). On the other hand, as explained in 
Section 4.1.1.2, the use of an ester group (such as Bz or Lev) at position 2 of the 
uronic acid residues will exclusively lead to the formation of 1,2-trans-directed 
glycosidic bonds. 
Besides the protective groups described above, the trichloroacetamido (TCA) moiety 
will also be used, but as a leaving group in glycosylation reactions, for the activation 
of the glycosyl donors. The activation of O-glycosyl residues presenting Fmoc 
protected hydroxyl groups with TCA moieties has been made possible thanks to 
work undertaken by Roussel et al. (2000). Fmoc groups are very easily cleaved under 
basic conditions, which are required for the introduction of a TCA moiety. However, 
as shown by Roussel and colleagues, using sodium hydride as a catalyst appears to 
overcome the problem and to grant high yield reactions as well. 
4.2.3. First target structure 
To test the relevance and feasibility of the synthetic strategy and to evaluate the 
reactivity of some of the building blocks, the preparation of a first target was planned 
(Scheme 5). The choice of this particular compound as the first target was motivated 
by two considerations. First of all, the use of elongation blocks that will afford 
different sulphation patterns is required, which allows the evaluation of the reactivity 
of different building blocks for the synthesis of a single compound. Secondly, an 
analogue A of this HS octasaccharide has already been isolated, characterised and 
screened in bioassays by Ahmed (2010) (Scheme 5). According to the activity assay 
results that were obtained, this structure appears to facilitate the interactions between 
FGF2 and the receptor FGFR1c.  
Unlike the compound that has been isolated from natural sources, the target molecule 
that will be synthesised will contain a linker at the reducing end. Thus, the impact of 
the linker on the ability of this structure to activate FGF-FGFR complexes will be 
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assessed, although no major difference is expected. The sequence of 1 will be as 
follows, from the non-reducing end to the reducing end (all glycosidic linkages are in 
α-conformation): IdoA-GlcNS-IdoA(2S)-GlcNS(6S)-IdoA-GlcNAc-IdoA-GlcNAc-
linker. As previously mentioned, several chemical moieties will be used to 
protect/mask the positions of interest. As depicted in Scheme 5, the retrosynthetic 
analysis of 1 leads to the molecule 2 – the final intermediate which will be obtained 
at the end of the elongation and capping processes. 
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Scheme 5: Retrosynthesis of the first target – Structures of the first target and its natural analogue. 
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4.3. Initial synthetic approach: synthesis of the elongation 
blocks 
Along with the preparation of the linker 6, the seeding block 8 and capping block 7, 
synthesising the precursor 2 will require the preparation of the three distinct 
elongation blocks 3-5, each presenting specific structural characteristics (Scheme 6). 
Thus, preparing the precursor 2 will provide a global appreciation of the feasibility of 
the synthesis of the elongation blocks in particular. Moreover, their reactivity in 
glycosylation reactions will also be assessed, corroborating or disproving the 
relevance of the modular approach initially drawn up. 
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Scheme 6: Retrosynthesis of the first target – Building block and linker structures. 
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As depicted in Scheme 7, preparing the elongation blocks 3-5 will only require the 
synthesis of two types of glycosyl donors 8 and 9, as well as two types of glycosyl 
acceptors 10 and 11, reducing the total number of glycosylating agents to be 
prepared to five (3- 5, 7 and 8). Thus, it clearly appears that this modular synthetic 
approach considerably limits the number of manipulations of the backbone between 
the elongation steps. In addition, most of the building blocks and precursors that will 
be developed in this case have not been previously described in the literature yet, 
further expanding the extensive library of glycosyl precursors that has been 
developed. 
 
Scheme 7: Retrosynthesis of the elongation blocks – Monomeric building 
block structures. 
 
In the next sections, the synthesis and evaluation of the seeding and elongation 
blocks in glycosylation reactions will be discussed as a matter of priority, unlike the 
capping block and linker that will be discussed later. 
4.3.1. Azidoglucose building block synthesis 
As explained in the previous section, the modular approach that has been chosen to 
prepare the intermediate 2 requires the synthesis of only two types of glycosyl donors 
8 and 9. Yet, the chosen approach allows the differentiation of the blocks at a late 
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stage of the process, as described in Scheme 8. This appears to be a considerable 
advantage in that it significantly reduces the number of steps and manipulations 
necessary to produce the desired compounds. Thus, in most cases, a high number of 
steps induces a low overall yield – a situation that we seek to avoid in the present 
case. 
 
Scheme 8: Synthesis of the glycosyl donors 8 and 9.  
Reagents and conditions: (a) (i) NaN 3, Tf2O, H2O, DCM; (ii) NaOMe, DMAP, 
TfN3 MeOH; (b) Benzaldehyde dimethyl acetal , p-TsOH, ACN (66%, 3 steps); 
(c) TBSCl, imidazole, DCM (70%); (d) NaH, TBAI, BnBr, DCM (85%); (e) 
EtSH, p-TSOH, DCM (89%); (f) BzCN, Et3N, ACN (90%); (g) LevOH, CMPI, 
DABCO, DCM (94%); (h) FmocCl, pyridine, DMAP, DCM (20, 96%; 21, 95%); 
(i) HF.pyridine, THF (22, 81%; 23, 78%); (j) Cl3CCN, NaH (8, 95%; 9 , 85%). 
 
The production of the imidates 8 and 9, completed in a nine-step sequence, started 
with the preparation of 17 from the commercially available 2-amino-2-deoxy-D-
glucose hydrochloride 12 (Guedes et al. 2013). First of all, 2-amino group of D-
glucosamine hydrochloride 12 was converted into the corresponding azide 13 by a 
diazo transfer reaction from trifluoromethanesulphonyl (trifyl) azide (TfN3). This 
direct method was described for the first time by Vasella and colleagues for the 
preparation of 2-azido-2-deoxy-D-gluco, D-manno, D-galacto and D-allo derivatves 
(Vasella et al. 1991). Although the diazo transfer reaction with TfN3 is nowadays 
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widely used, the unpredictability of the reaction (yields may vary, depending on the 
quality of the reagents used and the preparation of the trifyl azide solution), as well 
as the inherent explosiveness of TfN3 when dried, makes it a fairly unreliable 
reaction. However, the availability of the starting material (SM), its reasonable price, 
the fact that the reaction can be carried out on a fairly high scale and that the diazo 
transfer is carried out at a very early stage of the synthetic route makes it convenient 
to some extent. The resulting intermediate was then treated with benzaldehyde 
dimethyl acetal in the presence of p-toluenesulphonic acid (p-TsOH) in acetonitrile 
to afford the 4,6-O-benzylidene derivative 14. These two reactions may be realised 
on a relatively large scale (up to 100 g of SM, but usually on a 10-20 g scale for 
safety reasons) with comfortable yields, making them convenient for Hp/HS 
oligosaccharides synthesis. The regio- and stereoselective silylation of the anomeric 
centre was then carried out using tert-butyldimethylsilyl chloride (TBSCl) and 
imidazole, resulting in the exclusive formation of the β-anomer of the product 15. 
After protection of the anomeric center, the deprotonation of the hydroxyl group at 
position 3 of the intermediate was realised with sodium hydride (NaH), followed by 
its benzylation with benzyl bromide (BnBr) in presence of tetrabutylammonium 
iodide (TBAI), affording 16. Treating 16 with ethanethiol (EtSH) in presence of p-
TSOH resulted in the cleavage of the 4,6-O-benzylidene and the formation of the diol 
17 (Guedes et al. 2013). 
Making 17 one of the intermediates of this synthetic route is attractive as it can be 
synthesised on a large scale. The differentiation of the glycosyl donor residues was 
then carried out at this stage of the synthesis.  
4.3.1.1. Synthesis of the building block 9 
The regioselective 6-O-levulinoylation of 17 was performed with levulinic acid in 
dry DCM at -20 °C, in the presence of the activator 2-chloro-1-methyl-1-pyridinium 
iodide (CMPI) and 1,4-diazabicyclo[2.2.2]octane (DABCO), to afford 19 in a very 
satisfactory yield of 94% (Koeners et al. 1980). The hydroxyl group at position 4, 
which will be required for the oligosaccharide extension, was protected as Fmoc 
carbonate using 9-fluorenylmethoxycarbonyl chloride (FmocCl) in presence of the 
activator 4-dimethylaminopyridine (DMAP) in pyridine to afford the fully protected 
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compound 21 in a yield of 95%. The cleavage of the tert-butyldimethylsilyl ether 
moiety used to protect the anomeric centre was first attempted under standard 
conditions (AcOH/TBAF in THF), but the desired compound could not be isolated. 
The cleavage of the Fmoc group was indeed systematically detected for both SM 
(23a, Figure 25) and product (23b, Figure 25). Both 23a and 23b were not isolated 
and were only detected by LC-MS. 
 
 
Figure 25: Results for the desilylation of 21 using AcOH and TBAF. 
(a) Formation and possible structures of the by-products 23a and 23b;  
(b) LC-MS analysis results of the desilylation of the residue 21 using 
AcOH/TBAF in THF. Retention time: 3.8 min (calcd for C18H23N3O7: 393.1 
[M], found m/z 411.1 [M+NH4]
+
, 416.1 [M+Na]
+
): by-product 23b;  retention 
time: 5.91 min (calcd. for C24H37N3O7Si: 507.2 [M], found m/z 525.2 
[M+NH4]
+
, 530.1 [M+Na]
+
): by-product 23a; Unidentified peaks: retention 
times 4.25 min and 5.49 min.  
 
This may be explained by the base-labile property of the Fmoc group, which 
appeared to be unstable in the presence of tetrabutylammonium fluoride (TBAF). 
The deprotection of the anomeric centre of 21 was next realised with hydrofluoric 
acid.pyridine (HF.pyridine) in dry THF and afforded 23 as a mixture of anomers (α/β 
2/1, determined by 
1
H NMR) in 78% yield. No loss of Fmoc group was detected at 
any stage of the process; making HF.pyridine an attractive alternative despite being a 
relatively hazardous reagent that should be manipulated with extra care. The 
activation of 23 was then realised using trichloroacetonitrile and a catalytic amount 
of NaH, as described by Roussel and colleagues (Roussel et al. 2000) and afforded 
the imidate 9 as an α/β-mixture (α/β 1/4, determined by 1H NMR) in 85% yield. 
23b 
23a 
(a) 
(b) 
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4.3.1.2. Synthesis of the building block 8 
The regioselective 6-O-benzoylation was realised by treating 17 with benzoyl 
cyanide (BzCN) and a catalytic amount of triethylamine (Et3N) in dry acetonitrile to 
form 18, as described by Guedes et al. (2013). In analogy to the preparation of 
intermediate 21, the C-4 hydroxyl group was protected with FmocCl, in the presence 
of DMAP and affording 20 in 96% yield. The tert-butyldimethylsilyl ether moiety 
used to protect the anomeric center was then easily cleaved with hydrofluoric acid in 
pyridine in THF and produced 22 as a mixture of anomers (α/β 2/1, determined by 1H 
NMR) in 81% yield. The presence of a Bz group instead of a Lev group at position 6 
(as for 21) apparently did not have any effect on the overall reactivity of the D-
glucosamine residue. Finally, as for the preparation of 9, treating the lactol 22 with 
NaH and trichloroacetonitrile gave the trichloroacetimidate 8 in 95% yield (α/β 1/2, 
determined by 
1
H NMR). 
4.3.2. L-iduronic acid building block synthesis 
As mentioned in the previous sections, the synthesis of only two types of glycosyl 
acceptors 10 and 11 is required for the preparation of the fully protected 
octasaccharide intermediate 2. As for the glycosyl donor residues, the differentiation 
of the intermediates that will lead to the two final L-iduronic acid building blocks 
will be performed at a later stage of the synthetic route. 
Both L-iduronic acid and L-idose are commercially available, but very costly, making 
them not attractive as SM. For this very reason, many synthetic routes for the 
preparation of L-iduronic acid derivatives have been developed from diverse SMs.  
The preparation of the desired compounds 10 and 11 demanded the preparation of 
the well-known intermediate 30 (Scheme 9), available on a gram scale, obtained 
from the cheap and easily available D-glucose derivative 24 (diacetone glucose) in a 
6 step-sequence (Van Boeckel et al. 1985, Lu et al. 2006, Hung et al. 2012). First, 26 
was generated from 24 via the benzylation of the hydroxyl group at position 3 using 
BnBr, NaH and catalytic TBAI in dimethylformamide (DMF), followed by the 
selective cleavage of the 5,6-O-isopropylidene ring using a 66% solution acetic acid 
(88% yield, 2 steps). The diol 26 was next mesylated using to afford 27 in 90% yield. 
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The selective substitution of the primary mesylate group was performed by treating 
27 with potassium acetate (KOAc) in the presence of crown-ether to afford 28 in 
85% yield. The intermediate 30 was obtained after treatment of 28 with potassium 
tert-butoxide (t-BuOK) in tert-butanol (t-BuOH) and DCM, followed by acidic 
hydrolysis using 1 M H2SO4 in dioxane. At this stage of the synthetic route, the 
differentiation of the intermediate was undertaken.  
 
Scheme 9: Synthesis of the intermediate 30.  
Reagents and conditions: (a) BnBr, NaH, cat. TBAI, DMF; (b) AcOH (66%), 
H2O (88%, 2 steps); (c) MsCl, pyridine, DCM (90%); (d) KOAc, 18 -crown-6, 
ACN (85%); (e) t-BuOK, t-BuOH, DCM (74%); (f) 1 M H2SO4 , dioxane,  
120 °C, microwave (50%).  
 
4.3.2.1. Synthesis of the building block 10 
The regioselective benzoylation of the hydroxyl group at position 2 of 30 was carried 
out (Lee et al. 2004) (Scheme 10). The resulting residue 31 then underwent zinc 
iodide-assisted thiolysis with trimethyl(phenylthio)silane in dry conditions to give 
exclusively the α-thioglycoside 32 in 77% yield, as described by Guedes et al. 
(2013). The chemo- and regio-selective oxidation of the primary hydroxyl group at 
position 6 of 32 into the corresponding carboxylic acid was made possible in aqueous 
conditions (Siedlecka et al. 1990) and was accomplished with the combination of 
2,2,6,6-tetramethyl-1-piperidinyloxyl (TEMPO) and a catalytic amount of 
[bis(acetoxy)-iodo]benzene (BAIB) (Epp and Widlanski 1999, Codée et al. 2005).  
Chapter 4 – Chemical synthesis of HS oligosaccharide structures 
133 
 
 
Scheme 10: Synthesis of the building block 10.  
Reagents and conditions: (a) BzCl, pyridine (85%); (b) Me3SiSPh, ZnI2 (77%); 
(c) (i) TEMPO, BAIB, DCM, H 2O; (ii) MeOH, Amberlite IR-120 (H
+
), 4 Å ms, 
microwave (82%, 2 steps) . 
 
Initially, the conversion of the resulting intermediate into the corresponding methyl 
ester 10 was attempted via Steglich esterification with N-(3-dimethylaminopropyl)-
N′-ethylcarbodiimide hydrochloride (EDC.HCl) and a catalytic amount of DMAP. 
However, the results obtained with this method turned out to be unsatisfactory due to 
long reaction times (the complete consumption of the SM was detected after 48h of 
reaction) and low yields varying between 30% and 47%. Moreover, significant 
formation (about 25%) of the debenzoylated by-product 10a was observed by LC-
MS analysis (but not isolated), as depicted in Figure 26. 
 
 
Figure 26: Results of the Steglich esterification of 32.  
(a) Formation and structures of the product 10 and by-product 10a;  
(b) LC-MS analysis results of the Steglich esterification of the building block 
32 (48h reaction). Retention time: 4.55 min  (calcd for C20H22O6S: 390.1 [M], 
found m/z 408.1 [M+NH4]
+
, 413.1 [M+Na]
+
): by-product 10a; retention time: 
5.08 min (calcd. for C26H26O6S: 466.1 [M], found m/z 484.2 [M+NH4]
+
, 489.1 
[M+Na]
+
): starting material 32; retention time: 5.33 min (calcd for C27H26O7S: 
494.1 [M], found m/z 495.2 [M+H]
+
, 512.1 [M+NH4]
+
, 517.1 [M+Na]
+
): product 
10. 
 
10a 
10 
32 
(a) 
(b) 
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The microwave-assisted Fischer esterification of the intermediate was hence 
attempted using Amberlite IR-120 (H
+
), freshly prepared molecular sieves and dry 
methanol (MeOH). The impact of several parameters over the reaction outcome was 
assessed, such as the type of molecular sieve used, the reaction time and the 
temperature. From the results that were obtained and which are summarised in Figure 
27 (b), the type of molecular sieve used (beads over powder, entries 2 and 3) appears 
to be of critical importance, as well as the reaction temperature. The reaction time 
was drastically decreased by increasing the temperature (entries 1-3). However, 
using a mass to mass ratio (SM/Amberlite 1/1) resulted in the formation of the by-
product 10b (observed by LC-MS analysis, by-product not isolated), probably due to 
the acidity of the solution (entries 3 and 4). Finally, the desired L-iduronic building 
block 10 was obtained with a yield of 82% over two steps. 
 
Entry 
Reaction 
time 
Mass ratio 
SM/Amberlite 
Temp 
Molecular 
sieves type 
Yield (%) 
1 3h30 2/1 90 °C beads 74 
2 1h30 2/1 100 °C powder 57 
3 1h30 2/1 100 °C beads 82 
4 1h30 1/1 100 °C beads 33 
 
Figure 27: Preparation of building block 10.  
(a) Formation and structures of the product 10 and possible by-product 10b;  
(b) Reaction conditions and results for the esterification of 32. 
 
4.3.2.2. Synthesis of the intermediate 34 
The preparation of the synthon 11 was also undertaken (Scheme 11). As for the other 
type of L-iduronic building block 10, the direct selective levulinoylation of the 
position 2 of the intermediate 30 was attempted, with the same conditions used for 
the levulinoylation of 17. However, as the formation of 33 was not detected (the SM 
remain unchanged), which was probably due to a lack of reactivity of the SM, this 
(b) 
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method was abandoned in favour of a longer, but more reliable synthetic route, as 
depicted in Scheme 11.  
 
Scheme 11: Synthesis of the building block 11. 
Reagents and conditions: (a) LevOH, CMPI, DABCO, DCM; (b) (i) Me 3SiSPh, 
ZnI2 , DCM; (ii) Ac2O, pyridine; NaOMe, MeOH (78%, 3 steps); (c) 
PhCH(OMe)2, CSA, ACN (75%); (d) LevOH, EDC.HCl, DMAP, DCM (92%); 
(e) DCM/TFA/H2O (75%); (f) (i) TEMPO, BAIB, DCM, H2O; (ii) MeOH, 
Amberlite IR-120 (H
+
), 4 Å ms, microwave (76%, 2 steps) . 
 
Despite the fact that the synthesis of the known synthon 34 from the residue 30 in a 
four-step sequence (route A, Scheme 12) has previously been described by Tatai et 
al. (2008), the unsatisfactory results that were obtained with this method stimulated 
the investigation of a shorter and more efficient synthetic route (route B, Scheme 
12). Unlike the process undertaken by Tatai and colleagues, 30 was directly treated 
with trimethyl(phenylthio)silane and zinc-iodide to afford the triol 34 as a mixture of 
anomers which were arduous to purify. In order to simplify the purification and 
isolation of the compounds, the peracetylation of the triols α-34 and β-34 was 
performed using acetic anhydride (Ac2O) in dry pyridine. The peracetylated 
compound was obtained with a yield of 85% (2 steps, route B, anomers mixture) or 
with a yield of 55% (3 steps, route A, α-anomer only). The resulting peracetylated 
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anomers were directly deacetylated with sodium methoxide (NaOMe) in dry MeOH 
to afford 34, after simple filtration (79% yield over 3 steps for route B). Finally, 
despite the inevitable and unwanted formation of the β-anomer obtained with route 
B, it appeared that the formation of the thioglysosyl intermediate through the ring-
opening of the 1,6-anhydro compound 30 is more advantageous if the peracetylation 
is performed after the ring opening. 
 
Scheme 12: Possible synthetic routes to prepare the building block 34. 
 
4.3.2.3. Synthesis of the building block 11 
The hydroxyls groups at position 4 and 6 of 34 were then selectively protected with a 
benzylidene group using benzaldehyde dimethyl acetal and a catalytic amount of 
(1S)-(+)-10-camphorsulphonic acid (CSA) in acetonitrile to furnish 35 with a yield 
of 75% as a mixture of anomers (α/β 3/1, determined by 1H NMR). The anomers 
could be separated at this stage of the synthesis by flash chromatography. The 
levulinoylation of the remaining free hydroxyl group at position 2 of α-35 was then 
carried out using standard conditions (levulinic acid/DMAP/EDC.HCl in DCM) to 
afford 36 with a 92% yield. 
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The cleavage of the benzylidene acetal was then first attempted using EtSH and a 
catalytic amount of BF3.O(Et)2. The poor yield (35%) obtained prompted us to 
explore other approaches for the cleavage of the acetal. A combination of 
trifluoroacetic acid (TFA/DCM/H2O) was then tested at room temperature, 
increasing the yield of the reaction (51%). Another trial, with the same combination 
of reagents (TFA/DCM/H2O), but performed at 0 °C afforded 37 with a yield of 
76%.  
The chemo- and regio-selective oxidation of the hydroxyl group at position 6 of 37 
into the corresponding carboxylic acid was performed as for the synthesis of 32 into 
10, using a combination of TEMPO/BAIB. The resulting carboxylic acid 
intermediate was then dried and involved in the esterification step without any 
further purification. As for the synthesis of the building block 10, the Steglich 
esterification method (EDC.HCl/DMAP/dry MeOH) gave unsatisfactory results 
(35% yield). Based on the promising results obtained for the preparation of 10, the 
esterification of the carboxylic acid intermediate was attempted using Amberlite IR-
120 (H
+
) in combination with freshly activated molecular sieves in the presence of 
dry MeOH (Table 5). Finally, the microwave-assisted esterification, performed as a 
single cycle of 1h30 at 95 °C afforded 11 (76% over two steps). 
Entry 
Reaction 
time 
Mass ratio 
SM/Amberlite 
Temp 
Molecular 
sieves type 
Yield (%) 
1 1h30 2/1 100 °C powder 20 
2 1h30 2/1 90 °C beads 60 
3 1h30 2/1 95 °C beads 76 
 
Table 5: Reaction conditions and results for the preparation of the building 
block 11. 
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4.3.3. Elongation blocks synthesis: evaluation of the azidoglucose 
and iduronic acid building blocks in glycosylation reactions 
The next step was the evaluation of the two L-iduronic acid building blocks 10 and 
11 as glycosyl acceptors and the blocks 8-9 as glycosyl donors in glycosylation 
reactions to prepare the precursors 38-40.  
As described in Section 4.1.1.3, the reactions were always carried out in very dry 
conditions, as trichloroacetimidates are rapidly hydrolysed in moist and acidic 
environments and may even undergo rearrangement. The need to prevent these side 
reactions from occurring requires some precautions. Prior to use, all reagents and 
solvents needed to be perfectly dried. Glycosyl donors and acceptors are dried 
overnight under high vacuum conditions. The solvent is also dried over freshly 
activated molecular sieves and the reactions are performed in the presence of freshly 
activated molecular sieve powder. Moreover, the reactions can be performed in two 
ways: either the conventional (also called normal) procedure or the inverse 
procedure. The conventional procedure consists of adding the acid to a solution of 
donor and acceptor to initiate the reaction. The inverse procedure consists of a slow 
and dropwise addition of the donor to a mixed solution of acceptor and promoter. In 
difficult glycosylations (e.g. including acceptor of low reactivity), the inverse 
procedure offers slightly better results as the acceptor is present in large excess 
compared to the donor, at any given time point. However, the inverse procedure is 
not always required to carry out a glycosylation, as the side reactions 
(hydrolysis/rearrangement of the donor) are disadvantaged compared with the 
glycosylation reaction in most cases. To avoid loss of the base-labile Fmoc group, 
the reaction was quenched by the addition of water instead of a base such as 
triethylamine. 
To evaluate the impact of different parameters on the reaction results, several tests 
were realised (replicates were carried out and are not listed here). As depicted in 
Figure 28 (b), this evaluation was mostly carried out whilst coupling the synthons 9 
and 10, which were the first two to become available. In total, eight sets of 
parameters were tested for the preparation of 39 (Figure 28 (b), entries 4-11). Thus, 
the influence of the donor/acceptor/acid ratio over the reaction yields was assessed, 
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as well as the type of acid used and the concentration at which the reaction was 
carried out. Moreover, the ideal temperature to perform the reaction is also of great 
importance and was then investigated, in order to favour glycosylation over the 
hydrolysis/rearrangement kinetics. 
 
Entry Donor 
Equiv. 
of 
donor 
Equiv.  
of 
activator 
Temp 
Solution 
Conc. 
Procedure Product 
Yield 
(%) 
1 8 1.5 0.1
b
 -20 °C 0.1 M normal 40 21 
2 8 1.5 0.1
b
 -20 °C 0.1 M normal 38 32 
3 8 1.5 0.1
b
 -30 °C 0.1 M normal 38 30 
4 9 1.2 0.1
b
 -20 °C 0.05 M normal 39 24 
5 9 1.5 0.1
b
 -20 °C 0.05 M normal 39 51 
6 9 1.5 0.2
b
 -20 °C 0.05 M normal 39 43 
7 9 1.5 0.1
b
 -30 °C 0.05 M normal 39 36 
8 9 1.5 0.1
b
 -30 °C 0.2 M inverse 39 19 
9 9 1.5 0.1
c
 -30 °C 0.2 M inverse 39 25 
10 9 1.5 0.1
b
 -50 °C 0.1 M normal 39 32 
11 9 1.5 0.1
b
 -80 °C 0.1 M normal 39 23 
 
Figure 28: Evaluation of the building blocks 10 and 11 as glycosyl acceptor 
in glycosylation reactions.  
(a) Synthesis of the disaccharide intermediates 38-40 . Reagents and conditions: 
(i) TMSOTf or TBSOTf, DCM, for yields, see table (b);  
(b) Reaction conditions and results for the glycosylations of the glycosyl 
donors 8 and 9 with the glycosyl acceptors 10 and 11.  
b
TMSOTf; 
c
TBSOTf.  
 
(a) 
(b) 
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Based on the results that were obtained (Figure 28 (b)), the following conclusions 
could be drawn. First of all, and as expected, the 1,2-trans glycoside was virtually 
undetected (the nature of the new glycosidic linkage was determined by NMR, the 
value of the vicinal coupling constant 
3
JH1,H2=±4Hz confirmed the formation of the 
α-anomer). Secondly, monitoring the reaction by UPLC/MS and by TLC also 
revealed that the glycosylation takes place as the reagents are mixed, as soon as the 
donor is activated by the acid. Thirdly, it appeared that a concentration of 1.5 
equivalents of donor (entries 4 and 5), 0.1 equivalent of TMSOTf (entries 5 and 6), a 
temperature of -20 °C (entries 5 and 7) and a concentration of 0.05 M constituted the 
ideal set of parameters and afforded 39 in a yield of 51% (entry 5). The inverse 
procedure does not seem to afford better yields, even by lowering the temperature 
down to -50 °C or -80 °C. However, the results obtained with the replicates were not 
consistent (results not listed here) and the corresponding yields were varying from 
nearly 20% to around 40%, with a peak at 51%, which is rather low (entry 5). This 
inconsistency, which could be explained by a lack of control over some of the 
parameters impacting the glycosylation reaction, was also observed for the synthesis 
of the disaccharide building blocks 38 and 40, which were also obtained in low 
yields (entries 1-3). Yet, these low yields were expected due to the lower reactivity 
of L-iduronic synthons, as the hydroxyl group at position 4 of the glycosyl acceptor is 
considerably reduced by the presence of the electron withdrawing carboxylate 
function at position 5. 
Thus, despite the efforts put into finding the best conditions to obtain the elongation 
blocks 38-40 with satisfactory yields, the variability of the glycosylation reactions 
and the low reaction yields obtained, which were probably due to a mismatch of 
reactivity between the acceptor and donor, incited to bring some changes to the 
initial synthetic approach.  
4.3.4. Elongation blocks synthesis: revision of the initial strategy 
With the rather unsatisfactory results obtained for the synthesis of 38-40 in hand, 
some changes needed to be brought to the original synthetic route in order to 
circumvent the mismatch of reactivity between the glycosylating agents. For this 
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reason, new monomeric building blocks to synthesise 3-5 needed to be designed 
(Scheme 13).  
 
Scheme 13: Retrosynthesis of the new elongation blocks – Monomeric 
building block structures.  
 
The preparation of the known synthons 41 and 42 was hence undertaken. The 
glycosyl acceptor 42 has already been prepared by Ojeda et al. (1999) and 41 had 
been prepared for the first time by La Ferla et al. (1999). The coupling efficacy of 
these compounds has also been already evaluated by de De Paz et al. (2003) and was 
rather satisfactory (62% yield). They showed that the C-4-directed glycosylation of 
these two compounds is favoured over the C-2-directed glycosylation, probably due 
to the high steric hindrance of the C-2 position, caused by the presence of the 
dimethylthexylsilyl (TDS) installed at the anomeric centre of 42 (desired 4-O-
glycosylated product: 62%, recovered acceptor: 35%, by-products (including 2-O-
glycosylated disaccharide): 3%).  
The coupling of 42 with 8 and 9 was also evaluated to take advantage of the already 
existing compounds and to determine whether these could be of any use for the 
synthesis of the disaccharide building blocks. However, the glycosyl donor 41 was 
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prepared as well, on the assumption that a mismatch of reactivity could be detected 
whilst using 8 and 9 as glycosyl donors. 
At this stage, it is important to note that the preparation of the known building blocks 
41 and 42 would not offer the possibility of developing a new synthetic methodology 
for the synthesis of HS and heparin oligosaccharides. Nevertheless, the relatively 
short synthetic routes to prepare these compounds are already known and tested, 
allowing for a significant gain of time.  
4.3.5. New azidoglucose building block synthesis 
The choice of using 41 as the new glycosyl donor for the synthesis of the 
disaccharide building blocks was motivated by the fact that this new compound 
shares a couple of intermediates with the ones that were previously prepared (8 and 
9), which is undoubtedly a considerable advantage.  
Like the donors 8 and 9, the synthesis of 41 started with the preparation of 16 from 
the commercially available 2-amino-2-deoxy-D-glucose hydrochloride 12 as 
described in detail in Section 4.3.1. The final compound 41 was obtained in a two-
step sequence from 16 by conventional desilylation followed by the anomeric 
activation of the resulting intermediate using trichloroacetonitrile in the presence of 
1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU) as described by De Paz et al. (2003) 
(Scheme 14). 
 
Scheme 14: Preparation of the new glycosyl donor 41. 
Reagents and conditions:  (a) (i) TBAF, AcOH, THF; (ii) Cl 3CCN, DBU, DCM 
(85%, 2 steps). 
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4.3.6. New L-iduronic acid building block synthesis 
The synthesis of the new glycosyl acceptor 42 was performed as described by 
Lohman et al. (2003) and Ojeda et al. (1999) and was obtained in a seven-steps 
sequence from commercially available diacetone-D-glucose 24 (Scheme 15). 
 
Scheme 15: Preparation of the new glycosyl acceptor 42. 
Reagents and conditions: (a) BnBr, NaH, cat. TBAI, DMF; (b) AcOH (66%), 
H2O (90%, 2 steps); (c) NaIO4, silica gel, H2O, DCM; (d) (PhS)3CLi, THF; (e) 
(i) CuCl2, CuO, MeOH, H2O, DCM; (ii) K2CO3 , MeOH (83%, 4 steps); (f) TFA 
(90%), H2O (72%); (g) TDSCl, imidazole, DCM (65%). 
 
As for the synthesis of 10 and 11, the first step consists in the benzylation of the only 
free hydroxyl group of 24. Selective acetal cleavage afforded the diol intermediate 26 
that was then subsequently treated with an aqueous solution of sodium periodate 
adsorbed onto silica to afford the corresponding aldehyde 43 (Lohman et al. 2003). 
The latter was then treated with trithiophenylmethylithium and exclusively afforded 
the L-idose-configured thioortho ester intermediate 44 (no D-glucose product was 
detected unlike with other methods involving the use of organometallic reagents 
(Lubineau et al. 2000)). The freshly obtained thioortho ester was then directly treated 
with CuCl2/CuO to obtain the desired furano methyl ester derivative 45 along with a 
relatively small amount of the phenylthioester by-product that was converted into the 
desired intermediate by treatment with K2CO3 in methanol. The cleavage of the 
isopropylidene acetal was achieved using a 90% TFA solution (v/v) and led to the 3-
O-benzyl L-iduronic methyl ester residue 46 in its pyranose form (the 
1
C4 
conformation was confirmed by NMR). Regio- and stereo- selective silylation of the 
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anomeric position with dimethylthexylsilyl chloride was carried out in order to 
exclusively obtain the final compound 42. 
4.3.7. Elongation blocks synthesis: evaluation of the new 
azidoglucose and L-iduronic acid building blocks 
With all the glycosyl donors (8, 9 and 41) and acceptor (42) in hand, the preparation 
of the dimeric building blocks 47-49 was undertaken (Scheme 16). 
 
Scheme 16: Assembly of the disaccharides 47-49. 
Reagents and conditions: (a) TMSOTf or TBSOTf, DCM, for yields see Table 
6. 
 
A significant number of trials were carried out in this case, in order to determine the 
best conditions to perform the glycosylation reactions. Trials involving the donor 41 
to form the disaccharide 49 gave similar results to the ones obtained by De Paz et al. 
(2003) (Table 6, entries 6-9). As described in their work, the formation of the 2-O-
glycosylated disaccharide was also observed, as well as the formation of the 
trisaccharide, but with moderate ratios (determined by LC-MS analysis, results not 
shown here). Further trials were carried out with the glycosyl donors 8 (affording 47) 
and 9 (affording 48) in order to compare the reactivity of the three donors. 
Based on the results obtained (Table 6), a number of conclusions could be drawn. As 
expected, the dropwise addition of the donor to a solution of acceptor and acid 
afforded higher yields. Secondly, it appears that the coupling efficacy of 42 is 
undoubtedly higher than those of 10 and 11, as the yields obtained when using 42 as 
the glycosyl acceptor are relatively higher, with a peak at 65% (entry 3). Thirdly, two 
different catalysts were tested (TMSOTf and TBSOTf) at different concentrations, as 
well as different reaction temperatures. From the yields obtained, it appears that the 
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conditions determined by De Paz and colleagues were the most appropriate ones for 
the glycosyl donors 9 and 41. However, using TBSOTf as an activator significantly 
increased the yield of the assembly of the donor 8 and the acceptor 42 (entry 3). As 
already described by De Paz and hence, as expected, the formation of the 2-O-
glycosylated disaccharide and the trisaccharide were also observed (LC-MS analysis, 
not shown here). However, they were not isolated as their ratios were mainly 
negligible compared to the conversion rate of the desired product. The most 
appreciated aspect of using 42 over 10 and 11 is the constancy and the 
reproducibility of the results (replicates not listed here). 
Entry Donor 
Equiv. 
of 
donor 
Equiv.  
of 
activator 
Temp 
Solution 
Conc. 
Procedure Product 
Yield 
(%) 
1 8 0.6 0.2
a
 0 °C 0.03 M inverse 47 15
c
 
2 8 0.6 0.2
a
 -20 °C 0.03 M inverse 47 40
c
 
3 8 0.6 0.2
b
 0 °C 0.03 M inverse 47 65
c
 
4 9 0.6 0.1
a
 0 °C 0.03 M normal 48 39 
5 9 0.6 0.2
a
 0 °C 0.03 M inverse 48 45 
6 41 0.6 0.2
a
 0 °C 0.03 M inverse 49 59 
7 41 0.6 0.1
b
 0 °C 0.03 M inverse 49 47 
8 41 0.6 0.1
a
 -10 °C 0.03 M inverse 49 36 
9 41 0.6 0.2
a
 -10 °C 0.03 M normal 49 32 
 
Table 6: Reaction conditions and results for the assemblies of the glycosyl 
donors 8, 9 and 41 with the glycosyl donor 42.  
a
TMSOTf; 
b
TBSOTf; 
c
conversion
 
determined by LC-MS data analysis.  
 
Finally, choosing the new disaccharide 49 over the disaccharides 47 and 48 as the 
precursor for the synthesis of the elongation blocks appeared to be more judicious for 
many reasons. Using an excess of glycosyl acceptor instead of glycosyl donor is 
quite advantageous and valuable. The acceptor may indeed be recovered and used 
directly after purification, unlike the donor which will need to be reactivated in case 
of hydrolysis. It might also have undergone rearrangement which makes it unsuitable 
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for another glycosylation reaction. In addition, despite the promising results obtained 
during the coupling of 8 and 42 (65% yield), such good results could not be produced 
by coupling of 9 and 42 (45% yield). Coupling 8 and 9 with 42 also implied the post-
glycosylation installation of a levulinoyl/benzoyl group at position 2 of 47 and 48. 
Owing to the presence of the Fmoc group, these esterification reactions might be 
quite problematic, or even impossible, to perform, as they require the use of strong 
base. 
4.3.8. Conclusions 
One of the main objectives of the present project was the development of a new 
synthetic route and the synthesis of new glycosyl synthons which would ultimately 
help to generate Hp/HS oligosaccharide libraries quickly. The syntheses of the new 
monomeric building blocks (8-11) were successfully carried out with satisfactory 
yields for every PG manipulation step. Their respective coupling efficacies were next 
evaluated in glycosylation reactions. As expected, the trichloroacetimidate synthons 
8 and 9 proved to be very reactive and good glycosyl donors. Even though they 
underwent rearrangement (to afford the corresponding trichloroacetamide residues) 
or were hydrolysed, the detected by-products/product ratios were satisfactory and 
similar to the ones already reported in the literature. However, the L-iduronic acid 
synthons 10 and 11 turned out to be poor glycosyl acceptors, resulting in non-
reproducible and low- to moderate-yield glycosylation reactions, which was also 
expected. The mismatch of reactivity between the glycosylating agents compelled us 
to modify the original strategy. Two reported monomeric glycosyl donor and 
acceptor (respectively 41 (De Paz et al. 2003) and 42 (Ojeda et al. 1999)) were 
prepared and the assemblies of 8 and 9 with 42 were also evaluated. The 
glycosylation results obtained and the post-glycosylation transformations that would 
have been required if working with 8 and 9 invited a review of the whole synthetic 
strategy. It was hence decided to exclusively assemble 41 and 42 to form the 
precursors of the desired disaccharide elongation blocks. 
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4.4. New synthetic approach: synthesis of the new elongation 
blocks 
The decision to use different monosaccharide buildings blocks than the ones initially 
designed to prepare the elongation blocks naturally led us to rethink the scaffolds of 
the majority of the building blocks. As depicted in Scheme 17, the new retrosynthetic 
analysis of 2 provided a total of five building blocks that would be needed to 
complete the synthesis of the oligosaccharide target. Interestingly, the linker and 
capping blocks remained unchanged. Moreover, the preparation of only two new 
elongation blocks 50 and 51 was required – elongation blocks that would necessitate 
the synthesis of the two known monomeric building blocks 41 and 42. Finally, the 
new seeding block and the glycosyl donor 41 appeared to be the same molecule, 
thereby decreasing the number of distinct compounds required. In total, a limited 
number of seven glycosylating agents would be necessary to bring the synthesis of 
the target to completion. 
Unlike the previous approach, the backbone of the oligosaccharide target would need 
to undergo many modifications between two elongation steps: if required, the 
reduction of the azido groups and the acetylation of the amines newly formed; the 
cleavage of the benzylidene acetal moiety and the installation of the appropriate PG 
at the position 6 of the glucosamine/azidoglucose moiety at the non-reducing end. 
With the design of the new building blocks in hand, their syntheses were undertaken. 
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Scheme 17: Retrosynthetic analysis of the new building blocks.  
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4.5. New elongation blocks synthesis 
The preparation of the new elongation blocks started with the preparation of the 
precursor 49, as described in Section 4.3.7. The intermediate 49 was then 
differentiated at this stage of the synthesis (Scheme 18). 
 
Scheme 18: Synthesis of the elongation blocks 50 and 51. 
Reagents and conditions: (a) BzCl, pyridine (95%); (b) LevOH, EDC.HCl, cat. 
DMAP, DCM (83%); (c) HF.pyr, THF (80%); (d) Cl 3CCN, K2CO3, DCM (75%). 
 
The disaccharide 49 was converted into 50 in a three-step sequence as described by 
Lucas et al. (2003). The installation of the benzoyl group at position 2 of the L-
iduronic residue with benzoyl chloride (BzCl) in pyridine (affording 52) was 
followed by the desilylation of the anomeric centre with an excess of HF.pyridine in 
THF (affording 54). Finally, the activation of the anomeric centre was performed 
with trichloroacetonitrile and activated K2CO3 to afford 50. 
The disaccharide 49 was also converted into 51 in a three-step sequence as described 
by De Paz and Martín-Lomas (2005). The conventional 2-O-levulinoylation was first 
performed (affording 53), followed by the cleavage of the silyl group at the anomeric 
position with HF.pyridine (affording 55) and the anomeric activation with 
trichloroacetonitrile and K2CO3 to afford 51. 
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4.6. Towards the synthesis of the first target 
With the elongation and seeding blocks 41, 50 and 51 in hand, the synthesis of the 
target 2 was then initiated. The first step consisted of the derivatisation of the seeding 
block 41 with the linker 6, followed by the elongation of the backbone to form the 
corresponding oligosaccharide intermediates (trisaccharide, pentasaccharide and so 
on). 
4.6.1. Seeding block synthesis 
The linker N-(benzyl)-benzyloxycarbonyl-5-aminopentan-1-ol 6 was prepared from 
commercially available 5-amino-pentan-1-ol (Delcros et al. 2002, Noti et al. 2006). 
The preparation of the final seeding block 58 was performed in a three-step sequence 
(Scheme 19). The intermediates 56 and 57 had been previously reported by 
Arungundram et al. (2009), but here an alternative route to obtain these compounds 
is reported. 
 
Scheme 19: Synthesis of seeding block 58. 
Reagents and conditions: (a) TMSOTf, Et 2O (72%); (b) EtSH, BF3.O(Et)2, 
DCM (92%); (c) BzCN, Et 3N, ACN (89%). Linker = (CH2)5N(Bn)CBz. 
 
The derivatisation of 41 was first realised with 6 in a glycosylation reaction with a 
catalytic amount of TMSOTf in dry diethyl ether Et2O and afforded 56 as a mixture 
of anomers (α/β 2/1, determined by 1H NMR) in 72% yield. Both anomers α-56 and 
β-56 were obtained despite the non-participating effect of the azido group at position 
2 of 41 - which should have favoured the formation of the α-directed compound 
only, as explained in Section 4.2.2. However, both compounds can be separated by 
flash chromatography. Moreover, the choice of the solvent appeared to be of great 
importance. On the one hand, performing such glycosylation reactions with similar 
glycosyl donors (not listed here) in DCM indeed leads to more substantial formation 
of the β-anomer (nearly α/β 1/2 in some cases). On the other hand, performing the 
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reaction in Et2O afforded 56 as a mixture of anomers, with a ratio of α/β 2/1. This is 
explained by the fact that non-polar ethereal solvents, such as Et2O, participate in the 
reaction, preferably form the equatorial intermediate (Nigudkar and Demchenko 
2015) and, therefore, promote the formation of α-linkages, as explained in Section 
4.1.1.2. 
The cleavage of the benzylidene acetal of α-56 was then carried out with EtSH in 
presence of BF3.O(Et)2 and gave 57 with a yield of 92%. The resulting diol finally 
underwent regioselective benzoylation using BzCN and a catalytic amount of 
triethylamine in dry acetonitrile to afford the final compound 58 in 89% yield. 
4.6.2. Trisaccharide precursor synthesis 
With the seeding-linker building block 58 and the elongation blocks 50 and 51 in 
hand, the next step consisted in a first cycle of elongation of the backbone which 
afforded the first trisaccharide precursor. The latter was then modified in order to 
transform it into the glycosyl acceptor for the next elongation step. 
The trisaccharide precursor 59 was prepared by coupling the linker-derivatised 
seeding block 58 and the 2-O-benzoylated elongation block 50 in the presence of 
TMSOTf and molecular sieves in dry DCM (Scheme 20) and was obtained with 95% 
yield. As expected, the formation of the 1,2-trans product only was observed 
(coupling constant: 
1
JC1,H1=171Hz (Bock and Pedersen 1974)), due to the 
neighbouring group participation of the Bz group of the L-iduronic acid residue. 
 
Scheme 20: Synthesis of trisaccharide precursor 59. 
Reagents and conditions: (a) TMSOTf, DCM (95%).  
Linker = (CH2)5N(Bn)CBz. 
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Prior to the benzylidene acetal cleavage that will make the desired hydroxyl group at 
position 4 accessible for further glycosylation, the transformation of the azido groups 
into the corresponding acetamido groups was performed. The transformation had to 
be performed at such an early stage of the process to permit the simultaneous 
presence of differently protected amino moieties on the target molecule 2. 
4.6.2.1. Synthesis of the intermediate 60: preliminary results 
The direct transformation of the two azido groups of the azidoglucose residues into 
acetamido groups was attempted, using thioacetic acid AcSH, as first reported by 
Rosen et al. (1988). Several trials were carried out to determine the best conditions to 
perform the transformation of the diazido trisaccharide 59 into the diacetamido 
intermediate 60.  
For the first trial, thioacetic acid (100 equivalents) was added to a solution of 59 in 
dry pyridine under argon (Kuduk et al. 1998). After 24 hours of stirring at room 
temperature, LC-MS analysis of an aliquot of the reaction indicated that the reaction 
was taking place, but was sluggish and showed low conversion. Significant amounts 
of starting material 59 (around 70%) and intermediate compounds 60a (around 25%) 
were still detected (the intermediates were not isolated). Even after running the 
reaction for another 48 hours at 50 °C, only around 50% of the SM was converted. 
Both mono-acetylated intermediates accounted, for their part, for around 40% of the 
total of the carbohydrate mass. The addition of another 100 equivalents of thioacetic 
acid and stirring the reaction for 3 hours at 80 °C remarkably shifted the ratio 
between compounds (SM: around 20%, intermediates: around 50%, product: around 
30%), but completion of the reaction could still not be attained (Figure 29). It was 
then decided to perform another trial directly using thioacetic acid as both solvent 
and reagent.  
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Figure 29: Analysis of the evolution of the direct transformat ion of the 
azido groups of 59 into acetamido groups using thioacetic acid in pyridine.  
(a) Direct synthesis of trisaccharide precursor 60 using thioacetic acid in 
pyridine and possible structures of the mono -acetylated intermediates 60a. 
Reagents and conditions: (i) AcSH, pyridine.  
Linker = (CH2)5N(Bn)CBz;  
(b) LC-MS data for the conversion of 59 into 60 after 24 hours stirring at R.T.  
Retention time: 13.4 min (calcd for C85H91N3O21: 1489.6 [M], found m/z 1490.3 
[M+H]
+
, 1512.3 [M+Na]
+
): product 60; retention times: 14.8 min and 15.2 min  
(calcd for C83H87N5O20: 1473.6 [M], found m/z 1474.3 [M+H]
+
, 1496.3 
[M+Na]
+
: intermediates 60a; retention time: 16.1 min (calcd for C81H83N7O19:  
1457.6 [M], found m/z 1475.3 [M+NH4]
+
, 1480.3 [M+Na]
+
: starting material 
59; 
(c) LC-MS data for the conversion of 59 into 60 after 48 hours stirring at  
50 °C; 
(d) LC-MS data for the conversion of 59 into 60 after 3 hours stirring at 80 °C.  
 
For the second trial, the starting material 59 was dissolved in pure thioacetic acid and 
the solution was stirred at room temperature under argon (Schwarz et al. 1999). After 
72 hours, TLC and LC-MS analyses revealed that the SM had been completely 
consumed. However, an important formation (around 30%) of the undesired by-
products 60b was then detected as well (Figure 30, (b)) (the by-products were not 
(a) 
(b) 
(c) 
(d) 
 60a 
59 
60 
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isolated). No loss of the benzylidene acetal group was detected, despite the acidity of 
the reaction mixture.  
 
 
 
Figure 30: Analysis of the evolution of the direct transformation of the 
azido groups of 59 into acetamido groups using pure thioacetic acid. 
(a) Direct synthesis of trisaccharide precursor 60 using pure thioacetic acid and 
possible structures of the intermediates/by-products 60a/60b. Reagents and 
conditions: (i) AcSH.  
Linker = (CH2)5N(Bn)CBz;  
(b) LC-MS data for the conversion of 59 into 60 after 72 hours stirring at R.T.  
Retention time: 13.5 min (calcd for C85H91N3O21: 1489.6 [M], found m/z 745.6 
[M+2H]
2+
, 756.6 [M+H+Na]
2+
, 767.6 [M+2Na]
2+
): product 60; retention time: 
14.1 min (calcd for : 1505.6 [M], found m/z 753.6 [M+2H]
2+
, 764.6 
[M+H+Na]
2+
, 775.6 [M+2Na]
2+
): by-products 60b; retention times: 15.0 min 
and 15.3 min (calcd for C83H87N5O20: 1473.6 [M], found m/z 737.6 [M+2H]
2+
, 
748.6 [M+H+Na]
2+
, 759.6 [M+2Na]
2+
): intermediates 60a; retention time: 16.2 
min (calcd for C81H83N7O19: 1457.6 [M], found m/z 729.6 [M+2H]
2+
, 740.6 
[M+H+Na]
2+
, 751.6 [M+2Na]
2+
): starting material 59; 
(c) LC-MS data for the conversion of 59 into 60 after 30 min irradiation in a 
microwave oven at 90 °C.  
Linker = (CH2)5N(Bn)CBz. 
 
The irradiation of a solution of 59 in pure thioacetic acid for 30 min at 90 °C under 
inert atmosphere with microwave oven also led to the significant formation of these 
by-products (Figure 30 (c)) as they represented about 65% of the total of the 
(a) 
(b) 
(c) 60b 
60 
59 
60a 
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carbohydrates. Thus, using pure thioacetic acid appears to promote the 
transformation of the azido moieties, yet the absence of a base appears to lead to the 
formation of the thioamide by-products. Mühlberg et al. (2014) proposed that, in the 
absence of a base (low pH), the C=O tautomer of the thioacetic acid would be 
favoured over the C=S tautomer. The concerted cyclisation would therefore lead to 
the formation of the oxatriazolidine intermediate, which would ultimately deliver the 
corresponding thioamide.  
A last test was performed, using the conditions described by Williams and colleagues 
(Shangguan et al. 2003). In this case, the base 2,6-lutidine was added to a solution of 
starting material 59 in chloroform in order to prevent the formation of the by-
products (with a equivalent/equivalent ratio AcSH/2,6-lutidine of 1/1). The solution 
was irradiated in a microwave oven for 8 cycles of 1 hour, at 60 °C and under inert 
atmosphere. However, TLC monitoring of the reaction progress showed that the SM 
had not been completely consumed after 8 hours of irradiation. 
Entry 
Total 
reaction 
time 
Conditions Temp 
Compound distribution
b
 
SM 
59
 
(%) 
Int 
60a
 
(%) 
P 
60 
(%) 
BPs 
60b 
(%) 
1 73 h AcSH/pyridine 
R.T.to 
80 °C 
20 50 30 0 
2 72 h AcSH R.T. 0 5 65 30 
3 30 min AcSH
a
 90 °C 2 13 20 65 
4 8 h 
AcSH/2,6-lutidine 
CH3Cl
a
 
60 °C N.D. N.D. N.D. N.D. 
 
Table 7: Reagents, conditions and results for the direct synthesis of 60 
using thioacetic acid. 
a
microwave-assisted synthesis; 
b
determined by LC-MS data analysis;  SM: 
starting material; Int: intermediates; P: product; BPs: by-products; N.D.: no 
data. 
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The poor results obtained with this direct method (Table 7) motivated the evaluation 
of other methods for the transformation of the azido groups. Other methods are used 
widely, but require the reduction of the azides, followed by acetylation of the 
resulting primary amines. 
4.6.2.2. Synthesis of the intermediate 61 
As no direct synthesis of the diacetylated intermediate 60 could be performed, the 
reduction of the azido groups into primary amines and which would lead to the 
formation of the diamino intermediate 61 was hence attempted (Scheme 21). The 
common method for the reduction of such moieties implies the use of trisubstituted 
phosphines, such as triphenylphosphine PPh3 or even trimethylphosphine PMe3 
(Staudinger reaction) (Wuts and Greene 2006). 
 
Scheme 21: Synthesis of trisaccharide 61.  
Reagents and conditions: (a) PMe3, NaOH, THF, H2O (quant.). 
Linker = (CH2)5N(Bn)CBz. 
 
The reduction of the azido moieties was first attempted with an excess of 
triphenylphosphine PPh3 (3 equivalents per azido group) in a mixture of THF/H2O. 
The reaction was stirred at room temperature for 12 hours. Small aliquots were taken 
at regular intervals and analysed by MALDI-TOF mass spectrometry to monitor the 
progress of the reaction. The analyses revealed that the SM was completely 
consumed after 1 hour of stirring (Figure 31), but no product could be detected at any 
time point. As expected, the formation of the ions, resulting from the expulsion of N2 
due to the fragmentation of the azido moieties, was detected (Li et al. 2010). The 
MALDI-TOF mass spectra showed the formation of the very stable transient entities 
iminophosphoranes 61a and 61b (Figure 31 (c)). The loss of a benzoyl group was 
systematically detected for every iminophosphorane intermediate as well (by-
products 61c and 61d), due to the basicity of the reaction (Figure 31 (c)). Neither the 
transient entities nor the by-products were isolated. 
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Figure 31: Analysis of the reduction of the azido groups using PPh 3.  
(a) Possible structures of the main transient entities 61a and 61b and of the by-
products 61c and 61d detected by MALDI-TOF analysis.  
Linker = (CH2)5N(Bn)CBz; 
(b) MALDI-TOF mass spectrum of the starting material 59. Calcd for 
C81H83N7O19: 1458.6 [M], found m/z 1481.0 [M+Na]
+
, 1453.0 [M-N2+Na]
+
, 
1425.0 [M-2N2+Na]
+
;  
(c) MALDI-TOF mass spectrum of the reaction crude after 12 hours stirring at 
R.T. Calcd for C117H113N3O19P2: 1925.7 [M], found m/z 1927.2 [M+H]
+
): 
intermediate 61a; calcd for C110H109N3O18P2: 1821.7 [M], found 1823.2 
[M+H]
+
): by-product 61c; calcd for C99H100N3O19P: 1665.7 [M], found m/z 
1667.1 [M+H]
+
): intermediate 61b; calcd for C92H96N3O18P: 1561.6 [M], found 
m/z 1563.0 [M +H]
+
): by-product 61d.  
 
To circumvent the loss of any benzoyl group, the reduction of the azido groups was 
then attempted using resin-bound phosphine. Using such resin-bound reagents 
appears to be quite advantageous, because the purification of the product will be 
facilitated. A simple wash of the resin and filtration work-up should then be enough 
to isolate the product. 
(b) 
(c) 
[5
9
-N
2
+
N
a
]+
 
 
[59+Na]
+
 
[5
9
-2
N
2
+
N
a
]+
 
 
[61a+H]
+
 
 
[61c+H]
+
 
 
[61b+H]
+
 
 
[61d+H]
+
 
 
(a) 
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A first trial was realised in a mixture of THF/H2O using 1.1 equivalents of a resin of 
polystyrene-triphenylphosphine (PS-PPh3, 2.14 mmol/g) per azido group. The 
solution was stirred at room temperature for 6 hours and monitored by TLC and 
MALDI-TOF analysis. Aliquots were analysed every hour to control the adsorption 
of the SM onto the resin. However, no clear evolution was detected over the 6 hours 
of stirring as TLC and MALDI-TOF qualitative analyses both clearly showed the 
substantial presence of the SM in the supernatant at every time point. In addition, the 
product was virtually undetectable. 
A second test was performed using 5 equivalents PS-PPh3 (2.14 mmol/g) per azido 
group at room temperature. Unlike for the first trial, both the consumption of the SM 
and the formation of the product were detected. However, after 6 hours of stirring at 
normal temperature and pressure conditions, the SM had not been fully adsorbed 
onto the resin. To determine whether increasing the temperature of the reaction 
would influence the kinetics of the reaction, the reaction mixture was transferred into 
a microwave vial and irradiated at 40 °C for 30 min. Qualitative analysis of the 
supernatant by MALDI-TOF mass spectrometry hence clearly showed the complete 
adsorption of the SM onto the resin after irradiation. The product was isolated after 
filtration with a yield of 30%. The results obtained (poor yield and no detection of 59 
in the supernatant) clearly indicated that the SM was indeed adsorbed on the resin to 
form the stable resin-bound iminophosphorane transient entities, but the latter were 
not cleaved off the resin.  
Microwave-assisted synthesis of the diamino intermediate 61 was then attempted, 
using 5 equivalents of PS-PPH3 (2.14 mmol/g) per azido group. A solution of 59 and 
PS-PPh3 in THF/H2O in a microwave vial equipped with a stirring bar was irradiated 
in a microwave oven for cycles of 1 hour at 50 °C. After a total of 3 cycles, MALDI-
TOF analysis showed the complete consumption of the SM. However, the product 
was virtually undetected by LC-MS analysis (Figure 32, (a)). The solution mixture 
was then irradiated for another cycle of 30 min at 100 °C and analysed by LC-MS. 
As depicted in Figure 32 (b), the cleavage of the sugar from the resin was performed. 
The product was isolated and analysed by 
1
H NMR, which revealed an important 
contamination of the sugar sample by aliphatic residues (results not shown here). 
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Figure 32: LC-MS data for the microwave-assisted conversion of 59 using 
PS-PPh3. 
(a) LC-MS analysis data of the reaction after 3 hours of irradiation (3 cycles of 
1 hour at 50 °C). Both starting material 59 and product 61  could not be 
detected.  
(b) LC-MS analysis data of the reaction after 3.5 hours of irradiation (3 cycles 
of 1 hour at 50 °C followed by a 1 cycle of 30 min at 100 °C). Retention time: 
8.2 min (calcd for C81H87N3O19: 1405.6 [M], found m/z 1406.3 [M+H]
+
, 1423.5 
[M+NH4]
+
, 1428.5 [M+Na]
+
): product 61. 
 
Finally, PMe3 was evaluated as the reductive agent. The trisaccharide 59 in a mixture 
of THF/H2O (4/1 v/v) was then treated with a 1 M PMe3 solution in presence of 
NaOH at room temperature for 5 hours. The complete conversion of the SM was 
monitored by MALDI-TOF analysis and no by-product formation was detected. The 
NaOH solution was quenched by addition of a 1 M HCl aqueous solution to avoid 
any cleavage of benzoyl groups. However, due to the significant increase of polarity 
of the compounds caused by the presence of the amine moieties, the different 
attempts to isolate 61 remained unsuccessful. Routine flash chromatography resulted 
in very poor yield as elution of the compound could not be properly performed using 
the routine combinations of solvents (in this case, mainly methanol and 
dichloromethane). The use of a base such as Et3N did not improve the method. 
Purification using Sephadex LH-20 columns was also attempted, but several cycles 
of purification were necessary to obtain perfect separation of the salts and the 
(a) 
(b) 61 
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product. This resulted in a consequent loss of the product mass. In order to avoid the 
loss of such valuable compounds, it was decided to only dry the crude residue of the 
reduction reaction under high vacuum and carry it through to the next reaction. 
4.6.2.3. Synthesis of the intermediate 63 
The synthesis of the glycosyl acceptor 63 from the trisaccharide 59 was then 
performed in a four-step sequence (Scheme 22). As described in the previous 
sections, the azido moieties of 59 were first reduced using PMe3 in THF/H2O in 
presence of NaOH. The resulting residue was then thoroughly dried under high 
vacuum and directly acetylated using acetic anhydride in dry Et3N at 0 °C. The 
purification of the resulting crude was performed with a Sephadex LH-20 column 
and afforded the desired diacetylated trisaccharide 60 (69 %, 2 steps). 
 
Scheme 22: Synthesis of the glycosyl acceptor 63. 
Reagents and conditions: (a) PMe 3, NaOH, THF, H2O; (b) Ac2O, Et3N (69%, 2 
steps); (c) EtSH, TMSOTf, DCM; (d) BzCN, Et 3N, ACN (70%, 2 steps).  
Linker = (CH2)5N(Bn)CBz. 
 
The benzylidene cleavage was first attempted using EtSH in the presence of 
BF3.O(Et)2. As no initiation of the reaction was detected by MALDI-TOF analysis, 
the acid was then substituted by TMSOTf in another trial and the formation of the 
desired diol 62 could then be detected. The majority of salts formed during the 
reaction and excess of the reagents were removed using a Sephadex LH-20 column. 
The resulting diol residue was dried under high vacuum and directly treated with 
benzoyl cyanide (BzCN) and a catalytic amount of triethylamine (Et3N) in dry 
acetonitrile, as was the seeding block 57. The desired regioselectively protected 
trisaccharide 63 was obtained (determined by MALDI-TOF analysis and 
1
H NMR) 
with a yield of 70% over 2 steps. 
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4.6.3. Pentasaccharide precursor synthesis: preliminary results 
With the glycosyl acceptor 63 and the glycosyl donor 50 in hand, the second step of 
elongation was carried out to form the pentasaccharide precursor 64 (Scheme 23).  
The different tests for the assembly of 50 and 63 were realised using the normal 
procedure. The qualitative progress of the glycosylation reactions was mainly 
monitored by TLC and LC-MS, even though for the latter method, the varying 
number of chromophore groups amongst the compounds of interest did not allow any 
quantitative interpretation of the results. Analyses of aliquots taken at different time 
points (5 min, 15 min, 1 hour and 2 hours) suggested that the glycosylation reaction 
takes place as soon as the acid is added to the glycosyl acceptor/donor mixture as no 
clear evolution was detected as a function of time. All the LC-MS analyses realised 
for the different tests were in agreement with this observation (not shown here). 
 
Scheme 23: Test synthesis of the pentasaccharide 64.  
Reagents and conditions: (a) TMSOTf or TBSOTf, DCM, for yields, see Table 
8. 
Linker = (CH2)5N(Bn)CBz. 
 
From the results that were obtained (Table 8), several conclusive remarks could be 
drawn. First of all, the silylation of the glycosyl acceptor (by-product 64a) and the 
formation of the tetrasaccharide, resulting from the side glycosylation between the 
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glycosyl donor and its hydrolysed counterpart (by-product 64b), were systematically 
detected when TMSOTf was used as the promoter agent (Figure 33). To prevent the 
formation of the silylated by-product 64a, triflic acid (TfOH) was used as the 
promoter (Table 8, entries 6 and 7). However, the reaction was not initiated as no 
product could be detected at any point. Interestingly, the tetrasaccharide 64b was not 
detected either, suggesting than TfOH was not able to activate the donor 50. The 
option of using TfOH was then abandoned. 
Entry 
Equiv. of 
donor 
Equiv.  
of activator  
Temp 
Solution 
Conc. 
Compound distribution
c
 
Acc 
63
 
(%) 
P 
64 
(%) 
BP 
64a 
(%) 
1 1.5 0.1
a
 -20 °C 0.1 M 80 13 7 
2 1.5 0.2
a
 0 °C 0.5 M 57 27 16 
3 5 0.2
a
 -20 °C 0.01 M 62 33 5 
4 2.5 0.2
a
 -40 °C 0.01 M 90 6 4 
5 1.5 0.2
a
 -80 °C 0.01 M 65 15 20 
6 1.5 0.2
b
 -20 °C 0.01 M 100 0 0 
7 1.5 0.2
b
 -80 °C 0.01 M 100 0 0 
 
Table 8: Reaction conditions and results for the assemblies of the glycosyl 
donor 50 with the glycosyl acceptor 63. 
a
TMSOTf; 
b
TfOH; 
c
determined by LC-MS data analysis; Acc: glycosyl 
acceptor; P: product; BP: by-product. 
 
Secondly, several sets of conditions were tested in order to determine if any 
parameter would emerge as essential to attain high yield glycosylation (Table 8, 
entries 1-5). However, the yields remained quite low in every case. The highest 
conversion was obtained when performing the reaction with the conditions described 
in entry 3 of Table 8. However, a fairly large excess of donor was required to obtain 
such a result (5 equivalents), which was not an acceptable solution. In addition, the 
conversion obtained in this case was low and was not so different from those 
obtained in the other cases, which suggested investigation of other solutions. 
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Figure 33: Typical LC-MS spectrum profile obtained for the assembly of 50 
with 63. 
For conditions, see Table 8, entry 3. Retention times: 10.15 min and 10.63 min 
(calcd for C41H41N3O12: 767.3 [M], found m/z 785.4 [M+NH4]
+
, 790.4 
[M+Na]
+
): hydrolysed donor 54; retention time: 12.75 min  (calcd for 
C85H91N3O22: 1505.6 [M], found m/z 1506.8 [M+NH4]
+
, 1528.9 [M+Na]
+
): 
acceptor 63; retention time: 14.43 min (calcd for C88H99N3O22Si: 1578.8 [M], 
found m/z 1601.8 [M+Na]
+
): silylated acceptor 64a; retention time: 15.56 min 
(calcd for C82H80N6O23: 1516.5 [M], found m/z 1534.8 [M+NH4]
+
, 1539.8 
[M+Na]
+
): by-product 64b; retention time: 15.71 min (calcd for C126H130N6O33:  
2254.9, found m/z 1128.7 [M+2H]
2+
, 1140.2 [M+H+Na]
2+
): product 64. 
 
The low coupling efficiency between 50 and 63 that was observed may be explained 
by a strong mismatch of reactivity between the glycosyl donor and acceptor. While 
the trichloroacetimidate donor is indeed very reactive, both the presence of an L-
iduronic acid residue and the introduction of the acetamido moieties appeared to 
drastically lower the acceptor reactivity. The latter was still expected to have an 
impact on the outcome of the assembly reaction, as the hydroxyl group at position 4 
of D-glucosamine residues bearing an acetamido moiety has long been known to lack 
reactivity in glycosylation reactions (Paulsen 1982, Crich and Dudkin 2001). In 
addition, the unavoidable and important formation of the by-products, as well as the 
difficulties encountered for the isolation of the product, encouraged the synthesis and 
evaluation of a new type of acceptor for the formation of the desired pentasaccharide 
backbone. 
4.6.4. Synthesis of the new trisaccharide precursor 67 
Amongst the multitude of groups that are available for masking the amine moieties 
of the D-glucosamine residues, it was decided to resort to the trichloroacetamide 
(TCA) protecting group for several reasons. First of all, N-trichloroacetyl groups are 
more stable and less prone to migration than N-acetyl groups. In addition, the 
installation of the TCA protecting group is rather easily done, in mild conditions, 
which should not compromise the stability of the other PGs. Moreover, unlike with 
other PGs, TCA groups can be directly transformed into acetamido groups by radical 
64b 
64a 
63 64 
54 
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reduction using azobisisobutyronitrile (AIBN) and an organotin compound such as 
tributyltin hydride ((Bu)3SnH) as a source of hydrogen atom (Blatter et al. 1994). 
Despite being a robust method used for routine radical dehalogenation, the latter 
required slight modifications to be performed in some cases, as for the synthesis of 
chondroitin sulphate precursors by Hsieh-Wilson and co-workers, dimethylacetamide 
has been used as a co-solvent with benzene (Tully et al. 2004). In another case 
described by Bräse and coworkers, this method proved itself to be unsuitable, since it 
led to the decomposition of the SM and more specifically to the cleavage of the β-
1,4-glycosidic bond of the hyaluronic acid tetrasaccharide (Virlouvet et al. 2010). 
Moreover, the well-known high toxicity of stannane compounds and benzene remain 
major drawbacks which have motivated researchers to investigate new methods of 
dehalogenation. In the study published in 2010, Virlouvet and colleagues also 
attempted the dehalogenation of the hyaluronic acid precursors using a combination 
of zinc and acetic acid (Zn/AcOH) in 1,4-dioxane, another common way of reducing 
trichloroacetamides. In this case however, the formation of the desired product was 
detected in low yield (around 20%) and this method also led to the decomposition of 
the material. Finally, the reduction of trichloroacetamides can be performed under 
catalytic hydrogenation conditions (Kandasamy et al. 2014). In addition, the last two 
methods also allow the reduction of the azido groups, which make them very 
interesting and convenient for the synthesis of some specific octasaccharide targets.  
As for the preparation of the trisaccharide precursor 63, the four-step sequence 
synthesis of the desired glycosyl acceptor 67 started with the reduction of the azido 
groups using PMe3 in THF/H2O in the presence of NaOH (Scheme 24). The resulting 
residue was then dried under high vacuum for a minimum of 12 hours and the 
installation of the trichloroacetamide moieties was directly performed using 
trichloroacetyl chloride under basic conditions to quench the HCl formed during the 
reaction. The purification of the resulting crude was performed with a Sephadex LH-
20 column and afforded the desired trisaccharide 65 (55 %, 2 steps).  
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Scheme 24: Synthesis of the glycosyl acceptor 67. 
Reagents and conditions: (a) PMe 3, NaOH, THF, H2O; (b) Cl3CCOCl, Et3N 
(55%, 2 steps); (c) EtSH, TMSOTf, DCM; (d) BzCN, Et 3N, ACN (51%, 2 
steps). Linker = (CH2)5N(Bn)CBz. 
 
The benzylidene cleavage was performed using EtSH in presence of TMSOTf and 
the progress of the reaction was monitored by MALDI-TOF mass analyses (not 
shown here). As for the synthesis of the trisaccharide precursor 62, the majority of 
salts formed during the reaction and excess of the reagents were removed using a 
Sephadex LH-20 column. The resulting crude was dried under high vacuum and 
directly treated with benzoyl cyanide (BzCN) and a catalytic amount of triethylamine 
(Et3N). The desired regioselectively protected trisaccharide 67 was obtained 
(determined by 
1
H NMR) with a yield of 51% over 2 steps. 
4.6.5. New pentasaccharide precursor synthesis: evaluation of the 
new trisaccharide building block 67 
The newly synthesised trisaccharide building block 67 was then evaluated as 
potential glycosyl acceptor for the preparation of the pentasaccharide target (Scheme 
25). Two tests for the assembly of 50 and 67 were realised using the normal 
procedure. As for the preparation of the pentasaccharide 64, the qualitative progress 
of the glycosylation reactions was mainly monitored by TLC and LC-MS. Similarly, 
analyses of aliquots taken at different time points (5 min, 15 min, 1 hour and 2 hours) 
suggested that the glycosylation reaction takes place as soon as the Lewis acid is 
added to the glycosyl acceptor/donor mixture.  
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Scheme 25: Test synthesis of the pentasaccharide 68.  
Reagents and conditions: (a) TMSOTf, DCM, for yields, see Figure 34.  
Linker = (CH2)5N(Bn)CBz. 
 
TMSOTf was used as the promoter agent for both tests. As expected, the formation 
of the silylated glycosyl acceptor analogous 68a was observed by LC-MS analyses 
(Figure 34 (a)). Similarly, and as for the preparation of the pentasaccharide 64, the 
presence of the tetrasaccharide 64b was also detected (Figure 34, (a)).  
The results obtained with the first test suggested that the formation of the product 
was more important with the new glycosyl acceptor (Figure 34 (b), entry 1) and were 
very encouraging (52% compound distribution). In addition, a replicate of the 
reaction was carried out but gave an unexpectedly very low conversion. The coupling 
reaction between 50 and 67 hence showed signs of poor reproducibility. However, 
these observations were drawn from the results obtained with only two reaction tests. 
Other conditions must be assessed to determine their impact on the reaction outcome.  
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Entry 
Equiv. 
of donor 
Equiv.  
of 
TMSOTf 
Temp 
Solution 
Conc. 
Compound distribution
a
 
Acc 
67
 
(%) 
P 
68 
(%) 
BP 
68a 
(%) 
1 1.5 0.2 -20 °C 0.05 M 34 52 14 
2 1.5 0.2 -20 °C 0.05 M 68 15 17 
 
Figure 34: Analysis of the assembly of 50 with 67. 
(a) Typical LC-MS spectrum profile obtained for the assembly of 50  with 67  
(for conditions, see table (b), entry 1). Retention times: 10.10 min and 10.48 
min (calcd for C41H41N3O12: 767.3 [M], found m/z 785.4 [M+NH4]
+
, 790.4 
[M+Na]
+
)): hydrolysed donor 54; retention time: 14.97 min (calcd for 
C85H85Cl6N3O22: 1713.3 [M], found m/z 1714.4 [M+H]
+
, 1731.4 [M+NH4]
+
,  
1736.3 [M+Na]
+
): acceptor 67; retention time: 15.56 min (calcd for 
C82H80N6O23: 1516.5 [M], found m/z 1534.8 [M+NH4]
+
, 1539.8 [M+Na]
+
): by-
product 64b; retention time: 16.15 min (calcd for C88H93Cl6N3O22Si: 1785.5 
[M], found m/z 1786.5 [M+NH4]
+
,1803.5 [M+H]
+
,1809.5 [M+Na]
+
): by-product 
68a; retention time: 16.90 min (calcd for C126H124Cl6N6O33: 2463.1, found m/z 
1254.4 [M+2Na]
2+
): product 68. 
(b) Reaction conditions and results for the assemblies of the glycosyl donor 50 
with the glycosyl acceptor 67. 
a
determined by LC-MS data analysis; Acc: glycosyl acceptor; P: product; BP: 
by-product. 
 
4.6.6. Conclusions 
Following the unsuccessful development of a new synthetic route in the first part of 
this Chapter 4, the original plan was modified. Owing to time constraints, it was 
decided to resort to dimeric building blocks (50 and 51) that have already been 
described in the literature (Lucas et al. 2003, De Paz and Martín-Lomas 2005) and to 
include them in the current project. With the new dimeric building blocks in hand, 
the synthesis of the oligosaccharide target was initiated. The preparation of both the 
67 
68a 
68 
64b 
(b) 
(a) 
54 
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seeding block 58 and the first trisaccharide precursor 59 was successfully achieved. 
The direct transformation of the azido groups of 59 into acetamido groups was first 
attempted using thioacetic acid but led to the large formation of the reaction 
intermediates and could not be brought to completion. Other methods were explored, 
requiring the reduction of the azido groups into primary amino groups (to afford 61). 
This, however, led to drastic changes in reactivity in routine chemical reactions and 
workup/purification steps. This seriously hampered the successful synthesis of the 
other trisaccharide glycosyl acceptors 63 and 67. The preparation of the 
pentasaccharide precursors 64 and 68 were attempted but gave unsatisfactory results, 
probably owing to the gap of reactivity between the donors and the acceptors. 
4.7. General conclusions  
For the sake of simplicity and with a view to saving time and resources, chemists 
often aim for the preparation of rather short and homogenous structures. However, 
the latter do not reflect the complete range of intrinsic heterogeneity of these 
carbohydrates. With the perspective of developing a new modular synthetic strategy 
that would allow an easy and rapid preparation of structurally heterogeneous 
structures, the synthesis of the natural octasaccharide A (Scheme 5) isolated by Prof. 
Turnbull’s team (Ahmed 2010) was attempted. The new route was designed in such a 
way that the chemistry would ultimately be transferred to solid-phase synthesis. A 
number of novel advances were made. Firstly, convenient methods for the 
preparation of new monomeric and dimeric building blocks were successfully 
developed and oligosaccharide structures, up to pentasaccharide precursors, were 
successfully prepared. Secondly, the possibility of using resin-bound 
triphenylphosphine to achieve the reduction of azido moieties was also successfully 
demonstrated. Developing the use of such solid phase-based methods as well as the 
microwave-assisted synthesis in carbohydrate chemistry may be of upmost 
importance in the development of cheap, fast and hassle-free synthetic pathways.  
As anticipated, a number of issues arose during the syntheses of longer saccharides, 
including poor coupling efficacies and changes of reactivity. Owing to some of these 
issues, major modifications were brought to the initial plan and the modular strategy 
was eventually abandoned in favour of the development of a more versatile synthetic 
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route. During both phases, the poor coupling character of the L-iduronic acid residues 
turned out to be an obstacle to attainment of high-yield coupling reactions. With the 
reduction of the azido groups also arose other issues, such as difficult work-up and 
purification steps, as well as consequent changes in reactivity in routine chemical 
reactions.  
Therefore, some aspects arising from the work here require further investigation in 
the future. The poor coupling efficacies observed remain the major obstacle to 
overcome. Using more electron donating PGs to reduce the gap between the 
reactivity properties of both the glycosyl donor and acceptor may be a first plausible 
option. Using idose residues as glycosyl acceptors may represent another possibility, 
as they are well-known for being more reactive than their L-iduronic acid analogues. 
This option will require the late-stage C-6 oxidation into the uronic acid residues, 
which may become more problematic as the oligosaccharide size is extended. 
Another issue that would require attention is the impact of acetamido and 
trichloroacetamido moieties as PGs as they drastically affect the behaviour of the 
compounds, due to their electron withdrawing effect. Using different PGs such as N-
phthalimides may help prevent such an undesired effect. Additional trials of the 
synthesis of the pentasaccharide bearing trichloroacetamide moieties must be carried 
out in order to evaluate the reproducibility of this glycosylation reaction. Finally, 
with a pentasaccharide precursor in hand, it would be interesting to undertake the 
deprotection and sulphation steps in order to investigate their feasibility on such 
structurally disparate structures.  
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5.1. Introduction 
Fibroblast Growth Factors (FGFs) and their receptors (FGFRs) are involved in many 
biological processes such as cellular proliferation and migration, survival and 
differentiation, but also wound healing and angiogenesis, to name but a few 
(Beenken and Mohammadi 2009, Ornitz and Itoh 2015). Aberrant FGF signalling has 
been linked to many disorders and diseases such as metabolic and cardiovascular 
disorders (Li, Wang, et al. 2016) and cancers (Jorgen et al. 2011).  
Several studies showed that FGF signalling depends on the formation of FGF-FGFR-
HS complex to be effective (Flaumenhaft et al. 1990, Klagsbrun and Baird 1991, 
Rapraeger et al. 1991, Yayon et al. 1991). Deciphering the structure activity 
relationship (SAR) of HS in FGF signalling is hence of crucial importance for 
understanding the functional role of HS and potentially for the development of novel 
glycan therapeutics (Yip et al. 2006).  
Some major findings on HS SAR have been achieved over recent decades, such as 
determining the minimum size needed for HS-protein interactions (heparin 
octasaccharides were shown to be efficient to support FGF2 activity Ornitz et al. 
(1992)) and the fact that distinct structural determinants are required for different 
FGF-FGFR complexes (Guimond and Turnbull 1999, Pye et al. 2000, Ostrovsky et 
al. 2002). As developed in more detail in chapter 1, the regulation of FGF signalling 
has been shown to depend on many factors including the HS saccharides sulphation 
patterns (e.g. Guimond and Turnbull (1999); Pye et al. (2000)), the nature of the 
solvent/coordinated ions (Rudd et al. 2007, Guimond et al. 2009) and the plasticity 
of both the L-iduronic acid residues and the saccharide chains (Raman et al. 2003, 
Rudd and Yates 2010). Despite the intensive investigation that has been carried out 
to elucidate the molecular mechanisms of FGF signalling (see Section 1.7), the 
interactions between HS, FGF and FGFR which lead to functional activity still 
remain elusive. In particular, the concept of specificity/selectivity in these 
interactions is still extensively debated, as mentioned in 1.7.4, and clearly needs to be 
addressed.  
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Owing to the lack of efficient and appropriate methods to both prepare and sequence 
HS oligosaccharides (see Section 1.8), most of the studies assessing HS-FGF-FGFR 
interactions to date have been conducted using either oligosaccharide mixtures (e.g., 
Guimond and Turnbull (1999); Zhang, Zhang, et al. (2009)) or saccharides which 
were not fully structurally determined (for example, the nature of the exact 
sulphation pattern or the uronic acid residue was often unknown) (e.g. Guimond and 
Turnbull (1999); Ashikari-Hada et al. (2004)). In addition, the function of specific 
and unusual structural features - namely the 3-O-sulphate groups (Thacker et al. 
2014) and also unsubstituted glucosamine residues - could not be properly assessed. 
In several studies where the isolation of the saccharides was achieved, the structural 
differences between the compounds were however too diverse to determine the 
effects of small structural changes (Belford et al. 1992, Wu et al. 2003). 
Further advances in the meticulous study of HS SAR in FGF signalling now requires 
the use of pure and well-defined HS saccharides. Such compounds would allow the 
study of the impact of a variety of structural modifications on FGF activity. 
Ultimately, this would also provide the key to a better understanding of the 
specificity/selectivity of HS-FGF-FGFR interactions.  
5.1.1. Aim 
The work presented in this chapter aimed to evaluate the impact of several types and 
degrees of structural differences on the ability of HS saccharides to stimulate FGF 
signalling, using precise ligand-receptor activity assays with the help of structurally 
defined HS oligosaccharides of various sizes. More specifically, the impact of both 
general versus subtle modifications of the sulphation pattern, high versus low levels 
of sulphation, changes of uronic acid residues and size changes were all examined.  
5.1.2. Strategy and method 
Most of the structural and biochemical work published in the literature is based on 
the examination of FGF1-FGFR2 and FGF2-FGFR1 complexes only and other 
complexes have generally not been considered. This chapter focuses on a total of 4 
complexes: FGF2-FGFR1c, FGF1-FGFR1c, FGF1-FGFR2b and FGF7-FGFR2b. 
These complexes were chosen for several reasons. First of all, FGF1 is known to 
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signal through all types of receptors and is often termed the universal FGFR ligand 
(the complexes FGF1-FGFR1c and FGF1-FGFR2b would hence be used as positive 
controls). In contrast, FGF7 is known to signal exclusively through FGFR2b (Ornitz 
et al. 1996, Zhang et al. 2006). In addition, FGF2 and FGF1 both signal through 
receptor FGFR1c in a similar fashion (Guimond and Turnbull 1999). By comparing 
the results obtained with these different FGF-FGFR complexes, it may be possible to 
have some insights into the structural determinants that are optimal for each 
signalling protein and receptor combination.  
To assess the signalling activities, a total of 19 Hp/HS oligosaccharides, which are 
described in more detail in Section 5.2, were screened in these bioassays (BaF3 
assays are described in the following Section 5.1.2.1).  
5.1.2.1. BaF3 bioassays 
BaF3, the murine Interleukin-3 (IL-3) dependent pro-B cell line that does not 
naturally express either endogenous HS or FGFR was used in bioassays to 
investigate FGF signalling. Upon removal of IL-3, BaF3 cells undergo apoptosis 
(programmed cell death). Alternatively, the cells can be transfected with individual 
FGFRs and the survival, growth and proliferation of the cells are assured if they are 
incubated with the appropriate FGF and suitable Hp/HS saccharides to generate 
productive signalling (Ornitz et al. 1996). The cells used for this project were 
transfected with either FGFR1c or FGFR2b (Ornitz et al. 1996). They were 
previously used as an HS-dependent assay for FGF signalling responses (Guimond 
and Turnbull 1999). The transfected cells were incubated in the presence of either 
FGF1/FGF2/FGF7 and with Hp/HS oligosaccharides (for details about the 
saccharides, see Section 5.2). Upon activation of the FGF-FGFR complex by Hp/HS, 
the cells proliferate and their mitogenic activity is measured using the tetrazolium 
dye MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide). The 
mitochondrial reductase enzymes of viable cells reduce MTT to purple formazan 
which can be read at λ = 570 nm. The absorbance is proportional to live cells and cell 
proliferation, and therefore to FGF signalling (Guimond and Turnbull 1999). For 
more details about the conditions for bioassays, see Section 2.2. 
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Prior to any bioassay, the activity of the saccharides alone (cells in growth medium 
and in the presence of the oligosaccharides) was assessed. Responses to Hp/HS 
saccharides alone (cells in growth medium and in the presence of the 
oligosaccharides) were identical to the background controls (cells in BaF3 growth 
medium) (see Section 5.3). The saccharides were next screened in primary bioassays 
(at a concentration of 3 µg/mL, previously determined as optimal for heparin and 
heparin saccharides), as described in Section 2.2. FGFs were used at different 
concentrations (0.1 nM FGF2, 1 nM FGF1 and 3 nM FGF7) to obtain comparable 
assay response levels. Briefly, for each FGF-FGFR pair, three replicates of the 
bioassays were carried out, and triplicates were carried out in each bioassay plate (for 
a total of 9 absorbance values per oligosaccharide-FGF-FGFR combination). For 
dose response curves, the assays were carried out once (triplicates on each assay 
plate). For all types of assays, the values of the background controls (cells in culture 
medium and treated with FGF alone) were subtracted from the values of interest 
(cells in culture medium and in the presence of full-length Hp/HS oligosaccharide of 
interest). 
For primary bioassays, the data were normalised to that of full-length Hp (optimal  
3 µg/mL) in order to correct the variability caused by slightly different experimental 
conditions between plates (e.g., number and response levels of the cells). Normalised 
data also allowed assessment of the relative mitogenic activity of the compounds for 
each FGF-FGFR pair and to make comparisons between different FGFs or different 
FGFRs. The compounds were tested using a one-sample t-test (one tailed) to 
determine whether their relative activities were significantly higher than the different 
reference values or not (reference values: 5%, 50% and 100% activity, relative to 
full-length Hp). 5% was designated as the threshold value for minimum activity. 
Selected compounds were also tested using a two-sided t-test. Data analyses were 
performed with R statistical software v.3.3.0. 
5.2. Libraries of well-defined Hp/HS oligosaccharides 
[This work was carried out in collaboration with Prof. J. Liu (The University of 
North Carolina, Chapel Hill, NC, USA) and Prof. P. Tyler (Victoria University of 
Wellington, New Zealand), who provided the defined HS saccharides]. 
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5.2.1. From chemical sources  
Schwӧrer et al. (2013) successfully developed the chemical synthesis of a set of 
structurally varied HS oligosaccharides, ranging from hexa- to dodeca-saccharides. 
The oligosaccharides were targeted for inhibition of the BACE-1 protease, and were 
rather low sulphated (fully N-Acetylated and 6-O-sulphated oligosaccharides) and 
most displayed exclusively either L-iduronic acid or D-glucuronic acid residues. As 
part of the collaboration between our two teams, a total of 10 compounds (4 
octasaccharides, 4 decasaccharides and 2 dodecasaccharides) were generously 
provided by Prof. P Tyler’s team to be screened in BaF3 bioassays. These structures 
are illustrated in Table 9. The structural homogeneity of these structures repeat 
disaccharide units allowed mainly the investigation of the impact of the size, the 
nature of the uronic acids, 2-O-sulphation and the lack of N-sulphate groups on the 
functional activity of HS saccharides.  
5.2.2. From chemoenzymatic sources 
Since 2000, Prof. J. Liu’s team have been developing alternative, robust and fast 
synthetic and enzymatic strategies to prepare Hp/HS oligosaccharides (Liu et al. 
2010, Moon et al. 2012, Xu, Pempe, et al. 2012, Hsieh et al. 2014). Notably, Xu et 
al. (2014) successfully developed a chemoenzymatic method to prepare Low 
Molecular Weight Hp (LMWHp) structures. This method allowed the synthesis of 
saccharides ranging from hexa- to dodeca-saccharides, with some displaying the 
unusual structural feature 3-O-sulphate group towards the non-reducing end. 
Compared to the saccharides prepared by Prof. Tyler’s team, which were rather 
structurally homogeneous, Xu et al. (2014) successfully prepared structures 
containing both types of uronic acid residues. As part of collaboration between our 
two teams, Prof. Liu’s team generously provided a total of 9 compounds (3 
octasaccharides, 3 decasaccharides and 3 dodecasaccharides) for bioassay screening. 
These structures are illustrated in Table 10. The structural features of these 
compounds allowed assessment of the impact of the size, 6-O-sulphate and 3-O-
sulphate groups on the functional activity of HS saccharides.  
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Name Structure Legend 
Oct6SIdo 
 
 
GlcNAc 
 
 
 
 
 
 
IdoA 
 
 
 
 
 
 
GlcA 
Oct6SIdo2S 
 
Oct6SGlc 
 
Oct6SGlc2S 
 
Dec6SIdo 
 
Dec6SIdo2S 
 
Dec6SGlc 
 
Dec6SGlc2S 
 
Dod6SIdo 
 
Dod6SIdo2S 
 
 
Table 9: Schematic representation of the structures of the HS 
oligosaccharides prepared by chemical synthesis   (Schwӧrer et al. 2013). 2S: 
2-O-sulphate; 6S: 6-O-sulphate; GlcA: β-D-glucuronic acid; GlcNAc: N-acetyl-
α-D-glucosamine; IdoA: α-L-iduronic acid; MP: methoxyphenyl.  
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Name Structure Legend 
Oct2S 
 
 
GlcNAc 
 
 
 
 
GlcNS 
 
 
 
 
IdoA 
 
 
 
 
GlcA 
Oct2,6S 
 
Oct2,6+3S 
 
Dec2S 
 
Dec2,6S 
 
Dec2,6+3S 
 
Dod2S 
 
Dod2,6S 
 
Dod2,6+3S 
 
 
Table 10: Schematic representation of the structures of the HS 
oligosaccharides prepared by chemoenzymatic synthesis (Xu et al. 2014). 
2S: 2-O-sulphate; 3S: 3-O-sulphate; 6S: 6-O-sulphate; GlcA: β-D-glucuronic 
acid; GlcNAc: N-acetyl-α-D-glucosamine; IdoA:  α-L-iduronic acid; pNP: para-
nitrophenyl.  
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Overall, two sets of libraries were collected, for a total of 7 octasaccharides, 7 
decasaccharides and 5 dodecasaccharides. These 19 fully defined structures 
displayed interesting structural differences that allowed initial studies of the role of 
2-O-, 6-O- and 3-O-sulphation and the size of saccharides on FGF signalling.  
5.3. Results 
5.3.1. Assessing the ability of Hp/HS oligosaccharides to induce 
FGF2 and FGF1 signalling through FGFR1c 
Prior to any activity screening of the 19 compounds, the response of the cells 
expressing FGFR1c in the presence of FG2/FGF1 and of different concentrations of 
full-length Hp was assessed (Figure 35). The curves obtained here were in agreement 
with previously published values (Ornitz et al. 1996, Guimond and Turnbull 1999).  
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Figure 35: Dose response curves (mean ±S.D.) for full-length Hp activation 
of FGF2 (0.1 nM) and FGF1 (1 nM) signalling through FGFR1c.Values are 
the mean of triplicate samples.  
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The activity of the saccharides alone (cells in growth medium and in the presence of 
the oligosaccharides) was also assessed. Responses to Hp/HS saccharides alone (cells 
in growth medium and in the presence of the oligosaccharides) were identical to the 
background controls (cells in BaF3 growth medium) (Figure 36). 
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Figure 36: Evaluating the bioactivity of the compounds alone at 3 µg/mL in 
bioassays with cells expressing FGFR1c. The negative control refers to the 
cells in BaF3 medium only (background).  The values are the mean of triplicate 
samples and the error bars represent the standard deviation (S.D.).  
 
The capability of the oligosaccharides to stimulate the mitogenic activity through the 
ligand-receptor pairings of FGF2-FGFR1c and FGF1-FGFR1c was next assessed 
(Figure 37). To determine whether the relative activities of the compounds were 
higher than 5%, 50% or 100% activity (relative to full-length Hp), statistical tests 
were performed (one-sample t-tests (one tailed) - the results are listed in Table 11). 
Selected compounds were also compared using a two-sided t-test.  
For these two complexes, the oligosaccharides displayed various degrees of 
activation, independently of the FGF-FGFR complex. At the fixed concentration of 3 
µg/mL, some oligosaccharides were observed to be very potent activators (relative 
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activity higher than 100%, relative to full-length Hp – e.g., Dec2,6+3S and Dod2,6S) 
whereas some displayed very low to high levels of activation (relative activities 
ranging from 5% to 100%, relative to full-length Hp – e.g., Oct2,6S, Oct2,6+3S, 
Dec2,6S and Dod2,6+3S). Some Hp/HS saccharides also showed no activation at all 
(relative activities lower than 5%, relative to full-length Hp – e.g., all the chemically 
prepared compounds) or even displayed possibly negative activities (e.g, Oct2S and 
Oct2,6S), though the latter were not statistically significant. 
More specifically, in the case of FGF2-FGFR1c, the 4 compounds Dec2,6S, 
Dec2,6+3S, Dod2,6S and Dod2,6+3S were the only oligosaccharides capable of 
stimulating mitogenic activity (Figure 37 (a)). They displayed rather similar and high 
levels of activity (around 90%) and no significant difference was tested between the 
two decasaccharides and between the two dodecasaccharides. However, none of 
these compounds were more active than Hp (on a weight basis). 
In contrast, in the case of FGF1-FGFR1c, a total of 6 compounds (Oct2,6S, 
Oct2,6+3S, Dec2,6S, Dec2,6+3S, Dod2,6S and Dod2,6+3S) were capable of 
supporting FGF1 signalling, with the remaining 13 other compounds being inactive 
(Figure 37 (b)). Out of the 6 active compounds, 5 were shown to display an activity 
level significantly higher than 50%, whereas Oct2,6S showed a rather low level of 
activity – about 20%. Importantly, octasaccharides were also able to stimulate 
FGFR1c when FGF1 was the ligand. Two-sided t-tests showed that a significant 
difference could be observed between Oct2,6S and Oct2,6+3S (t2.698 = -8.568, p = 
0.005), Dec2,6S and Dec2,6+3S (t2.146 = -5.731, p = 0.025) but not between Dod2,6S 
and Dod2,6+3S. Also, unlike for FGF2, 2 compounds (Dec2,6+3S and Dod2,6S) 
were significantly stronger activators compared to Hp (on a weight basis, at the fixed 
concentration of 3 µg/mL). It was hence decided to study the ability of these two 
saccharides to stimulate mitogenic activity in more detail.  
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Figure 37: Assessing the capability of fully defined Hp/HS oligosaccharides 
(at 3 µg/mL) to regulate (a) FGF2 (0.1  nM) and (b) FGF1 (1 nM) signalling 
through FGFR1c.  The relative mitogenic activit ies (N=9) were expressed as a 
percentage of the Hp control and plotted as box plots . Box plots show median 
(horizontal line), 25
th
 and 75
t h
 percentiles (edges of the box),  minimum and 
maximum values (whiskers) and mean (cross). The activities were tested using 
a one-sample t-test (N=3) to determine if their relative activities were 
significantly higher than the reference values: 5% (green), 50% (blue) and 
100% (red) (all reference values are relative to full-length Hp); Selected 
compounds were also tested using two-sided t-test (N=3) (black); *p<0.05; 
**p<0.01; ***p<0.001; NS: non-significant (p≥0.05). Oligosaccharides are 
categorised as follows: octa- (light grey boxes), deca- (grey boxes), dodeca-
saccharides (black boxes). 
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 FGF2-FGFR1c FGF1-FGFR1c 
Oligosaccharide 
Relative 
mitogenic 
activity 
(%, mean±S.D.) 
Reference 
value  
(% activity) 
t 
Degree 
of 
freedom  
p value 
Relative 
mitogenic 
activity 
(%, mean±S.D.) 
Reference 
value  
(% activity) 
t 
Degree 
of 
freedom 
p value 
Oct2,6S - - - - - 
17.9 
±6.3 
5 3.53 2 0.036* 
Oct2,6+3S - - - - - 
97.9 
±14.9 
50 5.57 2 0.015* 
Dec2,6S 
84.5 
±2.4 
50 25.24 2 0.001*** 
79.9 
±3.2 
50 16.08 2 0.002** 
Dec2,6+3S 
89.6 
±15.6 
50 4.40 2 0.024* 
136.6 
±16.8 
100 3.76 2 0.032* 
Dod2,6S 
88.7 
±16.1 
50 4.16 2 0.027* 
124.6 
±12.8 
100 3.34 2 0.039* 
Dod2,6+3S 
89.7 
±5.2 
50 13.18 2 0.003** 
110.6 
±14.5 
50 7.26 2 0.009** 
 
Table 11: Results of one-sample t-tests (one-tailed, N=3) for FGF2-FGFR1c and FGF1-FGFR1c. Compounds were tested using one-
sample t-tests to determine if their relative activities were higher than the reference values 5% (green), 50% (blue) and 100% (red) 
relative activity (relative to Hp) .Compounds that are not shown were not significantly higher than the 5% reference value (threshold 
for minimum activity). *p<0.05; **p<0.01; ***p<0.001. 
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The dose response curves for these two compounds were generated and are shown in 
Figure 38. Both Dec2,6+3S and Dod2,6S showed some activation at very low 
concentrations and reached plateau at 3,000 ng/mL. These titration curves clearly 
demonstrate that both Dec2,6+3S and Dod2,6S are better activators than Hp, across 
concentrations ranging from 30 ng/mL to 3,000 ng/mL. This observation is 
particularly notable for Dec2,6+3S. It should be noted that these observations were 
made on a weight basis. The EC50 values (given in Figure 38), however, interestingly 
confirmed that Dec2,6+3S was effectively more potent than Hp for low 
concentrations (average of 10,000 Da for Hp versus 3,000-3,500 Da for the 
oligosaccharides). Above 8,000 ng/mL, the activation levels of the three species are 
relatively similar.  
1 10 100 1000 10000
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
M
T
T
 a
s
s
a
y
 (
A
5
7
0
)
[Saccharide] (ng/mL)
 Dec2,6+3S
 Dod2,6S
 Heparin
 
Figure 38: Dose response curves (mean ±S.D.) for Dec2,6+3S and Dod2,6S 
activation of FGF1 signalling through FGFR1c. FGFR1c cells were treated 
with 1 nM FGF1 and were grown in the presence of full-length Hp ( ), 
Dec2,6+3S ( ) or Dod2,6S ( ). Values are the mean of t riplicate samples. The 
EC50  values are also given. 
 
EC50 values 
Dec2,6+3S: 326 ng/mL (≈ 0.11 nmol) 
Dod2,6S: 868 ng/mL (≈ 0.25 nmol) 
Hp: 2032 ng/mL (≈ 0.20 nmol) 
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5.3.2. Assessing the ability of Hp/HS oligosaccharides to induce 
FGF7 and FGF1 signalling through FGFR2b 
The 19 compounds were next screened in bioassays involving FGF7-FGFR2b and 
FGF1-FGFR2b pairings. As for tests with FGF1/FGF2-FGFR1c, and prior to any 
activity screening, the response of the cells expressing FGFR2b in the presence of 
FG7/FGF1 and of different concentrations of full-length Hp was assessed (Figure 
39). The curves obtained were in agreement with previously published values (Ornitz 
et al. 1996). 
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Figure 39: Dose response curves (mean ±S.D.) for full -length Hp activation 
of FGF7 (3 nM) and FGF1 (1 nM) signalling through FGFR2b.Values are the 
mean of triplicate samples. 
 
The activity of the saccharides alone (cells in growth medium and in the presence of 
the oligosaccharides) was also assessed. Responses to Hp/HS saccharides alone (cells 
in growth medium and in the presence of the oligosaccharides) were identical to the 
background controls (cells in BaF3 growth medium) (Figure 40). 
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Figure 40: Evaluating the bioactivity of the compounds alone at 3 µg/mL in 
bioassays with cells expressing FGFR2b. The negative control refers to the 
cells in BaF3 medium only (background). The  values are the mean of triplicate 
samples and the error bars represent the standard deviation (S.D.).   
 
Statistical tests were also performed with these FGF-FGFR combinations (one-
sample t-tests (one tailed)) to determine whether the relative activities of the 
compounds were higher than 5%, 50% or 100% activity (relative to full-length Hp). 
The results are listed in Table 12. Selected compounds were also compared using a 
two-sided t-test. 
As previously observed for FGF2-FGFR1c and FGF1-FGFR1c, at the fixed 
concentration of 3 µg/mL, the oligosaccharides displayed various levels of 
activation, ranging from no activation (less than 5%, relative to full-length Hp - e.g. 
Dec2S and Dod2S) to high level of activation (higher than 50% but lower than 
100%, relative to full-length Hp – e.g., Oct2,6+3S, Dec2,6+3S and Dod2,6+3S) 
(Figure 41).  
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In the case of FGF7-FGFR2b (Figure 41 (a)), it clearly appeared that none of the 19 
compounds were able to stimulate the mitogenic activity as efficiently as full-length 
Hp. Only a total of 4 oligosaccharides (Dec2,6S, Dec2,6+3S, Dod2,6S and 
Dod2,6+3S) were able to support FGF7 signalling. The 3 most active structures 
(Dec2,6+3S, Dod2,6S and Dod2,6+3S) displayed activation levels significantly 
higher than the 5% threshold only. Comparatively, the activity levels of the 
compounds which were the most active for FGF1-FGFR2b (Figure 41 (b)) were 
significantly higher (relative to 50% level). Two-sided t-tests showed that a 
significant difference could be observed between Dec2,6S and Dec2,6+3S (t2.298 = -
5.839, p = 0.020) and between Dod2,6S and Dod2,6+3S (t3.774 = -8.532, p = 0.001). 
However, no significant difference was observed between Oct2,6S and Oct2,6+3S. 
In the case of the FGF1-FGFR2b pairing, Oct2,6S, Oct2,6+3S, Dec2,6S, Dec2,6+3S, 
Dod2,6S and Dod2,6+3S were capable of supporting FGF1 signalling through 
FGFR2b. Amongst those active oligosaccharides, Oct2,6S was the only one 
displaying a rather low level of activation (about 20%). Two-sided t-tests showed 
that a significant difference could be observed between Oct2,6S and Oct2,6+3S (t2.995 
= -10.682, p = 0.002) only. No significant difference was observed between Dec2,6S 
and Dec2,6+3S and between Dod2,6S and Dod2,6+3S. For the FGF7-FGFR2b 
pairing, no oligosaccharide was as active as Hp, whereas for FGF1-FGFR2b, the 4 
most potent saccharides displayed the same activity as Hp. 
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Figure 41: Assessing the capability of Hp/HS oligosaccharides (at 3 µg/mL) 
to regulate (a) FGF7 (3 nM) and (b) FGF1 (1 nM) signalling through 
FGFR2b. The relative mitogenic activities (N=9) were expressed as a 
percentage of the Hp control and plotted as box plots. Box plots show median 
(horizontal line), 25
th
 and 75
t h
 percentiles (edges of the box), minimum and 
maximum values (whiskers) and mean (cross). The activities were tested using 
a one-sample t-test (N=3) to determine if their relative activities were 
significantly higher than the reference values: 5% (green), 50% (blue) and 
100% (red) (all reference values are relative to full -length Hp); Selected 
compounds were also tested using two-sided t-test (N=3) (black); *p<0.05; 
**p<0.01; ***p<0.001; NS: non-significant (p≥0.05). Oligosaccharides are 
categorised as follows: octa- (light grey boxes), deca- (grey boxes), dodeca-
saccharides (black boxes).  
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 FGF7-FGFR2b FGF1-FGFR2b 
Oligosaccharide 
Relative 
mitogenic 
activity 
(%, mean±S.D.) 
Reference 
value  
(% activity) 
t 
Degree 
of 
freedom 
p value 
Relative 
mitogenic 
activity 
(%, mean±S.D.) 
Reference 
value  
(% activity) 
t 
Degree 
of 
freedom 
p value 
Oct2,6S - - - - - 
19.8 
±5.9 
5 4.31 2 0.025* 
Oct2,6+3S - - - - - 
61.1 
±3.1 
50 6.25 2 0.012* 
Dec2,6S 
9.3 
±1.9 
5 3.81 2 0.031* 
95.9 
±4.1 
50 19.62 2 0.001** 
Dec2,6+3S 
34.2 
±7.1 
5 7.10 2 0.009** 
92.9 
±10.6 
50 7.03 2 0.009** 
Dod2,6S 
26.1 
±4.1 
5 8.93 2 0.006** 
93.7 
±5.4 
50 14.09 2 0.003** 
Dod2,6+3S 
51.6 
±3.2 
5 25.35 2 0.001*** 
94.1 
±6.6 
50 11.51 2 0.004** 
 
Table 12: Results of one-sample t-tests (one-tailed, N=3) for FGF7-FGFR2b and FGF1-FGFR2b. Compounds were tested using 
one-sample t-tests to determine if their relative activities were higher than the reference values 5% ( green), 50% (blue) and 100% (red) 
relative activity (relative to Hp) .Compounds that are not shown were n ot significantly higher than the 5% reference value (threshold 
for minimum activity). *p<0.05; **p<0.01; ***p<0.001.   
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5.4. Discussion 
The work presented here was aimed at providing insights into the interactions 
between HS, FGF and FGFR. To do so, the impact of several degrees of structural 
changes on the ability of HS saccharides to activate specific FGF-FGF complexes 
was evaluated. Deciphering the molecular mechanisms that regulate these 
interactions will help understand the role of HS in biological processes in which FGF 
and FGFR are involved (reviewed in Ornitz and Itoh (2015)).  
To study HS structure-activity relationships (SAR), 19 chemically and 
chemoenzymatically prepared oligosaccharides of different sizes (ranging from octa- 
to dodeca-saccharides) and displaying various structural features were tested in BaF3 
assays. Several conclusions could be drawn from the activity screenings of these 
compounds (the results are summarised in Table 13).  
First of all, only a certain number of structures were shown to be activators whereas 
the majority did not show any ability to support activation at signalling. Interestingly, 
all the saccharides composed of N-acetylated glucosamine and unsulphated uronic 
acid residues only were unable to support FGF signalling (these compounds are 
coloured in grey in Table 13). This might be explained by the fact that these 
oligosaccharides lack two important structural features, which are thought to be 
crucial for both HS-FGF and HS-FGFR interactions: the N-sulphate groups and the 
2-O-sulphated iduronic acid residues (Turnbull et al. 1992, Guimond et al. 1993, 
Maccarana et al. 1993, Walker et al. 1994, Pye et al. 2000). Hence, the data here 
with fully defined saccharides confirm these basic structural requirements. 
Secondly, the active compounds were clearly shown to be active in an FGF-FGFR 
complex-specific manner (e.g., Oct2,6+3S activates FGF1-FGFR1c and FGF1-
FGFR2b complexes but does not activate FGF2-FGFR1c and FGF7-FGFR2b 
complexes, as shown in Table 13). This is in agreement with a number of studies 
published using complex Hp and HS mixtures or partially purified saccharides which 
demonstrated that each FGF-FGFR system may differ in their specific HS structural 
determinants to be activated (Guimond et al. 1993, Guimond and Turnbull 1999, Pye 
et al. 2000, Ye et al. 2001, Ostrovsky et al. 2002, Powell et al. 2002).  
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FGF-FGFR complex 
 
 
FGF2 
FGFR1c 
(±S.D.) 
FGF1 
FGFR1c 
(±S.D.) 
FGF1 
FGFR2b 
(±S.D.) 
FGF7 
FGFR2b 
(±S.D.) 
 
 
 
 
 
 
 
 
 
 
 
 
S 
A 
C 
C 
H 
A 
R 
I 
D 
E 
S 
 
 
 
 
 
 
 
 
 
 
 
 
Oct6SIdo 
-4.76 
±1.1 
0.61 
±1.1 
-0.62 
±2.8 
-6.62 
±2.2  
Legend 
Oct6SIdo2S 
-6.89 
±2.6 
0.12 
±3.7 
-0.43 
±3.2 
-5.32 
±2.4  
131-140% 
Oct6SGlc 
-5.56 
±2.8 
0.56 
±0.5 
-1.28 
±2.9 
-9.29 
±5.5  
121-130% 
Oct6SGlc2S 
-2.21 
±3.1 
-0.43 
±2.0 
-2.75 
±3.8 
-5.52 
±3.0  
111-120% 
Oct2S 
-16.23 
±8.6 
2.79 
±5.1 
2.00 
±0.4 
0.90 
±2.2  
101-110% 
Oct2,6S 
-13.85 
±10.3 
17.87 
±6.3 
19.81 
±5.9 
6.60 
±4.3  
91-100% 
Oct2,6+3S 
-5.91 
±7.6 
97.89 
±14.9 
61.08 
±3.1 
12.17 
±5.5  
81-90% 
Dec6SIdo 
-1.29 
±1.8 
1.35 
±1.0 
-1.27 
±2.6 
-3.43 
±4.9  
71-80% 
Dec6SIdo2S 
-0.67 
±0.6 
4.24 
±2.9 
1.71 
±2.4 
-4.35 
±3.4  
61-70% 
Dec6SGlc 
-1.82 
±1.8 
2.87 
±0.7 
0.84 
±0.4 
-1.36 
±4.4  
51-60% 
Dec6SGlc2S 
1.52 
±2.5 
2.44 
±1.1 
1.16 
±0.7 
-2.82 
±1.8  
41-50% 
Dec2S 
-15.04 
±6.4 
5.07 
±5.7 
4.29 
±2.8 
5.54 
±2.6  
31-40% 
Dec2,6S 
84.48 
±2.4 
79.88 
±3.2 
95.92 
±4.1 
9.29 
±2.0  
21-30% 
Dec2,6+3S 
89.61 
±15.6 
136.56 
±16.8 
92.93 
±10.6 
34.20 
±7.1  
11-20% 
Dod6SIdo 
-6.73 
±2.2 
1.21 
±1.0 
-1.36 
±2.9 
-3.17 
±2.4  
5-10% 
Dod6SIdo2S 
-1.72 
±2.5 
5.46 
±2.8 
1.40 
±2.3 
-6.09 
±0.7  
-20-4% 
Dod2S 
-17.25 
±6.5 
10.99 
±4.7 
6.01 
±1.5 
2.40 
±5.3   
Dod2,6S 
88.66 
±16.1 
124.64 
±12.8 
93.76 
±5.4 
26.09 
±4.1   
Dod2,6+3S 
89.67 
±5.2 
110.56 
±14.5 
94.10 
±6.6 
51.63 
±3.2   
 
Table 13: Summary of the ability of the Hp/HS oligosaccharides to activate 
FGF-FGFR complexes. The relative activities are given as a percentage  
(mean ± S.D.) of the Hp control . The saccharides are categorised as follow: 
chemically synthesised (grey) and chemoenzymatically synthesised (green). 
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The observed differences in levels of activation can be explained by two main 
factors: the size of the oligosaccharides and their sulphation/acetylation patterns. It is 
clear from the data that FGF1, independently of the receptor type, does not require 
long saccharides to signal, in contrast with FGF2 and FGF7. This is illustrated by the 
fact that FGF1-FGFR1c and FGF1-FGFR2b complexes were shown to be activated 
by oligosaccharides as small as octasaccharides (Oct2,6+3S) whereas FGF2-FGFR1c 
and FGF7-FGFR2b required longer saccharides (e.g., Dec2,6S) to achieve significant 
levels of activation (e.g., decasaccharides Dec2,6S for FGF2 and dodecasaccharide 
Dod2,6+3S for FGF7). The results obtained are in partial agreement with some 
published studies: Ostrovsky et al. (2002) suggested that both FGF7-FGFR2b and 
FGF1-FGFR1c might require long saccharides to be stimulated whereas Ornitz et al. 
(1995) showed that both FGF1 and FGF2 signalling through FGFR1c can be 
stimulated by saccharides as small as di- and tri-saccharides. The latter study has 
always been controversial and has never been repeated (Delehedde et al. (2002), Wu 
et al. (2003), J. Turnbull, personal communication). In contrast with Ornitz’s 
findings, FGF2-FGFR1c stimulation could not be achieved by saccharides smaller 
than decasaccharides in this study. In some studies, fully sulphated Hp 
hexasaccharides have been shown to activate FGF signalling, but only at high doses 
compared to those required for more optimal structures such as full-length Hp 
(Delehedde et al. 2002, Ostrovsky et al. 2002). Thus, it may be possible for some 
activity to occur with sub-optimal saccharides at high concentrations. 
In addition to the lengths of the saccharides, the ionic charges also play an important 
role in the activation of the complex (Ori et al. 2008). The importance of the 6-O-
sulphate groups for FGF signalling, which has already been reported for FGF1 and 
FGF2 and FGFR using modified Hp and HS saccharide mixtures (Guimond et al. 
1993, Pye et al. 1998, 2000, Powell et al. 2002), was clearly confirmed here using 
fully defined Hp/HS saccharides. Drastic changes in terms of activation were 
observed between 6-O-unsulphated oligosaccharides and fully 6-O-sulphated 
oligosaccharides (e.g. Oct2S, Dec2S and Dod2S were completely inactive whereas 
Oct2,6S, Dec2,6S and Dod2,6S were generally active at varying degrees).  
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Importantly, the role of 3-O-sulphation was also assessed here with defined 
saccharides for the first time. Interestingly, the addition of a single 3-O-sulphate 
group towards the non-reducing end of the saccharides appeared to have important 
consequences in terms of activation in some specific cases, resulting in very 
significant enhancement in activity. More specifically, this effect was observed for 
Oct2,6+3S for FGF1 signalling through both FGFR1c and FGFR2b, Dec2,6+3S for 
FGF1-FGFR1c and FGF7-FGFR2b and finally for Dod2,6+3S for FGF7-FGFR2b. 
This activity enhancement was clearly dependent on context, such as saccharide size. 
For example, for FGF1-FGFR2b, the addition of a 3-O-sulphate onto the N-, 2-O- 
and 6-O-sulphated backbone of the octasaccharide boosted activity, whereas for the 
equivalent deca- and dodeca-saccharides, it resulted in no additional activity. The 
role of 3-O-sulphation has long been discussed, but has been under evaluated. This 
has, however, changed since the publication of studies assessing its role for 
antithrombic activity (Walenga et al. 1988, Guerrini et al. 2013) and for  herpes 
simplex virus 1 entry (Shukla et al. 1999, O’Donnell et al. 2006, Hu et al. 2011), to 
name a few. To the author’s knowledge, the role of 3-O-sulphation for FGF-FGFR 
binding/signalling has previously been suggested only through indirect evidence. 
McKeehan et al. (1999) and Ye et al. (2001) showed that only Hp fractions having 
high affinity for antithrombin III (by implication containing 3-O-sulphated residues) 
were able to bind FGFR1c, were able to support FGF1 and FGF2 activity or even 
FGF1-induced DNA synthesis. Luo et al. (2006a, 2006b) suggested that saccharides 
bearing 3-O-sulphate groups may protect FGF7 from proteolysis and also induce 
FGF7 binding/signalling. On the other hand, Wu et al. (2003) reported in their study 
that oligosaccharides/full-length Hp bearing 3-O-sulphate groups may help in the 
formation of FGF1-FGFR1c-HS ternary complexes, and therefore may help in 
stimulating FGF1 signalling. Recent biological studies have implicated 3-O-
sulphation as important for regulating FGF10-FGFR2b signalling in salivary gland 
development (Patel et al. 2014). However, for all the studies cited above, the exact 
structures of the oligosaccharides were unknown and the authors solely suggested 
that the 3-O-sulphate groups may have a significant impact on Hp/HS activities. 
Here, the role of those rare 3-O-sulphate groups has been clearly demonstrated and 
linked to high levels of FGF signalling through FGFR1c and FGFR2b for FGF1 and 
through FGFR2b for FGF7, but not for FGF2 through FGFR1c.  
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The abilities of the oligosaccharides to stimulate FGF signalling were assessed using 
BaF3 assays. In such bioassay, the mitogenic activity is proportional to the activity of 
the FGF-FGFR complex and, therefore, to the ability of the oligosaccharide to 
stimulate FGF signalling (Ornitz et al. 1992). It also permits the comparison of the 
mitogenic activities of different FGF-FGFR complexes. The BaF3 assay has been 
used in many studies and is well known and appreciated for allowing the screening 
of multiple compounds at once, requiring relatively small amounts of material (about 
5 µg of compounds are enough to carry out the assays in triplicates), for being cheap, 
fairly fast and reliable (Ornitz et al. 1996, Guimond and Turnbull 1999, Zhang et al. 
2006). However, it does not allow truly high throughput screening of 
oligosaccharides, which considerably hampers the fast and meticulous study of HS 
SAR. Sterner et al. (2013) recently developed a BaF3 cell-based microarray platform 
which could grant the high throughput screening of all types of FGF-FGFR systems 
(Sterner et al. 2014). This might be useful in future studies as larger libraries of 
defined HS saccharides become available.  
The oligosaccharides, which were screened in this study, were selected for specific 
reasons. Using such compounds indeed offered two major advantages, compared to 
extracted and partially purified HS saccharides. First, a rather large quantity of 
material was readily available (about 100 µg was used here). This allowed the 
replication of the bioassays during this study (compared to, e.g., the amounts 
collected by enzymatic digestion of PMHS, as described in Chapter 3). Secondly, 
such compounds are, by definition, structurally fully defined. The position and nature 
of each residue and chemical moiety is known with precision. Therefore, this 
provided the possibility to begin to assess the effect of different parameters such as 
the oligosaccharide size, the sulphation pattern or the presence of specific residues on 
FGF signalling. Further studies are however required to have a better overview of the 
SAR of HS in FGF signalling, including the screening of larger libraries. A broader 
diversity and less homogeneity of the compounds would also be appreciated. Finally, 
it was observed in this study that some oligosaccharides (e.g., Oct6SIdo2S, 
Oct6SGlc, Dec6SIdo and Dod6SIdo2S) were showing negative relative activities. 
Carrying out well-designed inhibitory assays in the future would also give better 
insights into FGF-FGFR-HS interactions (Guimond and Turnbull 1999).  
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Differences in activation were indeed observed and related to the presence or 
absence of specific structural features, a number of which were consistent with 
previous studies using heterogeneous Hp and HS saccharides. Perhaps most notably, 
the presence of a single 3-O-sulphate group towards the non-reducing end of the 
oligosaccharides resulted in a significant increase of activation for FGF1-FGFR1c, 
FGF1-FGFR2b and FGF7-FGFR2b. Taken, together; the results clearly showed that 
FGF signalling may be regulated by some level of specificity and this provides a 
better understanding of the underlying rules governing how HS regulates FGF 
signalling. Understanding these rules in more detail is essential for the development 
of targeted HS-based drugs which could be developed for many diseases to which 
FGF and FGFR have been linked.  
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 Specificity/selectivity of HS in FGF signalling is regulated by both 
general and subtle structural changes 
Biomolecular interactions are key components of a living organism’s integrity and 
fate as they govern all its biological processes. Understanding how these interactions, 
driven by molecular recognition, are regulated is crucial to comprehend the functions 
of the biomolecules involved in the biological processes. Amongst the interacting 
biomolecules, the paracrine fibroblast growth factors (FGFs), which signal through 
their receptors (FGFRs) located at the cell membrane, are key players in many 
biological processes including developmental and physiological processes, as well as 
organogenesis (Beenken and Mohammadi 2009, Goetz and Mohammadi 2013, Li, 
Wang, et al. 2016). Paracrine FGF signalling is regulated by heparan sulphate (HS), 
a polysulphated polysaccharide which was found to govern the activity of a 
substantial number of proteins (Lamanna et al. 2007, Ori et al. 2008). FGF signalling 
is thought to depend on the formation of the ternary complex FGF-FGFR-HS 
(Klagsbrun and Baird 1991, Rapraeger et al. 1991, Yayon et al. 1991) and any 
malfunction of FGF or FGFR may lead to serious disorders, such as cancers and 
skeletal defects (Eswarakumar et al. 2005, Beenken and Mohammadi 2009, Jorgen et 
al. 2011, Ornitz and Itoh 2015). One possible route for treating diseases involving 
aberrant signalling may be HS saccharides, since they regulate FGF-FGFR 
interactions. In order to be able to develop HS-based drugs, but also to have a better 
understanding of the general molecular mechanisms underlying HS-protein 
interactions, it is essential to unravel the structure-activity relationships (SAR) of HS. 
Over the decades, a lot of attention has been brought to the study of FGF-FGFR-HS 
interactions (reviewed in Goetz and Mohammadi (2013); Pomin (2016)), yet, they 
still remain elusive. More specifically, the structural features that are required for 
optimal binding and functional activity, and how those two are inter-related, remain 
rather unclear and are at the heart of an ongoing debate. Some suggest that the ability 
of HS to activate the proteins is due to the fine structures of the saccharides, 
particularly the discrete and specific distribution of their anionic moieties (Guimond 
and Turnbull 1999, Pye et al. 2000, Nakato and Kimata 2002), whereas others 
suggest that it is due to the general structural layout of the glycans and not to fine 
structural differences (Kreuger et al. 2005, Jastrebova et al. 2006).  
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In order to gain a better insight into FGF-FGFR-HS interactions, and more 
particularly, to determine to what extent FGF signalling is governed in a 
specific/selective manner, HS oligosaccharides of varying sizes and motifs were 
screened in bioassays. These assays resulted in the identification of multiple 
parameters that may have a crucial impact on FGF signalling, including the size of 
the saccharides (as a first approximation, the longer the more potent), the N-sulphate 
groups and the 2-O-sulphation of the iduronic acids, as well as the 6-O-sulphate 
groups (as already described in many studies: e.g., (Ornitz et al. 1992, Turnbull et al. 
1992, Wu et al. 2003, Zhang, Zhang, et al. 2009)). Importantly, the presence of a 
single 3-O-sulphate group towards the non-reducing end of the saccharides was 
shown to significantly increase the mitogenic activity for specific complexes (namely 
FGF1-FGFR1C, FGF1-FGFR2b and FGF7-FGFR2b) but not for FGF2-FGFR1c. 
These findings therefore highlighted the importance of both general and subtle 
structural changes on the ability of the saccharide to support FGF signalling and also 
showed that they were dependent on the particular ligand and receptor involved.  
 The generation of HS oligosaccharides remains a challenge 
This study employed two main strategies to prepare the HS oligosaccharides that are 
required for the reductionist approach, which consists of the use of oligosaccharides 
rather than full-length polysaccharide chains for biochemical and biophysical 
experiments. The use of shorter saccharides greatly facilitates the studies of HS-
FGF-FGFR interactions by reducing the compound’s complexity, as native HS is a 
highly complex polyfunctional saccharide (Stringer and Gallagher 1997). The two 
main strategies used here are: the extraction of natural, tissue-derived, HS chains and 
their modification (upstream approach) and the chemical preparation of HS chains 
from monosaccharides (downstream approach). The combination of both strategies 
could, in theory, have resulted in an extensive library of oligosaccharides to be 
screened in bioassays. 
The upstream approach is well known for granting rather quick access to broad 
oligosaccharide libraries to be screened in bioassays (Powell et al. 2010). A major 
issue however lies in the fact that there is limited control over the structures that can 
be isolated, dependent on the content and diversity of the source material, and the 
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method (enzymatic or chemical) used to cleave the HS chains to saccharides. Also, 
the resulting structures are initially unknown, requiring sequencing of the saccharides 
to be performed at the end of the purification process. Sequencing is still difficult, 
even with recent advances in mass spectrometry approaches, and requires pure 
compounds to be effectively carried out. In addition, the lack of fast and efficient 
methods for sequencing means that exact structures cannot always be fully 
established, and often, only disaccharide composition analysis is performed 
(Ashikari-Hada et al. 2004, Zhang, Zhang, et al. 2009). Moreover, this approach 
grants access to very restricted amounts of material (typically of the order of low µg 
quantities), which can seriously hamper the downstream screening and analysis. 
Although in general the production of very low amounts of compounds is not a major 
issue for BaF3 bioassays, since they only require a few µg of compound (Guimond et 
al. 2009), the risk of losing material during purification is high, as shown during the 
CTA-SAX purification step in this study (Chapter 3), and can result in a lack of 
sufficient material for analysis and further applications. Ultimately, even though the 
upstream approach has led to major breakthroughs (Ornitz et al. 1992, 1995, 
Guimond et al. 1993, Guimond and Turnbull 1999), the exclusive use of compounds 
isolated from animal tissues currently limits the meticulous study of HS SAR, which 
requires broad libraries of structurally well-defined structures. This may be addressed 
in the future by access to larger amounts of starting material, for example from 
heparin manufacturing by-products (S. Taylor and J. Turnbull, personal 
communication), and scaling-up of the generation and purification of HS 
saccharides.  
As an alternative, the chemical synthesis of HS octasaccharides was also attempted 
here (downstream approach). Chemical synthesis, which theoretically can lead to the 
preparation of all types of compounds (including non-natural ones), grants control 
over the structures that are prepared through synthetic strategy design and monitoring 
throughout the preparation process by means of mass spectrometry and NMR. Rather 
large quantities of material can be synthesised (up to hundreds of mg), allowing their 
study in many biochemical and biophysical approaches. However, the synthetic 
pathways are rather long, owing to the extensive manipulation of protective groups. 
In addition, efficient coupling reactions are often complicated to achieved, due to the 
presence of low reactive L-iduronic acid residues (Polat and Wong 2007) or the 
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impossibility of controlling all the parameters (including temperature, reagent 
concentrations, similarity of the glycosyl synthon reactivities, etc.).  
Owing to the discussed complications of the methods used here (Chapters 3 and 4), 
the saccharides produced in this study were not suitable for exploring HS SAR in 
FGF signalling. Therefore, compounds produced by Prof. Liu and Prof. Tyler for 
other studies (Schwӧrer et al. 2013, Xu et al. 2014), by means of chemical and 
chemoenzymatic syntheses, were explored in further studies here. Like the chemical 
synthesis, both enzymatic and chemoenzymatic methods are robust solutions 
(downstream approach) to prepare HS oligosaccharides (Kuberan et al. 2003, Liu et 
al. 2010, Liu and Linhardt 2014) and resulted in a library of well-defined 
oligosaccharides with interesting, and in some cases, systematic variations in 
structure. Yet, some issues still need to be addressed, such as the high substrate 
selectivity of the enzymes (which are not yet well characterised) and the limited life-
time of the enzymes, amongst others. 
It is to be noted that the use of short saccharides is a reductionist approach and may 
lead to loss of biological information compared to HS saccharides within intact HS 
chains. This possible loss of information may be due to the fact that that many 
parameters may impact the three-dimensional structure of the saccharides when 
constrained within a HS chain (e.g., the sulphate groups can alter the glycosidic 
linkages’ variations and the thermodynamics of protein binding (Rudd and Yates 
2010)). However, these effects may be rather localised and not spread throughout the 
glycan chain, limiting the possible loss of information when working with 
oligosaccharides. Even more, the use of oligosaccharides greatly reduced the number 
of possible epitopes compared to the diversity found in intact chains. However, 
oligosaccharides can be fully structurally defined which allows for a better precise 
assessment of the role of each structural feature onto the activity of the saccharides, 
in contrast to full-length HS. 
 Bioassays are powerful tools to decipher specificity/selectivity in 
FGF signalling 
Defined HS saccharide compounds were screened in BaF3 bioassays to assess their 
ability to stimulate FGF signalling. BaF3 bioassay is a well-known cheap and robust 
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method, which has been used extensively for studying the interactions of HS with 
FGF and FGFR by measuring the mitogenic activity (Ornitz et al. 1992, Powell et al. 
2002, Wu et al. 2003, Sterner et al. 2013). The results which were obtained in this 
study clearly showed that specificity/selectivity regulates HS-FGF-FGFR 
interactions at the functional, cellular level and that both general and subtle structural 
modifications play a role in this phenomenon. In particular, this study highlighted the 
impact of a single 3-O-sulphate group towards the non-reducing end of the 
saccharides on the mitogenic activity of FGF1 on BaF3 cells expressing FGFR1c and 
FGFR2b and of FGF7 on cells expressing FGFR2b. However, it should be noted that 
these observations are based on the screening of a limited number of structures with 
limited variations, typically being mainly homogeneous repeat sequences. For 
example, owing to the limitations which hamper the production methods of 
saccharides (as mentioned earlier), it was not possible to prepare regioisomers of the 
screened structures to determine whether the position of the 3-O-sulphate group was 
crucial or not. For the same reasons, it was not possible to study whether the 
introduction of another type of sulphate group would have had the same impact or 
not (e.g., by performing the substitution of the non-sulphated glucuronic acid at the 
non-reducing end with a sulphated iduronic acid residue). Therefore, extra caution 
should be taken to avoid overgeneralisation of the results based on those obtained 
from activity screenings. To further extend the interesting results obtained here, 
systematic studies could be conducted on a more comprehensive library. However, 
owing to the lack of high throughput methods of synthesis, such studies are not yet 
possible via full chemical synthesis. The chemoenzymatic approach is increasingly 
generating larger libraries, but with the caveat that diversity that can be incorporated 
is still limited by the specificity of the enzymes used. Nonetheless, activity screening 
remains a powerful tool to aid in the accumulation of a significant amount of data on 
specific questions regarding HS biological functions. For the selected library of 
compounds studied here, the effects of subtle modifications provide important 
insights into HS SAR in FGF signalling. The data accumulated from these bioassays 
could lead ultimately to a better understanding of the interactions of HS with FGF 
and FGFR.  
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 But bioassays only give a truncated picture of FGF-FGFR-HS 
interactions 
Even though activity assays are powerful tools, they should, however, not be 
considered as the only source of information to decipher HS SAR in FGF signalling. 
Other aspects must be taken into consideration. The role of HS saccharide sulphation 
patterns were first thought to be the key to high level of FGF activity as many studies 
suggested that 2-O-, 6-O- and N-sulphate groups are essential for effective FGF 
binding and activity (Turnbull et al. 1992, Maccarana et al. 1993, Ashikari-Hada et 
al. 2004, Zhang, Zhang, et al. 2009). In recent years, many other factors such as the 
nature of the solvent/counter ions, the plasticity of the iduronic acid residues have 
also been shown to play a role in the regulation of the interactions of HS with its 
protein ligands (as previously mentioned), therefore indicating that the sulphation 
pattern is not solely responsible for high levels of activation. Some factors (e.g. the 
sulphation pattern and the plasticity of the L-iduronic acid residues (Guglieri et al. 
2008)) have also been shown to impact one another, resulting in another level of 
complexity for the study of HS-FGF-FGFR interactions. Alongside bioassays, other 
types of biochemical and biophysical analyses would therefore be useful to better 
understand the molecular mechanisms underlying FGF signalling. On the one hand, 
binding assays are another popular method to study HS-FGF-FGFR interactions 
(Ornitz et al. 1995, Rahmoune et al. 1998, Noti et al. 2006, Zhang, Zhang, et al. 
2009). However, assessing the ability of HS saccharides to simply bind FGF, FGFR 
and FGF-FGFR complexes does not necessarily provide a direct understanding of the 
structural determinants for activating FGF signalling. The situation is indeed rather 
complex, with many HS saccharides binding to proteins, but only a subset of these 
showing functional activity (Guimond and Turnbull (1999); Powell et al. (2004); Y. 
Ahmed and J. Turnbull, personal communication). Hence, the relationship between 
binding and activity is not simple. Indeed, some saccharides may also negatively 
regulate FGF signalling, as suggested by some data here, and this aspect requires 
future investigation. 
On the other hand, running molecular dynamics simulations or carrying out NMR 
analyses, with a selection of the oligosaccharides that were screened in this study, 
may offer the possibility of obtaining a better insight into the interactions at the 
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molecular level. In the present study, most of the compounds which were able to 
stimulate high levels of FGF signalling were slightly more enriched in sulphate 
groups at the non-reducing end than at the reducing end of the chains. This rather 
supports the symmetric model rather than the asymmetric model, as it is thought that 
for the symmetric configuration, the proteins interact with the non-reducing ends of 
the two saccharide chains (Harmer et al. 2004, Ibrahimi et al. 2005, Wu and Lech 
2005, Naimy et al. 2011, Brown et al. 2013, Nieto et al. 2013, Sterner et al. 2014) 
(see also Section 1.7.3, Figure 7). This could contribute to the decision of which 
model could be used for molecular dynamics simulations. Beyond the study of HS 
SAR in FGF signalling, the results of the present study may also provide a better 
insight into the formation of the functional complex, providing candidate structures 
for interaction and modelling studies.  
 Conclusions 
During this study, differences in FGF activation were detected and linked to the 
presence or absence of specific structural features borne by HS saccharides. More 
specifically, the presence of a single 3-O-sulphate group towards the non-reducing 
end of the oligosaccharides resulted in a significant increase of activation for FGF1-
FGFR1c, FGF1-FGFR2b and FGF7-FGFR2b. This indicated that a certain degree of 
specificity may regulate FGF signalling.  
The notion of specificity/selectivity is still at the heart of an intensive debate, owing 
to the abundance of contradictory data that has been gathered, and its contradictory 
interpretation, over the last years. This is also partly dependent on how these terms 
are defined. To illustrate this debate, both Antithrombin III and thrombin are often 
referred as the examples that respectively endorse the “high-specificity interactions” 
or the “non-specific interactions” theories (Mosier et al. 2012). However, these two 
hypotheses rule out the many other examples where a certain degree of redundancy 
in the HS structures which regulate the proteins’ activities has clearly been observed 
(Meneghetti et al. 2015). This redundancy could be explained by appreciating the 
three-dimensional aspect of the HS saccharide chains, rather than just their primary 
and linear structural layout and their substitution patterns only. The observed 
plasticity of the saccharides, which has been shown to be modelled by different 
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parameters (sulphate groups, glycosidic bonds, counter ions, etc.), as previously 
mentioned, may explain why compounds of various sizes and various substitution 
patterns may serve to stimulate protein activities in a similar fashion. Thus, two 
structurally different saccharides may stimulate a protein activity in a similar fashion, 
as the differences of flexibility between the two sequences would lead to a similar 
projection of the functional moieties of the saccharides towards the amino acids of 
the protein.  
HS, its biosynthesis, distribution within tissues and interactions with its protein 
ligands have been extensively studied over recent decades. Despite being template-
free driven, HS biosynthesis is strongly thought to be regulated (Chapter 1). This is 
mainly supported by the structural variations of HS chains that have been observed 
and which depend on the nature, the maturity and the state (healthy/diseased) of the 
tissues (Maccarana et al. 1996, Cheng et al. 2001, Netelenbos et al. 2001, Allen and 
Rapraeger 2003, Ledin et al. 2004). The structures of the HS extracted from the same 
tissues have, however, been shown to be consistent amongst individuals (Ledin et al. 
2004). On the other hand, HS interactions with proteins are thought to be regulated 
by some degree of specificity/selectivity, mainly through the spatial distribution of 
the sulphate moieties, as demonstrated in this study. Finally, these two observations 
support the notion of HS being a dynamically modulated system for controlling 
protein functions (Figure 42). Therefore, some hierarchy, mainly in terms of 
sulphation and epimerisation, could also be established. The formation of the N-
sulphated domains and the epimerisation of the D-glucuronic acid residues would 
serve as a template for creating core backbone structural patterns, which can then be 
further tuned via sulphation (2-O-, 6-O- and 3-O-sulphation steps). The extracellular 
tuning of the sequences would finally be further remodelled by the action of the two 
6-O-sulphatases. This hypothesis was supported in this study, with the significant 
increase of activity caused particularly by the addition of 6-O- and 3-O-sulphate 
groups for most of the ligand-receptor pairings.  
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Figure 42: Hierarchical regulatory system – Sulphation and remodelling 
versus diversity and functional impact.  
 
In addition to the disputed notion of specificity/selectivity, other questions remain to 
be answered. As a matter of example, differences in levels of interactions are usually 
observed in binding/activity assays, with compounds that are more active than others, 
as seen in the present project at the functional level. It has been shown, that HS 
interacts with its protein ligands mainly through anionic interactions (Rabenstein 
2002) and that the different conformations adopted by the L-iduronic acid residues 
allow the anionic moieties as well as the hydroxyl hydrogens to be presented to the 
protein’s amino acids in different ways, in order to favour stronger electrostatic 
interactions (Das et al. 2001, Raman et al. 2003). In addition, HS saccharides are 
rather flexible glycans and HS-protein interactions may rely on the conformations 
adopted by the saccharide chains, as mentioned above, rather than the solely spatial 
distribution of the sulphate groups. Taking these elements into consideration, it could 
be hypothesised that the biosynthesis of HS could be performed in such a way that a 
“minimum conformational state” of the chain would be obtained. This minimum 
conformational state refers to the most basic conformation that is capable of 
supporting functional activity, in order to assure, in a broader context, the living 
organism’s integrity. In addition, the addition/removal of sulphate groups would 
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enhance or inhibit the functional activity by locally modifying the conformation of 
the HS chain. This hypothesis could explain the differences in levels of activation 
that are observed in binding/activity assays.  
Overall, the present study has provided important new insights into HS SAR in FGF 
signalling by demonstrating that both general and subtle changes may impact greatly 
the biological activity of these proteins and confirming specificities for different 
ligand-receptor pairings. Further studies are nonetheless required, due to the 
complexity that characterises HS-protein interactions, to provide further evidence on 
the molecular mechanisms underlying a wider range of HS-protein interactions. This 
is vital not only for fundamental perspectives, but also for the potential development 
of HS-based drugs. 
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